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ABSTRACT 
 
Altered signaling pathways, which are mediated by post-translational modifications and 
changes in protein expression levels, are key regulators of cancer initiation, progression, and 
therapeutic escape. Many aspects of cancer progression, including early carcinogenesis and 
immediate response to drug treatment, are beyond the scope of genetic profiling and non-
invasive monitoring techniques. Global protein profiling of cancer cell line models, tumor tissues, 
and biofluids (e.g. serum or urine) using mass spectrometry-based proteomics produces novel 
biological insights, which support improved patient outcomes. Recent technological advances 
resulting in next-generation mass spectrometry instrumentation and improved bioinformatics 
workflows have led to unprecedented measurement reproducibility as well as increased depth 
and coverage of the human proteome. It is now possible to interrogate the cancer proteome with 
quantitative proteomics to identify prognostic cancer biomarkers, stratify patients for treatment, 
identify new therapeutic targets, and elucidate drug resistance mechanisms. There are, 
however, numerous challenges associated with protein measurements. Biological samples have 
a high level of complexity and wide dynamic range, which is even more pronounced in samples 
used for non-invasive disease monitoring, such as serum. Cancer biomarkers are generally 
found in low abundance compared to other serum proteins, particularly at early stages of 
disease where cancer detection would make the biggest impact on improving patient survival. 
Additionally, the large-scale datasets generally require bioinformatics expertise to produce 
useful biological insights. These difficulties converge to create obstacles for down-stream 
clinical translation. This dissertation research demonstrates how proteomics is applied to 
develop new resources and generate novel workflows to improve protein quantification in 
x 
complex biosamples, which could improve translation of cancer research to benefit patient care. 
The studies described in this dissertation move from assessment of quantitative mass 
spectrometry platforms, to analytical assay development and validation, and ending with 
personalized biomarker development applied to patient samples.  
As an example, four different quantitative mass spectrometry acquisition platforms are 
explored and comparisons of their ability to quantify low abundance peptides in a complex 
background are explored. Lung cancers frequently have aberrant signaling resulting in 
increased kinase activity and targetable signaling hubs; kinase inhibitors have been successfully 
developed and implemented clinically. Therefore, changes in amounts of kinase peptides in the 
complex background of peptides from all ATP-utilizing enzymes in a lung cancer cell line model 
after kinase inhibitor treatment was selected as a model system. Traditional mass spectrometry 
platforms, data dependent acquisition and multiple reaction monitoring, are compared to the two 
newer methods, data independent acquisition and parallel reaction monitoring. Relative 
quantification is performed across the four methods and analytical performance as well as 
downstream applications, including drug target identification and elucidation of signaling 
changes. Liquid chromatography – multiple reaction monitoring (LC-MRM) was selected for 
development of multiplexed quantitative assays based on superior sensitivity and fast analysis 
times, allowing for larger peptide panels. Method comparison results also provide guidelines for 
quantitative proteomics platform selection for translational cancer researchers.  
Next, a multiplexed quantitative LC-MRM assay targeting a panel of 30 RAS signaling 
proteins was developed and described. Over 30% of all human cancers have a RAS mutation 
and these cancers are generally aggressive and limited treatment options, leading to poor 
patient prognosis. Many targeted inhibitors have successfully shut down RAS signaling, leading 
to tumor regression, however, acquired drug resistance is common. The multiplexed LC-MRM 
assays characterized and validated are a publically available resource for cancer researchers to 
interrogate the RAS signal transduction network. Feasibility has been demonstrated in cell line 
xi 
models in order to identify signaling changes that confer BRAF inhibitor resistance and 
biomarkers of sensitivity to treatment. This analytical LC-MRM panel could support meaningful 
development of new therapeutic options and identification of companion biomarkers, with the 
end goal of improving patient outcomes.  
Multiplexed LC-MRM assays developed for personalized disease biomarkers using an 
integrated multi-omics approach are described for Multiple Myeloma, an incurable malignancy 
with poor patient outcomes. This disease is characterized by clonal expansion of the plasma 
cells in the bone marrow, which secrete a monoclonal immunoglobulin, or M-protein. Clinical 
treatment decisions are based on multiple semi-quantitative assays that require manual 
evaluation. In the clinic, minimal residual disease quantification methods, including multi-
parameter flow cytometry and immunohistochemistry, are applied to bone marrow aspirates, 
which is a highly invasive technique that does not provide a systemic evaluation of the disease. 
To address these issues, we hypothesized that unique variable region peptides could be 
identified and LC-MRM assays developed specific to each patient’s M-protein to improve 
specificity and sensitivity in non-invasive disease monitoring. A proteogenomics approach was 
used to design personalized assays for each patient to monitor their disease progression, which 
demonstrate improved specificity and up to a 500-fold increase in sensitivity compared to 
current clinical methods. Assays can be developed from marrow aspirates collected when the 
patient was at residual disease stage, which is useful if no sample with high disease burden is 
available. The patient-specific tests are also multiplexed with constant region peptide assays 
that monitor all immunoglobulin heavy and light chain classes, which could reduce analysis to a 
single test. In conclusion, highly sensitive patient-specific assays have been developed that 
could change the paradigm for patient evaluation and clinical decision-making, increasing the 
ability of clinicians to continue first line therapy in the hopes of achieving a cure, or to intervene 
at an earlier time point in disease recurrence. This study also provides a blueprint for future 
xii 
development of personalized diagnostics, which could be applied to biomarkers of other cancer 
types.  
Overall, these studies demonstrate how quantitative proteomics can be used to support 
translational cancer research, from the impact of different mass spectrometry platforms on 
elucidating signaling changes and drug targets to the characterization of multiplexed LC-MRM 
assays applied to cell line models for translational research purposes and in patient serum 
samples optimized for clinical translation. We believe that mass spectrometry-based proteomics 
is poised to play a pivotal role in personalized diagnostics to support implementation of 
precision medicine, an effort that will improve the quality and efficiency of patient care.  
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CHAPTER ONE: 
INTRODUCTION 
The Birth of Omics Technologies 
 All proteins are created through translation of RNA, which is transcribed from DNA, 
which we describe as “The Central Dogma” of molecular biology. With the sequencing of the 
human genome in 2001,3-4 in theory, this resource has provided the blueprint that results in all 
possible proteins found in the human body. The promise of accelerated treatments for disease 
and new cures following the release of the human genome has not come to fruition as 
researchers desired. Instead, this important accomplishment revealed many more unknowns 
than answers, including the fact that knowledge beyond DNA sequences is necessary to 
understand human disease and cancer in particular. For decades, the accepted paradigm has 
been that cancer is a disease of genetics.5 In recent years, this paradigm has been challenged 
and it is accepted that other factors, including environmental exposure, epigenetics, and post-
translational modifications, which are beyond the scope of DNA nucleotide sequences play a 
major role in cancer initiation, development, and resistance.6 While the advent of the human 
genome did not amount to all that scientists hoped for, it provided the groundwork for expansion 
of the “omics” fields of study: genomics, transcriptomics proteomics, and metabolomics.  
 Proteomics, one of the “post-genomics” fields of study, focuses on identifying and 
quantifying all the proteins in the proteome. Unlike genomics, there is no amplification method 
analogous to polymerase chain reaction (PCR) for proteins. Therefore, new methods and 
technologies were developed to support unveiling the proteome and increase our understanding 
of what is actually happening in cells, rather than inferring from a blueprint. We will discuss 
2 
recent advancements in the proteomics field and how “omics” and systems biology approaches 
have improved our understanding of cancer biology, ultimately changing the face of cancer 
patient treatment today.  
 
Applications of Omics in Cancer Biomarker Discovery to Clinical Implementation 
Next-generation Sequencing Paves the Way for Implementation of Molecular Diagnostics 
Genomics was the first of the “omics” approaches to develop and therefore has had the 
most time to mature. Genomics research has led to numerous ground-breaking discoveries 
producing a more comprehensive understanding of tumor biology and the identification of 
predictive, prognostic, and diagnostic biomarkers, which have improved cancer treatment and 
patient outcomes. Currently, most biomarkers used to direct treatment strategies are at the 
genetic level (e.g. mutations or chromosomal abnormalities), such as testing lung cancer 
patients for EGFR-mutations and treating those who are positive with an EGFR inhibitor.7-8 
Great strides have been made regarding incorporation of molecular testing into treatment 
guidelines using genomic data, including the release of the first multiplexed next-generation 
sequencing (NGS) panels as companion diagnostics (CDx) to guide cancer treatment 
recommendations; these include Oncomine Dx Target Test (Thermo), MSK-IMPACT9, and 
FoundationOne CDx (Foundation Medicine). However, limitations of genetic testing have left a 
large group of patients with no identifiable driver mutation (~40% of all lung cancers, for 
example), and other patients harbor driver mutations that remain unresponsive to therapy.10-11 
To develop new treatment strategies for these patients, methods beyond the scope of genetic 
profiling are required to gain a more comprehensive understanding of each patient’s tumor 
biology.  
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Proteins as Cancer Biomarkers – A Story of Trials and Tribulations 
Proteomics platforms for global profiling of proteins in cancer have emerged as the ideal 
tool to improve our ability to target tumors through molecular analysis of cells, tissues, serum, 
and other biological fluids. Because proteins are the functional product encoded by genes, they 
more accurately elucidate the tumor phenotype by providing additional layers of information, 
representing the convergence of diverse genotypes to the cancer phenotype. To this end, large-
scale proteogenomics studies have demonstrated that protein abundance cannot always be 
predicted using DNA or RNA level information, which has an impact on therapeutic efficacy of 
targeted therapeutics when patients are selected solely based on mutation status or other 
genetic markers.12-14 Proteomic profiling can be used to identify different splice 
variants/isoforms, post-translational modifications, structural information, sub-cellular 
localization, and protein-protein interactions, all of which are vital to understand the dynamic 
system of cancer biology that cannot be observed through genetic profiling. However, the high 
level of complexity and large dynamic range found in biological protein samples and amount of 
data generated makes proteomics analysis and down-stream clinical applicability particularly 
challenging.  
Initial efforts to create early cancer detection diagnostic tests utilizing surface-enhanced 
laser desorption/ionization time-of-flight (SELDI-TOF), yielded disappointing results and created 
controversy in the field.15 This initial controversy, which is well-summarized in a Clinical 
Chemistry editorial16, had a negative impact on confidence in MS-based diagnostic protein 
biomarker diagnostic tests, which was a substantial setback for the field. The controversy did, 
however, bring to light the need for guidelines and standards on protein biomarker assays and 
in the end resulted in suggestions to improve study design  for future studies.17 In total, the 
overall outcome was positive, because we are more prepared to thoroughly develop proteomics 
approaches for clinical biomarker measurements.  Shortly after, Zhang et al. published a well-
designed multi-center study identifying and validating a panel of ovarian cancer biomarkers 
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using SELDI-MS.18 This study resulted in the OVA1 test, which is the first FDA-approved In Vitro 
Diagnostic Multivariate Index Assay (IVDMIA) used to screen for ovarian cancer in women prior 
to surgery.19-20 While the FDA-clearance of this multivariate protein biomarker test for early 
cancer detection was an exciting step for the field, the test was only marginally better than the 
previous (CA-125) due to sensitivity and specificity issues. It was also translated to an 
immunoassay rather than the SELDI MS platform originally used for development due to 
insufficient analytical performance.20 Despite these weaknesses, it is still the only FDA-cleared 
multivariate protein biomarker test for OvCa and is a well-designed study that can be used as a 
model for future IVDMIAs. 
 
Quantitative Proteomics  
Bottom-up Proteomics  
“Bottom-up” proteomics utilizing liquid chromatography tandem mass spectrometry (LC-
MS/MS) has emerged as a versatile approach to maximize coverage of proteins in any 
biological sample.21-22 The defining feature of this approach includes the detection and 
quantification of surrogate peptides produced from enzymatic digestion, typically trypsin, of 
proteins from complex biological and clinical samples. Due to technical limitations of LC-MS, the 
larger the molecule, the more difficult it is to achieve resolution necessary to accurately identify 
it in a complex mixture. To get around this limitation, proteins are cut into peptides. Not only is 
better resolution achieved at lower mass to charge values (m/z), but when intact analytes are 
 fragmented, the smaller the analyte, the less complex the resulting MS/MS spectrum will be.23 
Peptides have a predictable structure built from amino acids, each with their own unique side 
chain but attached to the same backbone. Bottom-up proteomics takes advantage of this due to 
predictable fragmentation at the amide bond (Figure 1). This predictable pattern and unique 
amino acid molecular weights (MW), with the exception of leucine and isoleucine, allow peptide 
sequencing from MS/MS spectra. 
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 Peptide Spectral Matching with the Human Genome as a Roadmap. The human 
genome, which contains an estimated 20,050 protein-coding genes,24 is used as a reference to 
match identified peptide sequences to proteins. In this approach, proteins are digested in silico 
to create a list of peptides from each protein. Then, the theoretical tandem mass spectra 
predicted from the reference database are matched to the spectra derived from endogenous 
peptides generated from the protein digest. Many algorithms, with SEQUEST25-26 as the first, 
have been created to optimize this function programmatically or to tune it to specific need, such 
as identification of glycosylated peptides. Efforts to improve matching ability while increasing 
speed are top priority for database matching algorithms. This is the approach used to identify 
peptides in shotgun proteomics discovery datasets. As of 2017, the Human Proteome 
Organization (HUPO) announced that 17,008 proteins out of the 20,050 for which there is 
transcript evidence have been identified by MS, most of which were detected by shotgun 
Figure 1. Predictable Fragmentation Patterns of a Tryptic Peptide, YYADSVK. Peptides fragment 
at the amide bond to generate a predictable spectrum. Tryptic peptides predominantly show more y-
ions because the K/R cleavage ensures the C-terminus will be charged. The highest signal fragment 
ions are selected for targeted reaction monitoring (y6, y5, and y4). LC-MRM peak contains 
overlapping fragment ions maintained in the same ratio. 
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proteomics using LC-MS/MS.24 Although the number of proteins in the human proteome is ever 
evolving, evidence is mounting that completion of a draft of the humane proteome is near. 
Following in genomics foot-steps, the next step following near-complete coverage is improving 
quantitative and analytical capabilities to support clinical implementation and achieve the overall 
goal in the biomedical research field of improving patient care and human health. 
 
Liquid Chromatography – Multiple Reaction Monitoring Mass Spectrometry  
MS-based proteomics approaches can be divided into two categories: discovery and 
targeted assays. Multiple reaction monitoring (MRM) mass spectrometry, also known as 
selected reaction monitoring (SRM), is a targeted technique used to accurately measure specific 
analytes across multiple samples.27-28 MRM is used to overcome difficulties in detecting and 
quantitatively measuring low abundance peptides in a complex mixture without the use of 
chemical or metabolic labeling.27, 29-30 MRM is generally carried out on a triple quadrupole 
(QqQ), the most widely used mass spectrometer in the clinical laboratory. This instrument uses 
the first and third quadrupoles for mass selection of the precursor and fragment ions, 
respectively, and the second quadrupole as the collision cell (Figure 2). The QqQ utilizes a 
predetermined list of peptides containing the mass to charge (m/z) value for the precursor ion 
and specific fragment ion pairs, called transitions, to filter and analyze only the selected ions, 
leading to improved sensitivity. Due to the multiple filtering of precursor and fragment ions, 
interference from co-eluting precursor ions is less problematic compared to quantification using 
only precursor ions. Using MRM, multiplexed analysis of many proteins within a system can be 
performed at one time.31-33 
 
Absolute Quantification. Analyte quantification has been further improved by the use of 
stable isotope labeled standard (SIS) peptides identical to the proteolytic peptide from the 
endogenous protein, with the exception of 13C or 15N labels that modify its mass by a known 
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difference. Building upon the isotope dilution method developed initially for small molecule 
analysis (e.g. drugs and metabolites),34-35 a known amount of the SIS peptide is spiked into the 
sample either before or after protein digestion.28, 36-37 The mass spectrometer is capable of 
differentiating between the two peptides due to the mass difference, not only in the precursor 
m/z, but in some cases also in the fragment m/z. 
 
Other MS Platforms. Two MS acquisition methods have been described so far: discovery 
LC-MS/MS, also known as data dependent acquisition (DDA), and LC-MRM for targeted 
quantification (Figure 2).38 Improved instrumentation and computational power has led to the 
advent of a growing number of options. Similar to MRM, parallel reaction monitoring (PRM) uses 
fragment ions from a user-defined target list for quantification. The differences are, PRM is 
carried out on an Orbitrap instrument (Thermo), and all fragment ions from the specified 
precursor are monitored. Data from the fragment ions are acquired with high resolution and 
accurate mass (HRAM). The downside is the process is limited by the Orbitrap, which has 
slower acquisition times than the triple quadrupole. As an alternative to DDA, data-independent 
acquisition has emerged as somewhat of a hybrid method. Many strategies exist, but the main 
difference is that instead of precursor fragmentation being based on the population of observed 
precursors in the MS1 scan for DDA, the instrument is told to step through small windows of 5 – 
25 m/z and fragmenting all available precursors. Next, tandem spectrum must be deconvoluted 
and matched to a high quality spectral library is employed to improve confidence in 
identifications. This way, under-sampling common to DDA data will not be a problem. The 
downside is that data quality is dependent upon assembly of a high quality spectral library, so 
true “new” observations will not be made. As high quality publically available datasets become 
available and nearly all proteins with transcript evidence have been observed, this aspect 
becomes less of a problem. These different acquisition methods will be explored in greater 
detail in Chapter 2. 
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Clinical Proteomics Tumor Analysis Consortium Assay Guidelines. Over the last few 
years, the cancer research field as a whole has taken efforts to address reproducibility issues 
and an overall lack of both availability and consistency in data quality. To make progress on 
addressing complex health problems and human diseases, the proteomics community has 
specified guidelines for nearly every aspect of the proteomics workflow, from instrument and 
database search parameters to experimental design in efforts to address initial pitfalls in 
implementation described earlier. The overall goal has been to increase transparency and 
improve access and usage of data produced by the research community to accelerate 
Figure 2. Schematic Diagram of Mass Spectrometry Platforms used for Discovery and 
Targeted Proteomics. The top three MS acquisition diagrams are specific to Thermo instruments 
that utilize the Orbitrap for measuring ion signal. Multiple or selected reaction monitoring is done on a 
triple-quadrupole mass spectrometer and ion signal is measured after Q3 by the electron 
multiplier/ion gauge.  
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improvements in healthcare. Molecular and Cellular Proteomics is leading the way for 
quantitative proteomics by announcing new standards for publication of quantitative proteomics 
datasets; it is expected that other journals will follow suit.39-41 Another group, the Clinical 
Proteomics Tumor Analysis Consortium or CPTAC, has published recommendations for many 
aspects of quantitative assay development, from peptide handling and storage to specifying 
what experiments need to be done to characterize and validate quantitative assays. They have 
compiled this information into various guidance documents which have been implemented in 
Chapters 3 and 4 of this dissertation. In my opinion, the strides made in the last two to three 
years have been game changing and the delayed impact will no doubt be quite meaningful for 
the development of MS-based biomarker assays. 
 
Clinical Applications of MS-based Biomarker Assays 
To successfully achieve clinical implementation of MS-based protein assays, the 
following challenges must be overcome: wide dynamic range, increased sample complexity 
following enzymatic digestion of proteins, and high measurement variability. To address these 
issues, different sample preparation and analytical methods are employed. Typically, in bottom-
up discovery proteomics, proteins digested into peptides by trypsin are separated using ultra-
high pressure liquid chromatography (UPLC) at 200-400 nL/min prior to electrospray ionization 
and MS/MS (LC-MS/MS). Sensitivity, specificity, and reproducibility are improved by employing 
low-flow, high-pressure separation prior to MS analysis. Other commonly used methods of 
separation include sample high pH reversed phase LC, gel-based, and filter-based fractionation 
(up to 30 fractions) prior to LC-MS/MS of each fraction. Recent deep proteome studies utilizing 
two-dimensional fractionation and LC-MS/MS have achieved depths of 11,000 – 12,000 proteins 
identified in cell lines or tumor tissue samples.14, 42-43  
Tumor-derived material (e.g. RNA, DNA, proteins, metabolites, and exosomes) can also 
be secreted by cancer cells into circulation where they can be detected and monitored as 
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cancer biomarkers.44 Early detection of cancer using a blood test, also called a liquid biopsy, is 
an area with high unmet need and currently an active area of research.44-45 Liquid biopsies are 
advantageous because they are less invasive and can provide a systemic evaluation of cancer 
progression, which is invaluable for detecting disease onset, recurrence, and metastasis. Serum 
and plasma contain a few highly abundant proteins that can limit proteome coverage, thus 
reducing detection of potential cancer biomarkers and hampering analytical assay robustness.46 
Sample enrichment or depletion approaches can greatly improve assay sensitivity, reduce the 
dynamic range, and improve specificity by minimizing background interference.47-48 
Immunodepletion of the most abundant plasma proteins, such as albumin, transferrin, and 
immunoglobulins, is a commonly used approach to reduce low abundance analyte suppression, 
allowing their quantification.47, 49 Using an optimized method including both abundant protein 
depletion and peptide fractionation, Keshishian et al.50 were able to confidently detect an 
average of 4,600 proteins in each plasma sample (n = 16, FDR < 1.5%), with the identification 
of >300 candidate biomarkers. Another recent report demonstrates the ability of proteomics to 
quantify ~900 proteins in 500 patient plasma samples.51 While the depth achieved in these 
studies is impressive, multiple days of instrument time are required for each sample, which is 
not practical for clinical implementation. Proteomics analysis of 1,000 plasma samples, which is 
the largest cohort to date, introduced an automated, high-throughput sample-prep workflow52 
that was capable of quantifying >300 proteins in the cohort, demonstrating clinical applicability.53  
In order to use MS analysis for cancer biomarker evaluation in patients, a clinically 
relevant platform must be used that will have high throughput capability, sensitivity, 
reproducibility, and relative accuracy. Targeted analysis using multiple reaction monitoring 
(MRM) MS is poised as the ideal platform for implementation of protein clinical assays, because 
it is well established in clinical labs for small molecule quantification.54 Furthermore, absolute 
and accurate quantification of up to 400 tryptic peptides can be achieved using heavy stable-
isotope labeled standard peptide dilution (AQUA/SID) coupled to LC-MRM.32, 55-56 Efforts from 
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the CPTAC showed good reproducibility, sensitivity, and transferability of highly multiplexed 
peptide assays with interlaboratory (8 – 11 sites) CVs < 20% even for peptide concentrations in 
the low µg/ml range.57-58   
 
Protein Quantification using Peptide Immunoaffinity Enrichment  
Another method that has emerged for improving assay sensitivity is immunoaffinity 
enrichment at the peptide level, also called stable isotope standards and capture by anti-peptide 
antibodies (SISCAPA), which can be coupled to MALDI-TOF MS, LC-MRM, or LC-PRM for 
quantification.59-61 SISCAPA is automatable and has achieved low ng/ml to pg/ml quantification 
of proteins in plasma, which is competitive with current clinical ELISA assays.62-65 Furthermore, 
assay robustness has been demonstrated in an interlaboratory study.66 Immunoassays, the 
dominant platform for protein clinical assays, have many weaknesses that limit their specificity 
and sensitivity, including autoantibodies, anti-reagent interferences, and hook effect.67 
Quantification of serum thyroglobulin (Tg) is an excellent example of clinical implementation of 
an immunoMRM assay that overcame these analytical issues with traditional immunoassays.63 
Serum Tg is used as a tumor marker for thyroid carcinoma; however, up to 25% of patients 
produce Tg autoantibodies, which interfere with the immunoassay.68 The LLOQ for the MS 
assay now clinically available is ~0.2 ng/mL, which is comparable to the 0.1 ng/mL 
immunoassay, but without the antibody interference issues.  
MALDI-TOF MS is an attractive platform following peptide affinity enrichment due to 
rapid analysis capabilities (< 10 s per sample) enabling high-throughput analysis; also, because 
the resulting sample is highly pure, separation by liquid chromatography is often not 
necessary.69-70 A SISCAPA-MALDI-MS assay quantifying a peptide surrogate marker from 
Protein C Inhibitor in prostate cancer patient sera as a marker for disease recurrence was 
developed and shown to have CVs of <10% with an LOQ of 20.2 fmol (below endogenous 
levels), demonstrating the analytical robustness of the SISCAPA-MALDI MS platform for clinical 
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validation.70 Similarly, immuno-affinity enrichment and top-down MS analysis of intact proteins 
can be applied to reduce time requirements and variability introduced by sample digestion.71 
The entire process can be automated and a study from Oran et al. produced a workflow that 
could accurately quantify insulin-like growth factor (IGF1), a potential cancer biomarker, in 1,000 
patient serum samples.72-73 The entire process, from sample preparation to analysis was 
completed in ~9 hours with costs being the same or less than ELISA. These studies clearly 
demonstrate that MS-based diagnostic assays are ready for mainstream clinical 
implementation.   
 
Dissertation Overview  
 Despite the large amount of literature focused on biomarker discovery, there is a dearth 
of bona fide clinical biomarkers for cancer diagnostics; therefore, development of companion 
biomarker assays to support effective patient treatment and improved outcomes remains a high 
unmet need.74-77 The reasons for this discrepancy, insights into the causes, and discussion of 
possible solutions will be common themes explored throughout this dissertation and will be 
reviewed in-depth for specific topics, including multiple myeloma biomarkers. The studies in this 
dissertation aim to improve understanding of quantitative mass spectrometry platforms, provide 
new resources for cancer biomarker development, and demonstrate personalized assay 
development to monitor minimal residual disease in multiple myeloma patients (Figure 3). The 
following chapter begins with highly technical analytical research and with each progressive 
chapter building closer to clinical implementation. Together, the utility of quantitative proteomics 
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 to support translational cancer research with the end goal of improving patient care is 
demonstrated. 
 
Figure 3. Overview of Dissertation Studies. Each chapter builds in complexity and clinical 
relevance, with Chapter 2 being very MS technical, Chapter 3 analytical, and Chapter 4 clinical. 
14 
 
 
 
CHAPTER TWO 
 
COMPARISON OF QUANTITATIVE MASS SPECTROMETRY PLATFORMS FOR 
MONITORING KINASE ATP PROBE UPTAKE IN LUNG CANCER 
  
 
(Note to reader: This section has been published previously in Hoffman et al. Journal of 
Proteome Research doi: 10.1021/acs.jproteome.7b00329 and has been reproduced with 
permission from American Chemical Society copyright 2018. 
 
Introduction  
Lung Cancer Kinase Signaling and Inhibition 
Many cancers, e.g. lung adenocarcinomas, are driven by genetic and epigenetic 
abnormalities and a dysfunctional microenvironment, resulting in altered signal transduction 
pathways; these complex networks require phosphorylation profiling and other proteomics 
approaches to enable comprehensive examination.6, 78 Protein phosphorylation, through 
regulation of protein-protein interactions and enzyme activity levels, leads to changes to cellular 
phenotype in response to external cues.79-80 Because kinases modulate signaling events vital to 
cancer progression, including proliferation, motility, and cell survival, their activity is frequently 
altered in cancer cells.6, 80 Improvements in detection of these alterations have led to a 
renaissance in targeted therapy development, primarily kinase inhibitors (KIs), over the last 
decade. While dozens of newly approved inhibitors hold great promise in improving patient 
outcomes, the effectiveness of treatments relies largely on predictive biomarkers.81-82 Clinically 
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significant responses have been observed for targeted therapy in non-small cell lung cancer 
(NSCLC) patients harboring KI sensitizing mutations, such as Erlotinib treatment of EGFR 
(Figure 4) mutant tumors.83  However, 
drug resistance is eventually acquired 
through numerous mechanisms.84-85 
Therefore, quantification of kinase activity 
and changes in phosphorylation are 
necessary to identify effective biomarkers, 
elucidate drug resistance mechanisms, 
repurpose existing FDA approved drugs, 
and define new avenues for patient 
treatment. 
 
Activity Based Protein Profiling  
However, kinases present a 
challenge for global profiling methods, like 
proteomics. To overcome this, enrichment 
methods including activity-based protein profiling (ABPP) have emerged as useful approaches 
to identify active signaling pathways in model systems and patient tumors.29, 86-89 Activity-based 
protein profiling uses an ATP mimetic probe to desthiobiotinylate lysines near the active site in 
order to use avidin-biotin capture chemistry for enrichment.88 The chemical probe enriches all 
ATP-binding proteins, pulling down a large number of other enzyme classes, including those 
involved with metabolism and stress-response. While 100-200 kinases can be typically be 
observed in ABPP experiments of NSCLC cell line samples using data dependent acquisition 
LC-MS/MS, kinase peptides represent less than 10% of the total observed peptides and 
datasets may have large numbers of missing values for desthiobiotinylated kinase peptides. 
Figure 4. Schematic of EGFR Signaling Inhibition 
by Erlotinib. EGFR, a receptor tyrosine kinase, 
activates many oncogenic signaling cascades in 
response to ligand binding, like EGF, although EGFR 
mutations result in activation without ligand binding. 
Erlotinib, a specific EGFR inhibitor will block this 
signaling cascade and cause cancer regression and 
cell death in EGFR mutant lung cancer. 
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Therefore, this ABPP kinase model system serves as a microcosm of the general proteomics 
problems related to quantification of low abundance components of a complex mixture. Here, 
we quantify desthiobiotinylated kinase peptides amongst the complex background of higher 
abundance labeled peptides from all ATP-binding proteins using multiple approaches to 
compare sensitivity, reproducibility of detection, and quantification.   
 
Quantitative MS Platforms  
Multiplexed liquid chromatography-multiple reaction monitoring mass spectrometry (LC-
MRM or selected reaction monitoring, SRM) is a useful tool in translational cancer research, 
providing novel biological insights including drug resistance mechanisms, which can be used to 
examine tumor biology in situ or measure correlates in clinical trials.90-93 Using discovery 
datasets from LC-MS/MS with data-dependent acquisition (DDA), relevant targets are selected 
for LC-MRM analysis on a triple-quadrupole mass spectrometer. LC-MRM panels, consisting of 
specific precursor and fragment ion pairs, can be designed to quantify peptides from proteins 
involved in the same biological process or signaling network, resulting in pathway analysis.94 In 
order to interrogate perturbations resulting from promiscuous kinase inhibitors that cause 
diverse changes in signaling, scheduled, multiplexed LC-MRM panels have been developed to 
interrogate about half the kinome.29, 87 LC-MRM is the established method for quantitative 
proteomics, but the advent of novel hybrid mass spectrometers with high resolution and 
accurate mass measurement capabilities has led to the development of new quantitative 
approaches. Parallel reaction monitoring mass spectrometry (PRM) uses precursor selection to 
generate full-scan high resolution MS/MS spectra with mass measurement error for the 
fragment ions expected to be less than 10 ppm. LC-MRM using a triple-quadrupole instrument, 
on the other hand, uses comparatively low resolution mass filtering for both precursors and 
fragments (often widths of 0.7 Th), which can result in interference. LC-PRM has emerged as a 
powerful tool to profile cellular phenotypes using protein assay panels with similar capabilities to 
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LC-MRM that relies on high resolution accurate mass measurements to reduce or remove 
interference.95-98  
Building on improvements in instrumentation, a new acquisition strategy has been 
developed for LC-MS/MS: data-independent acquisition (DIA).99-101 Instead of attempting to 
isolate and fragment individual precursors (i.e. DDA), DIA samples all peptides across specified 
m/z windows sequentially selected to cover the desired mass range.100 The fundamental nature 
of DDA, which samples the most abundant ions in each scan, results in under-sampling as well 
as a decrease in repeated identification of lower abundance peptides; ultimately, the challenges 
of missing data will result in the reduction of sample number, negatively impacting precision. 
With DIA, under-sampling can be reduced, yielding more consistent and comprehensive peptide 
datasets leading to more effective quantification. The improvement in peptide quantification 
using DIA compared to DDA has been demonstrated.102-104 However, the resulting chimeric 
spectra are more challenging to interpret; therefore, specific software and a high-quality spectral 
library are necessary to determine peptide identifications.105 The goal is to achieve the precision 
of quantification expected for LC-MRM/PRM (shortened to MRM or PRM throughout the paper) 
approaches, while retaining the ability to detect and quantify other peptide by library matching or 
make novel discoveries using additional database search strategies. To compare the four 
methods described above (review Figure 2), quantification of low abundance 
desthiobiotinylated peptides from kinases in a complex mixture is evaluated in this study using 
cell line models of lung cancer treatment. The strengths and weaknesses of each platform are 
explored using a lung cancer cell line, H1993, treated with different multi-target kinase inhibitors 
to examine the ability to detect known drug targets (as positive controls) and changes in 
downstream signaling. 
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Materials and Methods 
Cell Culture and Lysis 
NCI-H1993 cells were obtained from the Moffitt Cancer Center Lung Cancer Center of 
Excellence Cell Line Core, where they have been authenticated with short tandem repeat 
analysis and routinely tested to certify that they are free of mycoplasma contamination. Cells 
were grown in RPMI-1640 media containing L-glutamine and HEPES (Gibco), supplemented 
with 10% fetal bovine serum (HyClone), 10 U/mL Penicillin/Streptomycin (Gibco), and 2.5 g/L 
glucose (Sigma).  Cells were grown to 70% confluence for about 24 hours, and then treated with 
DMSO, 200 nM BEZ-235, or 500 nM Crizotinib (Selleck Chemicals) for 24 hours before 
harvesting. Plates were washed twice with ice cold PBS containing 1 mM Sodium 
orthovanadate (Sigma) prior to scraping the cells off the culture dish in 600 µL of Pierce IP Lysis 
Buffer containing protease inhibitors (Thermo). Cell extracts were sonicated on ice and cleared 
by centrifugation at 18,000 x g for 20 minutes at 4° C prior to desalting using Zeba Spin 
Columns (Thermo).  The protein concentration in each lysate was determined using Bradford 
Assays (Coomassie Plus Protein Assay, Thermo).  
 
Activity-based Protein Profiling and MS Sample Preparation 
Cell lysates were labeled for activity-based protein profiling (ABPP) following the 
manufacturer’s recommendations for the Pierce Kinase Enrichment Kit with ActivX Probes 
(Thermo).88 Briefly, 1 mg of total protein from each desalted lysate was used in quadruplicate for 
each treatment condition.  Following incubation with 20 mM MnCl2 for 5 minutes, lysates from 
cells (from the vehicle controls described above) were treated with DMSO, Dasatinib, or 
Erlotinib (Selleck Chemicals) at a final concentration of 10 µM for 10 minutes. Lysates were then 
incubated with 10 µM desthiobiotin-ATP probe for an additional 10 minutes. All incubation steps 
were performed at room temperature. Labeled lysates were denatured in 5 M urea and 5 mM 
DTT for 30 minutes at 65° C, and then alkylated with 40 mM iodoacetamide (Sigma). Samples 
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were desalted again into a HEPES digestion buffer and digested overnight with 20 µg Trypsin 
(Worthington) at 37° C.  Digested lysates were incubated for 2 hours at room temperature with 
high-capacity streptavidin beads to enrich for desthiobiotinylated peptides. Beads were 
sequentially washed multiple times with lysis buffer, 1x PBS, and water; labeled peptides were 
eluted using aqueous 50% acetonitrile (ACN) with 0.1% TFA. Eluted peptides were vacuum 
concentrated (SpeedVac, Thermo) and reconstituted in 20 µL of A solvent (2% ACN with 0.1% 
formic acid) containing 1 fmol/µL Pierce Retention Time Calibrator (PRTC) standard peptides 
(Thermo). Samples were pooled to form two biological replicates to allow for multiple injections 
using different LC-MS acquisition methods (see Figure 5 for a simplified workflow diagram). 
Untreated H1993 cell line bulk ABPP sample was serially diluted into buffer (A solvent) 4 times 
to create the following dilution series: A is undiluted, B = 1:3, C = 1:12, D = 1:36, E = 1:108. 
PRTC standard peptides were spiked into each sample for a quality control metric.  
 
Mass Spectrometry Analysis 
LC Separation Methods. Kinase peptide selection for targeted analysis and LC-MRM 
were performed as previously described.29 All samples were separated by reversed phase 
nano-liquid chromatography (Dionex RSLC, Thermo) and analyzed by DDA, DIA with 
quantification using extracted ion chromatograms of peptide precursors (previously described as 
pSMART),102 PRM, and MRM. Each condition was analyzed with the four LC-MS methods a 
total of three times from two biological replicates. For DDA and PRM analysis, peptides were 
separated using a two-step gradient, ramping from 5 – 15% B solvent (90% ACN containing 
20 
  
Figure 5. Workflow Diagram of Sample Preparation for the Method Comparison Study. 
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0.1% formic acid) in 5 minutes, followed by a 90 minute linear gradient from 15 – 35% B Solvent 
in A solvent prepared as described above, on a C18 column 75 µM ID x 50 cm (Acclaim 
PepMap, Thermo). To be consistent with the gradient used to create the spectral library, 
peptides were separated using a gradient from 5 – 15% B over 5 minutes, then15 – 50% B 
solvent for the DIA experiment. Prior to MRM acquisition, peptides were separated on a 90 
minute gradient from 5 – 35% B solvent on a C18 column, 75 µM ID x 25 cm (Acclaim PepMap, 
Thermo).  
A different gradient was used for DDA and PRM compared to DIA, because the gradient 
was optimized specifically for desthiobiotinylated peptides after original datasets were acquired 
for the spectral library.  A longer column (50 cm) is used for discovery data acquisition on the Q 
Exactive, compared to the 25 cm column used for LC-MRM.  Because of this difference in 
column length, the starting amount of B solvent was decreased to improve hydrophilic peptide 
separation on the shorter column. 
 
MRM MS Method. MRM analysis was performed on a TSQ Quantiva (Thermo) with a 
capillary temperature of 275° C and a spray voltage of 2100 V.  The Q1 and Q3 resolution 
values were set to 0.4 and 0.7, respectively, with a dwell time of 10 ms per transition. A method 
containing 1,627 transitions corresponding to 409 desthiobiotin-labeled peptides was scheduled 
using iRT in Skyline.106-107 Variable retention time windows were used, with the center of the 
gradient utilizing 10 minute acquisition windows. Collision energy (CE) values were calculated 
using CE optimization equations empirically derived with previous datasets in Skyline.2   
DDA, pSMART/DIA, and PRM samples were analyzed using a Q-Exactive Plus MS with 
a capillary temperature of 250° C and spray voltage of 2400 V. A DDA “top 16” method with an 
isolation window of 2 Th around the precursor (0.5 Th offset) and 30 normalized collision energy 
value (NCE) were used. MS1 resolution was 70,000 and MS/MS resolution was 17,500, with ion 
accumulation times of 100 and 80 ms, respectively.  
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DIA was performed using the isolation list in using variable steps of 5, 8, and 10 m/z with 
a 1 m/z offset, covering the mass range from m/z 450 to m/z 1,332 in 7 cycles. The instrument 
performed MS1 scans with a resolution of 70,000 and ion accumulation time of 200 ms, followed 
by eighteen MS/MS scans at a resolution of 17,500 with an ion accumulation time of 80 ms, in 
each ~2.5 s cycle.  PRM analysis used the same kinase desthiobiotin-labeled peptide panel 
previously described for MRM; the scheduled PRM precursor list is shown in Appendix A. To 
reduce crowding, PRM retention time windows were set to 8 minutes around the expected 
precursor detection time. PRM analysis did not include MS1 data acquisition, and MS/MS 
resolution was 17,500 with a maximum accumulation time of 100 ms. DDA and DIA data are 
available through PRIDE108 and ProteomeXchange109; MRM and PRM data are available 
through Panorama.110 
 
Data Processing and Statistical Analysis 
Database Searching. The spectral library used for DIA analysis was generated using 
DDA files acquired on the same LC-MS/MS platform described, from many lung cancer cell 
lines. The spectral library was built using Proteome Discoverer 2.1 (Thermo) with the Percolator 
algorithm (q-value cut off = 0.01) following UniProt database searching using SEQUEST. DIA 
data files were analyzed using Pinnacle software (v. 1.0.42.0, OPTYS) to perform spectral 
matching and quantification. DDA LC-MS/MS analysis was carried out using Andromeda111 and 
MaxQuant112 for peptide identification and quantification searching data against human entries 
in UniProt  (downloaded December 2015) with the following dynamic modifications: methionine 
oxidation, cysteine carbamidomethylation (camC), and lysine desthiobiotinylation (+196.121178 
Da).  DDA and DIA datasets were searched again with Mascot using similar parameters to be 
compatible with PRIDE requirements.
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Data Processing in Skyline. Skyline was used for peak integration of all PRM and MRM 
data and DIA data used for the dilution series analysis.106 Spiked PRTC peptides and peptides 
from two metabolic proteins, ENOA_HUMAN and G3P_HUMAN, were assessed for retention 
time stability and ion signal consistency, respectively (Figure 6A, B). ENOA and G3P peptides 
were also used as a quality control for the sample processing and peptide enrichment. Peptides 
lacking peaks in the control samples (DMSO) were removed from the dataset.  Following 
manual evaluation of peak picking to eliminate incorrect assignments or transitions with 
interference, MRM data were exported from Skyline, with quantification by the sum of all 
transitions. The PRM Skyline document initially scanned for all b and y fragment ions from ion 3 
(i.e. b3 and y3) to the second to last ion in both series (i.e. b(n-2) and y(n-2), where n is the number 
of amino acids in the peptide). The document was then automatically refined to include only the 
Figure 6. Retention Time Stability and Ion Signal Consistency Assessed as Quality Control 
Metrics. (A) Pierce retention time calibrator (PRTC) peptides were monitored in each LC-MS run (5 
fmol/ injection) for retention time stability across the entire cohort.  (B) Peptides from ATP-utilizing 
metabolic proteins, ENOA and G3P, were quantified as a control for sample preparation and peptide 
enrichment consistency (n = 18). 
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top 5 ions for each peptide, favoring higher m/z fragment ions. Each peak was manually 
assessed and all transitions with an error greater than 10 ppm were removed.      
Raw peak area values for DDA and DIA datasets were processed to remove minor 
variability using iterative rank order normalization (IRON)113 implemented in Galaxy.114 Statistical 
analysis and data visual generation was performed using R programming in R Studio.115-116 The 
following R packages were used for data processing and visualization: ggplot2,117 dplyr,118 
reshape2,119 LSD,120 VennDiagram,121 and stringr.122  
In DIA and DDA datasets, all peptides with less than 3 values across the dataset (n = 18) or that 
were not seen in the control (DMSO) sample were removed. Peptides with a Pinnacle score 
less than 3, meaning inadequate MS/MS data (less than 4 fragment ions matched and ≤ 0.65 
MS/MS dot product score) for identification or poor MS1 ion signal insufficient for quantification 
(≤ 0.94 MS1 dot product score), were removed from DIA datasets. Retention time correlations 
were also used to remove outliers from the datasets. Concordance across quantitative analysis 
methods was assessed between peak areas for each data point (protein, peptide, treatment) 
computing Pearson’s correlation coefficient (R).   
 
Calculations for Analysis and Statistics. Relative quantification (without stable-isotope 
labeled standards) was performed by log2 transforming the peak areas and the calculating fold 
changes of inhibitor treatment compared to DMSO vehicle controls. If a peak area was missing 
in controls or deviated by more than 4x the average peak area across the control replicates, the 
DMSO peak area for a different technical replicate was used to calculate the fold change (5-
15% of peptides, depending on the dataset). Standard error (SE), 95% confidence intervals, and 
boxplot statistics were calculated for each drug treatment MRM, PRM, and DIA datasets. 
Significance between SE boxplots was determined using the Wilcoxon Rank-Sum Test for data 
that did not fit to a normal distribution. Significance of log2-fold change values was determined 
using the student’s one-tailed t-test when identifying proteins or peptides that are down-
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regulated in response to treatment (p < 0.05). To identify peptides that were differentially 
regulated (up or down), a two-tailed t-test was used. Forest plots show 95% confidence intervals 
for all peptides observed across MRM, PRM, and DIA that had a log2 fold change less than -1 
and a p-value ≤ 0.05 in at least one MS quantification platform. The dilution series dataset was 
filtered using a mean bias cutoff (observed versus expected peak area ratio compared to 
highest average peak area per peptide) of 100% and peak areas of < 1500 were removed.  
 
Pathway Enrichment Analysis 
To determine which biological processes were altered following 24 hour BEZ-235 
treatment, enrichment analysis using MetaCore GeneGO (Thomson Reuters) gene ontology123 
was performed using all protein/peptide pairs with a mean positive or negative fold change 
larger than 1.8 and a p-value ≤ 0.05 in each platform, analyzed separately or together. This 
information identified the top ten cellular processes impacted by BEZ-235 treatment, which 
could indicate potential biomarkers or drug resistance mechanisms. Proteins with changing 
ATP-uptake computed by both PRM and MRM datasets were used to generate a schematic 
representation of the altered signaling pathway, using MetaCore GeneGO pathway map creator 
to identify protein-protein interaction mechanisms. 
 
Results and Discussion 
To elucidate the strengths and weaknesses of different quantitative proteomics 
approaches in the context of low abundance peptides in a complex mixture, the MET amplified 
lung adenocarcinoma cell line, H1993, was used as a model system due to identification of 
many kinases and pY sites in a preliminary lung cancer cell line LC-MS/MS (DDA) screening.  
This study (Figure 5) examined the impact of each MS acquisition method from the raw data 
level to the biological insights drawn from downstream interpretation. Specifically, the global 
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data metrics (correlations, coverage, missingness, and precision), identification of potential drug 
targets, and elucidation of signaling changes in response to therapy are explored.  
 
Global Comparison of ATP-Uptake in Lung Cancer Cells in Response to Drug Treatment 
Dataset quality and general agreement were assessed by determining concordance 
between DDA, DIA, PRM, and MRM (Figure 7, 8). Following normalization (IRON), log2 
transformation and filtering for kinase peptides, a Pearson’s product-moment correlation (R) 
was calculated to confirm the consistency across datasets (Figure 7A, B). Each data point in 
the correlation plots (Figure 7D, E and Figure 8A, B) are specific to a peptide and treatment, 
resulting in up to 18 measurements for each peptide. The 903 measurements for kinase 
peptides observed by both DDA and DIA (Figure 8A) had a strong correlation (R = 0.92, p-
value < 0.001). PRM and MRM peak areas (Figure 8B) also strongly correlate (R = 0.8, p-value 
< 0.001). Distance from the regression line correlating LC retention times in the different 
experiments was used to eliminate outliers for data analysis moving forward. Outliers generally 
presented themselves as a cluster of points, which would correspond to the same peptide, 
resulting in removal of data for 6 peptides from the MRM and PRM datasets due to poor data 
quality (based on poor LC elution profiles and peak shapes, or fluctuating retention time). 
Reduced correlation in quantification using PRM and MRM datasets may be attributed to the 
use of different instrumentation (quadrupole-orbital ion trap vs. triple-quadrupole) and 
quantification was performed using potentially different sets and numbers of MS2 fragment ions.  
Across all four platforms, peptides from a total of 260 kinases were observed. The MRM 
and PRM panels consist of 264 kinases, with a large portion of those identifiable in the H1993 
cell line. DDA, DIA, PRM, and MRM were able to quantify 109, 132, 206, and 208 kinases, 
respectively, across the whole dataset (Figure 8C). A total of 73 kinases (28% of the total) were 
quantified across all four platforms. The DDA dataset had the fewest quantifiable kinases, 
although more were identified, not all were observed consistently enough for quantification. The  
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Figure 7. Comparison of Retention Time (RT) Correlation, Peak Areas, and Peptide Coverage 
across all Quantitative Methods. (A) Correlation plot of RTs from each identified peak per 
replicate, corresponding to a kinase peptide that was observed between both DDA and DIA (n = 
1,411) in cells or lysates treated with different kinase inhibitors. Correlation plot of average RTs per 
kinase peptide observed by both MRM and PRM (n = 228) is shown in (B). Each rectangle in (C) 
represents the presence of a quantifiable desthiobiotin labeled peptide across the four datasets. 
Comparison of peak areas for detected kinase peptides in DIA, MRM, PRM datasets (D-E).  In both 
panels, each point represents a specific peptide measurement in a single replicate and the 
marginal distribution of measurements across the log2 transformed peak areas or intensities is 
shown as histograms on the opposite axis.  R values are calculated for Pearson correlation. 
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Figure 8. Global Comparison of Detection of Desthiobiotinylated Peptides from Kinases Across 
Data Acquisition Approaches. Correlation between log2 transformed peak area or intensity values 
following IRON normalization for desthiobiotinylated kinase peptides detected in DDA and DIA LC-
MS/MS experiments (A). Comparison of peak areas for detected kinase peptides in LC-MRM and LC-
PRM datasets (B).  In both panels, each point represents a specific peptide measurement in a single 
replicate and the marginal distribution of measurements across the log2 transformed peak areas or 
intensities is shown as histograms on the opposite axis. R values are calculated for Pearson 
correlation and p-values < 0.001. Venn diagram (C) comparing the numbers of kinases detected and 
quantified by each method.  Assessment of kinase peptide detection and data missingness across 
platforms (D). Coverage is defined as the percentage of peptides quantified in each method compared 
to the total identified across all MS methods.  Missingness is the percentage of missing values for 
peptides detected with each method. Boxplots showing the distribution of standard errors for means of 
log2 fold-change ratios following drug treatment (E). Outliers were removed from the boxplots to retain 
scale. (**: p-value < 0.01, calculated using a paired t-test, compared to each other method). 
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21 kinases quantified by only DDA and DIA represent unique information gained from including 
the “discovery” aspect of an LC-MS/MS experiment. MRM and PRM acquisition methods, 
however, were able to quantify 97 unique kinases, which is an improvement on the discovery 
acquisition methods (DDA/DIA). Next, the coverage and consistency of measurement at the 
peptide level was assessed (Figure 8D). Out of the 409 peptides included in the MRM/PRM 
panels, 356 peptides were observed between MRM and PRM datasets. About 78% were 
observed in both (276 with MRM and 277 with PRM), each with their own set of unique peptides 
(Figure 7C). Of the peptides in the targeted panels, 130 and 112 were quantifiable by DDA and 
DIA, respectively. 286 peptides total were quantified by DIA, however, indicating that the DIA 
dataset included a higher number of peptides per protein. To assess reproducibility of peptide 
detection, missingness across samples for the set of observed peptides specific to each method 
was assessed. MRM and PRM both had less than 100 missing values for the whole set of 
kinase peptides (43 missing from MRM and 58 missing from PRM), representing less than 2% 
of the observed values. DIA dataset resulted in 884 missing values (17%), while DDA contained 
the most missing values: 987 (31%).  
The distribution of standard errors (SE) following log2 transformation and fold-change 
calculation (the final datasets for biological interpretation) were compared (Figure 8E). The SE 
was used to evaluate the precision of measurement in each dataset. PRM had the lowest 
average standard error, 0.122, which was significantly lower than the other three methods (p-
values ≤ 0.01). MRM acquisition resulted in an average SE of 0.132 and DIA’s was 0.143, 
although the difference was not significant. DDA was the poorest performer in this analysis, 
which was expected due to the larger number of missing data points for statistical calculations. 
Both DIA and DDA had increased variability of standard error values and more outliers, 
(removed from Figure 8E). MRM acquisition resulted in the lowest variability and fewest 
outliers. Larger SEs often resulted for peptides that were either increasing or decreasing in the 
dataset due to variability from biology and experimental preparation.   
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Results indicate strong agreement across datasets, showing the quality of all data 
acquisition and processing methods is sufficient for quantification and downstream analyses for 
a selected subset of labeled kinase peptides. Global results demonstrate that both MRM and 
PRM acquisition allow quantification of the largest numbers of peptides. DIA and DDA are still 
able to provide additional value through the identification of new kinases or desthiobiotinylation 
sites, with DIA showing improved coverage and fewer missing values than DDA. The kinases 
quantified by the discovery acquisition methods could be added to the MRM/PRM kinase panel. 
However, this leads to the main limitation to PRM and MRM: targeted MS/MS panels can only 
include a few hundred peptides due to MS acquisition speed limitations and the resolution of the 
chromatography. While data quality is improved by PRM and MRM, clear upper limits on the 
number of peptides and kinases should be considered when deciding which quantitative method 
to use. DIA can be used to maximize the number of proteins and peptides quantified, while 
reducing missingness and improving coverage compared to DDA. Even in the context of low 
abundance peptides amongst great complexity, its superiority to label-free DDA quantification is 
demonstrated. For targeted quantification, average and median SEs calculated from the MRM 
dataset were higher compared to PRM. This difference could result from noise and interfering 
ions due to the wider mass filtering compared to PRM high resolution data analysis. 
Additionally, PRM data from the orbital ion trap does not include the baseline, which could also 
impact measurement precision. 
 
Comparison of MS Quantification Methods for Determining Kinase Inhibitor Targets 
Kinome profiling using chemical proteomics has identified numerous kinases as off-
targets for selective KIs.124-125 Identification of all inhibitor-kinase interactions can identify drug 
repurposing opportunities in different cancer types and explain unintended side effects in 
patients.126 Therefore, we have selected a few KIs as a test case to compare the different data 
acquisition strategies.  H1993 cell lysates were treated with 10 µM Erlotinib, an EGFR inhibitor, 
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or Dasatinib, a SRC family-kinase inhibitor, prior to labeling with the desthiobiotinylating ATP-
probe (see workflow diagram, Figure 5). Erlotinib and Dasatinib molecular targets should have 
reduced ATP-pr0be uptake in treatment samples compared to lysates treated with vehicle 
(DMSO). Erlotinib and Dasatinib were selected as the model for method comparison because 
they are well characterized KIs.127 Because many kinase targets have been identified,128-130 the 
two KIs provide a known system to tease apart the differences between quantitative platforms. 
Only down-regulated peptides were included in the analysis because lysates, not live cells, were 
treated, resulting in inhibitors competing with the ATP-probe for the kinase domains. Any 
peptides that were increased upon lysate treatment may be artifacts, rather than biological 
feedback or therapeutic escape mechanisms. Artifacts may include ion suppression or a false 
increase in ATP-uptake by non-targeted kinases as a result of inhibitor treatment with a high 
concentration (10 µM) of promiscuous inhibitors, thus increasing the amount of unbound probe.  
MRM, PRM, and DIA identified a number of peptides corresponding to known kinase 
targets131 upon Erlotinib treatment, including EGFR (Figure 9A-C). PRM and MRM exhibited 
similar distribution of fold-changes and p-values, while down-regulated peptides quantified by 
DIA resulted in increased p-values because of higher variability in the measurements (Figure 
9A). MRM analysis resulted in 15 peptides corresponding to 12 kinases (log2-Fold-change ≤ -1, 
p-value ≤ 0.05) while PRM yielded 23 peptides with decreasing signal corresponding to 18 
kinases; the majority (11) of the kinases were shared between the two platforms (Figure 9B). 
While quantification using DIA resulted in fewer peptides (17) and kinases (11) with decreased 
ATP-uptake, the number of peptides per kinase was higher than either PRM or MRM, increasing 
confidence in these identifications and perhaps improving the confidence in the quantitative 
differences despite lower p-values at the peptide level. All kinases with significantly reduced 
ATP-uptake upon Erlotinib treatment (EGFR, EPHB4, ILK, MET, SLK, STK10, ULK3) have been 
previously identified as Erlotinib targets.124, 130  
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Dasatinib treatment resulted in a greater number of kinases (32 compared to 25 after 
Erlotinib treatment) with reduced ATP-uptake, which is consistent with expectation due to the 
larger number of known Dasatinib targets, shown in Figure 9D-F.127, 129, 132 Significantly 
decreased peptides from PRM analysis had lower p-values and higher negative fold-change 
values compared to MRM and DIA (Figure 9D).  Both MRM and PRM identified CSK as the 
kinase with the largest reduction in ATP-uptake (Figure 9E-F). Quantification in response to 
Dasatinib by MRM, PRM, and DIA showed a greater degree of correlation, although the DIA 
dataset had more missing values in peptides observed across all platforms. Nine kinases that 
are known Dasatinib targets (CSK, EGFR, EPHA2, FYN, ILK, LYN, M3K2, M3K4, and MLKL) 
were reduced in all analyses. Seventeen out of 32 kinases were common between PRM and 
MRM results. Kinases only reduced with statistical significance in PRM (BRAF and FER) had 
either poor peak quality in MRM or the p-value was not significant. Of note, 5 peptides that were 
observed to be significantly reduced in MRM quantification were completely missing from the 
Dasatinib post-treatment dataset in PRM analysis, even though they displayed strong signals in 
control samples. These included peptides from known Dasatinib targets: ABL1, CSK, ILK, and 
LYN. For the purpose of this analysis, imputation was not performed. When using PRM 
quantification, imputation could be necessary or peptides that are strongly differentially 
expressed in datasets (or not detected in one sample group) in order to fully evaluate the 
relevant biology.  
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Figure 9. Kinases downregulated by Erlotinib and Dasatinib across three quantitative 
platforms. Volcano plot (A) of average desthiobiotin-labeled peptide fold changes (n = 2-3) with 
statistical significance in H1993 cell lysate treatment with 10 µM Erlotinib. P-values were calculated 
using a two-tailed T-test. The cut off lines are at a p-value > 0.05 and a log2(FC) of ± 1. Overlap 
between the platforms is demonstrated (B), with the list of proteins down-regulated by all platforms 
listed on the lower right. Proteins in bold have been previously identified as Erlotinib molecular targets. 
The asterisk indicates that the peptide(s) identified are not unique to that protein. Proteins that had a 
log2(FC) ≤ -1 and a p-value ≤ 0.05 were included. Beneath each quantitative method name is the 
number of down-regulated proteins (bold) followed by the number of peptides. Desthiobiotin-labeled 
peptides down-regulated by Erlotinib treatment in at least two MS platforms (C) are shown grouped by 
kinase family. Points represent the average a log2(Fold Change) with bars indicating 95% confidence 
intervals. Panels D-F show similar analyses for H1993 cell lysates treated with 10 µM Dasatinib. 
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The peptides that were observed 
across all platforms and significantly 
decreased in at least one dataset 
demonstrate the consistency in quantification 
(Figure 9C, F). There was a greater degree 
of agreement in MRM and PRM results, with 
occasional conflicting data from DIA. The 
DIA dataset had the largest number of 
kinases that had not been previously 
identified as drug targets, perhaps indicating 
novel information, but also raising potential 
concerns related to false discovery rate. One 
advantage of DIA is that method scheduling 
is not required, which can be challenging 
with PRM and MRM quantification of large 
panels. For example, a DBT-peptide from 
STRAA_HUMAN indicated reduced ATP-
probe uptake (~50 fold decrease) in the 
DIA dataset, but not in MRM and PRM results. The peak quality and low mass measurement 
error of the DIA identification indicate that this is the correct peptide, revealing an incorrect 
retention time window in PRM and MRM methods that led to data loss for this peptide. DIA 
requires less upfront work for acquisition method programming and testing compared to PRM 
and MRM, but more effort on subsequent data analysis.   
Comparison of PRM and MRM Sensitivity. PRM and MRM each exhibited advantages 
and disadvantages in a peptide-specific manner. PRM provides improved sensitivity in 
quantification of peptides that have interfering ion signals in MRM due to comparatively low 
Figure 10. Comparison of LC-MRM and LC-PRM 
Quantification of Differences in a Modified 
Peptide Ion Signal due to Target Inhibition by 
Dasatinib and Erlotinib. Example peaks for a 
peptide from ILK are shown, which is a stronger 
target for Dasatinib compared to Erlotinib. 
Quantifiable peaks are present in LC-MRM data 
(A), but not LC-PRM (B). N.D. indicates not 
detected.  
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resolution of quadrupole mass selection (0.4 or 0.7 m/z resolution for the mass selection 
windows in Q1 and Q3). Larger peptides with more opportunity for fragment ion signal 
dispersion (i.e. signal splitting) do not perform as well in MRM when compared to PRM. With 
proper peptide and fragment ion selection for peptides 7 to 15 AA in length, results indicate that 
MRM has a superior lower limit of detection. Following lysate incubation with Erlotinib and 
Dasatinib, known targets were sometimes missing all together in post-treatment PRM datasets, 
while detectable in MRM. Figure 10 shows representative peaks for WQGNDIVVKVLK from 
ILK, a known target of both Erlotinib and Dasatinib. Patricelli et al.88 reported ILK IC50 values of 
1.1 µM and 0.24 µM for Erlotinib and Dasatinib, respectively. ABPP-LC-MRM quantification 
recapitulates that Dasatinib has increased potency against ILK compared to Erlotinib. MRM 
quantification (Figure 10A) showed a 6-fold decrease in ILK ATP-uptake upon Erlotinib 
treatment and an 11-fold decrease when treated with Dasatinib. PRM analysis (Figure 10B) of 
this ILK peptide had a quantifiable peak in the untreated sample, but no peak present following 
treatment with either inhibitor, indicating that ILK is a target for both, though the extent of 
inhibition cannot be determined. 
 
Reproducibility and Sensitivity Explored. Reproducibility was assessed for a dilution 
series spanning 3 orders of magnitude (Figure 11 A,B) to further investigate the lower limits of 
detection across quantitative platforms.  When examining the relationship between the 
coefficient of variation (CV) versus peptide response (peak area), MRM quantification 
maintained the majority (≥ 75%) of measurements below 20% CV across the largest range of 
ion signals, indication superior linear range for quantification compared to PRM and DIA (Figure 
11B).  A similar trend of increasing CVs as response decreases can be seen qualitatively for 
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both MRM and PRM, although less obvious for DIA quantification. MRM was able to detect 40 
peptides, 24 of which were reproducibly quantified (CV < 20%) in a sample with a dilution factor 
of 108.  Supporting previous results, PRM acquisition outperformed DIA, resulting in 
reproducible measurements for >50% down to a 0.0833 dilution (1:36), compared to <25% of 
DIA measurements.  While additional analytical experiments are necessary to confirm, results 
indicate that MRM has superior sensitivity compared to PRM and DIA.Multiplexed MRM assays 
can be developed in silico using LC-MS/MS discovery datasets, but without standard peptides 
for assay development and collision energy optimization, the MRM ion signal may not be 
optimized, negatively impacting sensitivity. Stable isotope-labeled standard (SIS) peptides can 
be used to characterize the targets for assay development (e.g. determine lower limits of 
detection and quantification) and spiked into each sample for absolute quantification.28 
However, the financial burden, reagent availability/stability (e.g. FMOC protected 
desthiobiotinyl-lysine for peptide synthesis is not available), and time requirements are not 
 
Figure 11. Reproducibility assessment of MRM, PRM, and DIA quantification of a dilution 
series. Peptides were serial diluted from 1x to 0.028x (or a 1 to 36 fold-dilution) and analyzed in 
triplicate by MRM, PRM, and DIA. All results are shown (A), with an observable inverse relationship 
between log2 peak area and CV. The dotted horizontal line indicates a 20% CV cut-off.  (B) The 
percentage of peptides that fall below the 20% CV cut-off across the three platforms is presented for 
each dilution.  
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always feasible, especially when targeting a panel of 400+ labeled peptides. PRM target panels, 
on the other hand, require minimal a priori knowledge other than LC-MS/MS. There should be 
no difference in fragmentation or retention time, because analysis is performed on the same 
instrument; PRM fragment ion selection and collision energy optimization are unnecessary, 
stream-lining implementation. The high-resolution accurate mass measurements (<10 ppm) 
afford improved confidence in peptide identification without spiked SIS peptides. However, cycle 
time due to ion accumulation and Fourier Transform mass spectrometry is a significant limitation 
for PRM, decreasing the number of peptides that can be monitored simultaneously. In order to 
achieve a minimum of 7 points across a 25 second peak with 100 ms for each mass analysis, 
only 35 precursors can be monitored during the same period in the experiment. If SIS peptides 
are used for absolute quantification, then only 17 peptides can be analyzed by PRM in any 
given scheduled elution time window. Triple quadrupole transition monitoring is quicker with 
dwell times as low as 5 ms per transition, which leads to higher multiplexing capability. If four 
transitions, on average, are monitored per precursor with 10 ms dwell times, then about 90 
Figure 12. PRM directs fragment ion selection for MRM assay development. Shown is an example 
of MRM method refinement using PRM for VQVAVKHLHIHTPLLDSERK from RIPK2. Fragment 
selection for MRM was created previously from ion trap MS/MS data and appears to be an incorrect 
match based on the error (-13.9 ppm) in the PRM data. Because all fragments are monitored by PRM, 
their selection can be changed to improve quantitation. Chromatograms were exported from Skyline. 
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peptides can be concurrently quantified. To compensate for this limitation, PRM scheduled time 
windows were reduced by ~50%. The ABPP PRM platform described here is at the limit of what 
can be monitored with this acquisition method during the most congested parts of the gradient 
(e.g. the elution periods with the highest peptide density); some peptide peaks found in the 
middle of the gradient contain fewer than 7 points. The MRM ABPP assay, on the other hand, 
can accommodate more than double the amount of peptides analyzed here. Additional assay 
content can then be included to increase kinome coverage as more kinases are observed in 
discovery datasets and determined to be relevant for cancer treatment. 
 
PRM to Improve MRM Assay Refinement. PRM is a useful tool for MRM assay 
refinement, especially when developing targeted assay panels from discovery datasets acquired 
using linear ion-trap fragmentation typical of linear ion trap-orbital ion trap hybrid instruments 
(e.g. LTQ-Orbitrap). The LC-MRM ABPP peptide panel was initially created by selecting the top 
fragments from linear ion-trap data. Once incorporating high resolution and accurate mass 
(HRAM) data (acquired on the Q Exactive Plus) into the spectral libraries, the top fragment ions 
changed and were more consistent with QqQ fragmentation. For some peptides, the top ions 
selected from the PRM experiment were not the same as the MRM transitions chosen from 
linear ion trap fragmentation data (Figure 12). In addition, a PRM error cut-off can be used to 
eliminate interfering transitions that were indistinguishable by ion trap MS/MS and MRM, which 
relies on deviations in transition ratios to observe interferences. PRM data was used to refine 
MRM transition selection and improve the ABPP-LC-MRM panel. 
 
 
 
 
 
39 
BEZ-235 Treatment Induces Cell Cycle and Autophagy Regulation Signaling Changes 
Kinome profiling with ABPP is a useful tool to identify perturbed signaling pathways in 
response to drug treatment. In this study, H1993 cells, not lysates (see workflow diagram, 
Figure 5) were treated with either Crizotinib, a Met inhibitor, or BEZ-235, which was originally 
marketed as a dual PI3K/MTOR inhibitor133 to improve MTOR inhibition by blocking AKT1 
reactivation through a PI3K feedback mechanism134-135 and later shown to be a potent inhibitor 
of ATM and DNA-PKcs.136 Because BEZ-235 targets multiple known pathways, it is expected to 
show quantifiable changes for comparison of MS acquisition methods. 
 
Impact of MS Acquisition Method on Biological Implications. To assess fold-changes 
quantified across MRM, PRM, and DIA, 95% confidence intervals for peptides shared across 
the three datasets (ERN1 and AKT1 peptides were included, although not observed in DIA 
Figure 13.  ABPP Comparing BEZ-235 Treatment to Controls Shows Signaling Changes 
Impacting Cell Cycle Regulation. Differentially regulated desthiobiotinylated peptides (A) have been 
selected by |log2(fold change)| > 1 in at least two MS  and grouped by kinase family.  Data points 
represent the average log2(Fold Change) with bars indicating 95% confidence intervals.  For pathway 
mapping, proteins in each dataset were selected based on peptide fold changes > 1.6 or <-1.6 
between control and BEZ-235 treatment.  The top ten statistically significant GeneGO process 
networks enriched across the three methods are shown for each MS dataset (B). Proteins used were 
filtered from each analysis separately (fold changes greater than 1.6 or less than -1.6), then combined 
for MetaCore GeneGO network analysis. 
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analysis) that had an average fold change in either direction of at least 1.8 (Figure 13A). 
Results indicate agreement between MRM and PRM identification of differentially regulated 
peptides, although the degree of change differed. DIA, on the other hand, showed little to no 
change or fold-change values in the opposite direction, compared to MRM and PRM for 7 
peptides (46%). In addition, the top list of differentially regulated proteins identified by DIA 
differed from MRM and PRM. Metacore GeneGO analysis was conducted to determine the 
biological significance of the disparate list of differentially regulated kinases following DIA 
quantification. Pathways regulated by BEZ-235 in H1993 cells are consistent between MRM and 
PRM results, but not DIA (Figure 13B). MRM and PRM shared 3 out of 10 of the most 
statistically significant GeneGO process networks, although at least half of the top ten process 
networks for each method involved cell cycle or autophagy. DIA, on the other hand, only had 2 
process networks in common with MRM and PRM, and no common pathway themes when 
examined alone. The networks identified were driven by proteins unique to the DIA dataset, 
including MET and EGFR. Initial analysis was carried out at the peptide level, without review at 
the protein level. EGFR and MET had many peptides quantified in the DIA dataset, and the 
majority were not statistically different following treatment. EGFR, for example, had only one of 
eleven detected peptides significantly decreasing and that peptide contained a missed cleavage 
(~50% of total ion signal) and at least two modification sites (K716 and K737). If all peptides 
were considered for a protein level comparison, these two proteins would not be included. This 
observation underscores the importance of extensively reviewing the peptide level data and 
rolling them up to the protein level to fully understand the biological relevance of the data. 
After removing proteins that had peptides with conflicting fold changes and lowering the 
cut off (fold-change of at least ± 1.6), the resulting enriched process networks from the DIA 
dataset had improved agreement between MRM and PRM (5/10 processes). However, 
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reduction in protein number pushed the FDR past the cutoff threshold of 0.05 (< 5% false 
positives), reducing confidence in the results. Overall, the lack of consistency compared to other 
methods and increased FDR indicate that gaining meaningful biological insights from kinome 
profiling using ABPP and DIA to elucidate signaling changes may be challenging, when 
compared to reaction monitoring strategies.  
 
 
Figure 14. Pathway Map Annotated with Detection and Quantification of Changes in 
Desthiobiotinylated Kinase Peptides in Response to BEZ-235 Treatment.  Schematic diagram of 
protein-protein interactions and downstream processes of a subset of kinases with differentially 
regulated probe labeling at 24 hours after BEZ-235 treatment. Proteins included had at least one 
peptide significantly increasing or decreasing (with an average fold-change > 1.6 or < -1.6and p-
values < 0.05 using student’s two tailed t-tests.  Known BEZ-235 targets (ATM, MTOR, PI3K) are 
indicated with the red inhibition arrow.  Proteins with red fill colors are increasing while those with blue 
fill colors are decreasing, and grey proteins are not detected in the dataset, but are included as known 
mediators of downstream signaling. The colored dots on the right of each protein indicate 
quantification results specific to each method, as indicated in the legend.  
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Ability to Cover Protein Network Connected to Known BEZ-235 Targets. To examine the 
ability for each method to detect changes in probe uptake across a biological network, Figure 
14 presents a schematic representation of kinases that had BEZ-235 induced differential kinase 
ATP-uptake by both PRM and MRM analysis and above the fold change cut-off in at least one 
of the two datasets (gray proteins were not observed). Relationships were curated using 
GeneGO Pathway Maps and interactions found in the literature.133, 136-138 Known targets, like 
MTOR and ATM, had decreased ATP-uptake when quantified by MRM; PLK1 and AKT1 also 
emerged as signaling hubs perturbed by BEZ-235 treatment. The signaling pathways perturbed 
by BEZ-235 inhibition block DNA damage response, proliferation, and cell cycle progression by 
disrupting regulation at multiple points, while increasing autophagy signaling through ULK1 and 
IRE1/ERN1. Detection of kinases was assessed in this diagram for all four MS acquisition 
methods. Only CSK, PLK1, and AURKA were significantly changing across all four datasets out 
of the 18 kinases in the diagram, representing the subset that was quantifiable by DDA. DIA 
analysis improved quantification with significant changes seen in ~48%, or 8, of the kinases. 
The majority of these were quantifiable by both MRM and PRM, with only 3 kinases calculated 
to have a significant change by only one quantitative method. 
 
Conclusions and Future Directions 
HRAM MS and MS/MS as well as improvements in bioinformatics have resulted in 
numerous possibilities for data acquisition. These platforms should be compared to evaluate 
their strengths and weaknesses for investigating biological questions. This study assessed the 
differences in relative quantification using four different MS/MS acquisition platforms: DDA, DIA, 
PRM, and MRM (Table 1). Specifically, we examine the ability to reproducibly quantify low 
abundance peptides in a complex mixture.  Activity-based protein profiling enrichment of 
kinases was used to examine drug target profiles and quantify downstream signaling events of 
clinically relevant KIs in human lung cancer cells. Consistent with other studies in the 
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literature86, ABPP is a valuable tool to identify kinase inhibitor targets and to understand 
downstream signaling changes.  DIA, PRM, and MRM effectively identified inhibitor-protein 
interactions that were consistent with the literature. Pathway enrichment for kinases significantly 
changing after BEZ-235 treatment demonstrated that both PRM and MRM quantification led to 
similar profiles of differentially regulated biological processes. PRM quantification yielded a 
slight improvement on reproducibility, which could be explained in part by the reduction in noise 
and interference compared to MRM. MRM quantification demonstrated superior sensitivity with 
shorter, doubly-charged peptides.  
DIA reduced missingness across the dataset and increased quantifiable kinase 
identifications compared to DDA, but quantification was inferior, in these datasets, to both MRM 
and PRM. Both DDA and DIA identified many kinases that were eliminated throughout data 
analysis because there were not enough observations for quantification or statistical analysis. In 
the future, we would like to examine the capability of different types of DIA methods, including 
massively parallel PRM and SWATH, which use MS2 quantification instead of the MS1 
quantification used in this study, and continue to improve data analysis workflows to quantify 
low abundance peptides, thus increasing our ability to gain biological insights into the 
mechanisms of cancer treatment. 
 
Recommendations Based on Study Results. 
 In summary, DIA improves quantification compared to traditional DDA, while not limiting 
observations to an a priori target list like MRM and PRM. These discovery acquisition methods 
are ideal when asking the question, “What proteins can be observed in these biological 
samples?’ rather than “How much do these proteins change in different conditions?” For 
quantification, MRM should be selected when quantifying larger panels or low abundance 
peptides that require the most sensitivity, while PRM is an excellent choice for targeted 
quantification of peptide panels with limited size and where the sample complexity leads to 
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interference that can only be eliminated with high resolution data acquisition. In addition, MRM 
reproducibility and sensitivity is improved with the use of stable isotope labeled peptides and 
PRM can be used to direct and refine transition selection, supporting MRM assay development.  
 
However, quantification of these kinase peptides in the absence of standards per 
peptide combined with reduced resolution likely increased the incidents of false hits. One caveat 
is that this cannot be assessed with this current data set. To assess each method’s FDR, 
validation experiments with another method, such as Western blot, are necessary.  In the case 
of low abundance peptides in a complex matrix, LC-PRM would be my method of choice. The 
many issues that plague LC-MS/MS, including ion suppression from matrix effects and reduced 
robustness of the nanoflow LC and autosampler, particularly in a shared resource setting, are 
compounded in LC-MRM analysis. Targeted MS does result in higher sensitivity, but it comes at 
a cost. Samples are being analyzed with a specific target list and are essentially blinded to the 
background. Typical metrics an investigator would use for LC-MS/MS QC and normalization are 
total TIC and reliance on the concept that most measurements will be unchanging and therefore 
strategies like IRON can be employed. With MRM, only specified targets are monitored, so 
there is no ability to determine the influence of the background within the sample. With PRM, 
the high resolution fragment ion data is extremely helpful for assessing if interference is present. 
Feature DDA DIA PRM MRM 
Depth ++++ +++ + + 
Throughput +++ ++++ + ++ 
Missingness + ++ +++ ++++ 
Resolution* ++++ ++++ +++ + 
Accuracy* +++ ++ ++++ + 
Precision* + ++ ++++ +++ 
Sensitivity* + ++ +++ ++++ 
A priori Knowledge + +++ +++ ++++ 
Data Analysis ++ ++++ ++ ++ 
Table 1. Summary of Characteristics across the Four Quantitative MS Methods: DDA, DIA, 
PRM, and MRM. 
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In the future it would be interesting to determine exactly much the HRAM measurements help to 
improve analytical characteristics of assays in a controlled experiment comparing MRM and 
PRM quantification with and without SIS peptides for each target. In summary, this study greatly 
improved my ability to identify which platform is most applicable in different scenarios. Lessons 
learned on the impact of LC-MS parameters on acquired data have been invaluable for 
assessing MS data quality to determine what is “believable”. Based on this method comparison 
study, LC-MRM was selected for targeted assay development to achieve the greatest degree of 
sensitivity and reproducibility and all quantification going forward was done using SIS peptides 
matched to each target analyte in every sample. 
The importance of kinase signaling to cancer progression and survival has been clearly 
demonstrated and oncogene addicted cancers rely heavily on these over-activated pathways. 
When cancer survival depends heavily on specific signaling, elucidating the important signaling 
hubs can be useful for identifying targetable nodes. While not shown here, this platform has 
been applied to non-small cell lung cancer tissue samples with the goal of profiling each patient 
tumor’s kinome to stratify patients for therapy selection based on kinase signatures. 
Development of lung cancer drug treatment models in cell lines is an important part of this 
process and signatures developed from these models will be applied to the patients to support 
personalized medicine. This approach could be valuable for identifying which patients will 
benefit from specific patients using information beyond the few genetic markers currently used. 
Combining proteomic information on kinase activity and expression with the mutation markers 
could dramatically improve patient response rates and survival. 
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CHAPTER THREE: 
 
QUANTITATIVE ASSAY DEVELOPMENT TARGETING RAS SIGNALING PROTEINS 
 
Introduction 
Ras-Driven Cancers 
Despite recent advances in cancer research and the development of new therapeutic 
options, patients with Ras-driven cancers continue to have limited treatment opportunities.  Up 
to 30% of all human cancers are driven by Ras mutations (K-Ras, N-Ras, or H-Ras),139-144 with 
K-Ras alterations representing about 86% of all Ras alterations. The different Ras forms are 
preferentially found in different types of tumors. Mutant K-Ras, for example, can be detected in  
36-45% of colorectal, 65-95% of pancreatic, and 20-25% of lung cancer,144 whereas N-Ras 
mutations are predominantly found in skin and hematological cancers140, 145-146. Of the three 
primary Ras proteins, 86% of cancer related alterations are found in K-Ras, Ras mutant cancers 
are often associated with an aggressive phenotype, leading to poor patient prognosis.147 In 
addition, other proteins involved in Ras signaling, including BRAF, PTEN, and MTOR can be 
mutated or have alterations impacting cancer initiation and progression.  
While Ras itself has proven undruggable thus far, interrogating other components of the 
Ras signaling pathway may lead to the identification of targetable signaling hubs, supporting the 
development of new therapies and companion biomarkers.148-150 For example, effector proteins, 
BRAF and PI3K are common across multiple cancer types.135, 151  Additionally, inhibition at 
multiple points in the Ras signaling pathway is often necessary to effectively treat patients.152-154 
Diverse resistance mechanisms, including feedback loop activation occur; therefore, it is 
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important to monitor as many Ras signaling related proteins both up and downstream of Ras to 
capture patient responses to therapy.135, 147, 155-157 In summary, therapeutic options in Ras-driven 
cancers are limited and a diverse population of Ras signaling phenotypes further complicate 
matching patient to effective therapies. Development of resources to study Ras signaling and 
quantify biological responses would support overcoming these obstacles in treating patients with 
Ras-driven cancers. 
 
LC-MRM Assay Panel Description 
Translation of protein “biomarkers” identified in cell line and animal models to the clinic 
remains a challenge in cancer research.  Analytical platforms for multiplexed measurement of 
proteins relevant to Ras-driven cancers would make a significant contribution to fill this area of 
unmet need, particularly if they are transferable from cell line models to tumor specimens 
obtained from patients.  Therefore, as part of the NCI RAS Initiative, we have developed a mass 
spectrometry assay panels for Ras signaling proteins, which measure both protein expression 
and levels of phosphorylation at specific, biologically-relevant sites (Figure 15). These proteins 
include Ras effector proteins, downstream signaling proteins, including important transcription 
factors, and upstream RTKs that increase Ras signaling.158 LC-MRM assays have been 
developed for 116 tryptic peptide targets with spiked stable isotope labeled internal standards 
(SIS) to measure expression of 30 different proteins in a single experiment from 1 µg of protein 
digest without prior enrichment.  Immobilized metal affinity chromatography (IMAC) 
phosphopeptide enrichment from 500 µg of protein digest prior to analysis is used to examine 
35 phosphorylation sites from 23 proteins relevant to Ras cancer biology using 49 peptide 
reporters. 
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Assays have been characterized following the Clinical Proteomic Tumor Analysis 
Consortium (CPTAC) guidelines for validation of target proteomics assay, with the end goal of 
sharing this resource with the research community.159-160 To demonstrate the utility of the assay 
to measure endogenous proteins, the multiplexed LC-MRM assays are applied to BRAF 
inhibitor treated melanoma and colorectal cancer cell lines, which is a well-characterized model 
system. This chapter will go through the characterization experiments (e.g. response curves, 
repeatability) and assay validation demonstrating that 30 RAS signaling proteins can be 
Figure 15. RAS Signaling Pathway Targets.  The schematic shows RAS signaling proteins included 
in the multiplexed LC-MRM panel in blue. Proteins important for the overall diagram but not in the 
assay are grey. Relevant phosphorylation sites or each protein are marked. 
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quantified in a single 80 minute LC-MRM experiment. Select examples of phosphopeptide 
quantification are also shown. 
 
Materials and Methods 
All plastic consumables, including tubes and tips, were acquired from Eppendorf. All 
chemicals and HPLC solvents used in the following experiments were purchased from Sigma-
Aldrich and Honeywell Burdick & Jackson, respectively, unless otherwise specified. 
 
Cell Culture and Lysis 
The background matrix digest used for analytical characterization experiments, including 
the reverse calibration curve and assay reproducibility, and the reference lysate used for 
validation of endogenous detection and for study QC, were grown, harvested, and stored by 
collaborators at the NCI Frederick National Lab (Matthew Holderfield and Gordon Whiteley), 
then had proteins extracted and concentrations determined by investigators at the Fred 
Hutchinson Cancer Research Center (Jeff Whiteaker and  Amanda Paulovich) as part of an 
inter-laboratory assay validation study. All cell lines used to prepare these samples are listed 
below in Tables 2 and 3. They were acquired from ATCC and grown according to the 
manufacturer’s recommendations. Cells were washed in D-PBS, harvested, and frozen as 
pellets. Cell pellets were lysed on ice in a urea lysis buffer containing 6 M Urea, 25 mM Tris pH 
8.0, 1 mM EDTA, 1 mM EGTA, 1% per phosphatase inhibitor (Sigma cocktail 1 and 2). Cell 
lysates were sonicated and cleared by centrifugation; lysate protein concentrations were 
determined by the BCA assay (Pierce). The lysates were then mixed as specified in the tables 
above, aliquots prepared, and stored at -80 oC until they were shipped to sites, including our 
lab, or digested as described in the next section. 
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Additional cell lines were analyzed for cell line screening experiments to illustrate the 
feasibility of peptide detection in whole cell lysates. Human cell lines H2122, H2444, AsPC-1,  
 
 
and BxPC-3 (ATCC) were grown in 1640 
RPMI media (Gibco) supplemented with 10% Fetal Bovine Serum (PEAK Serum) and antibiotics 
(Pen/Strep, Sigma) at 37 °C with 5%  
CO2. Cells were grown to ~80% confluence then detached from the plate by treating with 0.25% 
Trypsin with EDTA (Gibco). Trypsin was deactivated with cell culture media, and trypsinized 
cells were washed twice with PBS. During the final wash, cells were aliquoted into 1.5 
microcentrifuge (MCF) tubes (Eppendorf), PBS removed, and pellets stored at -80 °C. Cells 
were lysed using a denaturing buffer (9 M urea, 30 mM Ambic). Each lysate was sonicated 
three times (30 s, pulsed), then incubated on ice to prevent sample heating. Proteins were 
separated from other cell materials by centrifugation (18,000  x g) for 20 mins at 4 °C (Beckman 
Coulter, Microfuge 22R Centrifuge) and transferred to new tubes. Protein concentrations were 
determined using Coommassie Plus Protein Assay (Thermo). 
 
 Cell Lysate Relative contribution 
to the pooled lysate 
A375 1 
HCT116 1 
HT29 2 
MCF10A- KRAS 3 
SK-Mel-2 2 
BxPC-3 1 
Cell 
Lysate 
Relative contribution to the 
pooled lysate digest 
MCF10A-MT 5 
T47D 1.25 
CCRF-CEM 1 
COLO205 2 
COR-L23 2.5 
H2444 3 
H2122 3 
H1792 1.25 
HEPG2 2 
K-562 1.25 
NCI H226 3.75 
Table 2. Composition of Background Lysate 
Digest Matrix  
Table 3. Composition of Background 
Reference Lysate  
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In-Solution Trypsin Digestion 
 All samples digested for CPTAC analytical characterization experiments used the 
protocol described. The background matrix digestion was done by collaborators at Fred 
Hutchinson Cancer Research Center (Jeff Whiteaker, PhD), and the reference lysates were 
digested daily as required by assay characterization guidelines. Prepared reference lysates 
were thawed on ice. Lysates were diluted to 2 mg/mL in the urea buffer described above and 
separated into 500 µg aliquots in 2 mL MCF tubes. They were incubated with 16.5 µL of 0.5 M 
TCEP (Pierce), at 37 oC in a Thermomixer (Thermo) at 600 rpm for 30 min. Next, samples were 
alkylated with 36.5 µL of freshly prepared 0.5 M iodoacetamide (IAM) solution and incubated at 
RT in the dark for 30 min. Next, the urea concentration was reduced to 0.6 M by addition of 
1200 µL of 200 mM Tris, pH 8.0 to each tube. LysC (Wako) was added to achieve a 1:50 
enzyme-to-substrate ratio and digested while mixing at 600 rpm in the Thermomixer at 37 oC for 
2 h. Immediately following LysC incubation, trypsin was added to a 1:50 enzyme-to-substrate 
ratio and digested under the same conditions for 16 h. The digestion reaction was quenched by 
addition of 20% TFA to a final concentration of 1% TFA in preparation for sample clean-up. 
 Samples digested for the screening study using the H2122, H2444, AsPC-1, and BxPC-
3 cell lines were prepared according to the following protocol. Each sample was reduced with 2 
mM TCEP for 30 mins at 37 °C followed by alkylation with 20 mM IAM for 30 mins at room 
temperature in the dark. The samples were diluted with aqueous 30 mM ammonium bicarbonate 
to reduce the urea concentration to ≤ 1 M prior to adding 30 µg of trypsin (Worthington). 
Proteins were digested into peptides overnight at 37 °C. 
 
Protein Digest Sample Clean-Up 
 Any light or SIS peptides spiked into samples were added following digestion and prior 
to sample desalting. All sample clean-up was performed using HyperSep C18 cartridges 
(Thermo) to remove salts and other contaminants from the lysis and digestion, following the 
52 
manufacturer’s instructions. Briefly, the C18 packing material was activated with 100% 
acetonitrile, washed with HPLC water containing 0.1 % TFA, loaded with protein digest, washed 
3 times with additions of 1 mL water with 0.1% TFA, then peptides were eluted sequentially 
using aqueous 40%, 50%, and 55% ACN solutions with 0.1% TFA. Extracted peptide solutions 
were frozen at -80 °C overnight then lyophilized and stored at -80 °C as a dry powder until 
sample analysis. 
 
Synthetic Peptide Selection and Assay Assembly 
 Biologically Relevant and Technically Feasible Target Selection. Protein targets (n = 31) 
were selected by Frank McCormick’s research team and their colleagues (NCI RAS Initiative) 
due to their importance to RAS biology and/or difficulty in detection with current available 
reagents. Target peptides were selected based on empirical MS datasets. Publically available 
and in-house discovery LC-MS/MS datasets as well as previously developed LC-MRM assays 
were mined for evidence of peptide detection and prioritized based on their uniqueness to 
protein of interest, frequency or intensity of detection in mined datasets, length (ideally 7-20 
amino acids), charge state distribution (z = 2 preferable), and composition. In total, 117 peptides 
were selected as surrogate markers for 31 protein targets for multiplexed LC-MRM assay 
development (Table 4). If possible, at least four peptides were selected to monitor for each 
protein.  
 
Peptide Synthesis. All peptides used for this project were synthesized by New England 
Peptide (NEP), with a desired purity of >95% for use in quantitative assays. Each peptide was 
subjected to quality control (QC) testing. Purity was assessed by HPLC, identity by MS analysis, 
and the net concentration was determined by amino acid analysis (AAA).  
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Protein   Peptide 
AKT1 FFAGIVWQHVYEK 
AKT1 FYGAEIVSALDYLHSEK 
AKT1 RPHFPQFSYSASGTA 
AKT1 SLLSGLLK 
AKT1 TF(camC)GTPEYLAPEVLEDNDYGR 
AKT1S1 LNTSDFQK 
AKT2 EGISDGATMK 
AKT2 FYGAEIVSALEYLHSR 
AKT2 LLPPFKPQVTSEVDTR 
AKT2 SLLAGLLK 
AKT2 THFPQFSYSASIR 
AKT2 THFPQFSYSASIRE 
AKT3 DEVAHTLTESR 
AKT3 EGITDAATMK 
AKT3 FYGAEIVSALDYLHSGK 
AKT3 RPHFPQFSYSASGR 
AKT3 TDGSFIGYK 
ARAF DSGYYWEVPPSEVQLLK 
ARAF GLNQD(camC)(camC)VVYR 
ARAF IGTGSFGTVFR 
ARAF NLGYRDSGYYWEVPPSEVQLLK 
ARAF TQADELPA(camC)LLSAAR 
ARAF  VSQPTAEQAQAFK 
BRAF AGFQTEDFSLYA(camC)ASPK 
BRAF DSSDDWEIPDGQITVGQR 
BRAF GDGGSTTGLSATPPASLPGSLTNV
K 
BRAF GLIPE(camC)(camC)AVYR 
BRAF RDSSDDWEIPDGQITVGQR 
BRAF SNNIFLHEDLTVK 
CCND1  A(camC)QEQIEALLESSLR 
CCND1  AEET(camC)APSVSYFK 
CCND1  AYPDANLLNDR 
CCND1 FLSLEPVKK 
CCND1  VIK(camC)DPD(camC)LR 
CDH1 GLDARPEVTR 
CDH1 GQVPENEANVVITTLK 
CDH1 NDVAPTLMSVPR 
CDH1 NTGVISVVTTGLDR 
CDH1 TAYFSLDTR 
Protein   Peptide 
CDH2 GPFPQELVR 
CDH2 IDPVNGQITTIAVLDR 
CDH2 LNGDFAQLNLK 
CDH2 LSDPANWLK 
CDH2 SAAPHPGDIGDFINEGLK 
CTNNB1 RTSMGGTQQQFVEGVR 
CTNNB1 TSMGGTQQQFVEGVR 
EGFR GSHQISLDNPDYQQDFFPK 
EGFR GSTAENAEYLR 
EGFR IPLENLQIIR 
EGFR NLQEILHGAVR 
EGFR 
YSSDPTGALTEDSIDDTFLPVPEY 
INQSVPK 
EIF2A SDKSPDLAPTPAPQSTPR 
EIF2A SPDLAPTPAPQSTPR 
ERBB2 ELVSEFSR 
ERBB2 GIWIPDGENVK 
ERBB2 GTPTAENPEYLGLDVPV 
ERBB2 LLDIDETEYHADGGK 
ERBB3 ANDALQVLGLLFSLAR 
ERBB3 GDSAYHSQR 
ERBB3 LTFQLEPNPHTK 
ERBB3 SLEATDSAFDNPDYWHSR 
ERBB3 YLERGESIEPLDPSEK 
 
FOS APHPFGVPAPSAGAYSR 
FOS GSSSNEPSSDSLSSPTLLAL 
FOS LEFILAAHR 
FOS SALQTEIANLLK 
FOS TEPFDDFLFPASSR 
FOXO3  AVSMDNSNK 
FOXO3  AVSMDNSNKYTK 
GSK3B LLEYTPTAR 
GSK3B QTLPVIYVK 
GSK3B TPPEAIAL(camC)SR 
GSK3B TTSFAESCKPVQQPSAFGSMK 
GSK3B VIGNGSFGVVYQAK 
MAP2K1 IPEQILGK 
MAP2K1 ISELGAGNGGVVFK 
MAP2K1  VSHKPSGLVMAR 
MAP2K2 L(camC)DFGVSGQLIDSMANSFVG
TR 
Table 4. RAS Signaling Protein and Peptide Targets for LC-MRM Assay Panel 
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Table 4. 
Continued
Continued 
Protein   Peptide 
MAPK1  VADPDHDHTGFLTEYVATR 
MAPK14 HTDDEMTGYVATR 
MAPK3  ALDLLDR 
MAPK3 GQPFDVGPR 
MAPK3 IADPEHDHTGFLTEYVATR 
MAPK3  YLQSLPSK 
MAPK3  SQQLSNDHI(camC)YFLYQILR 
MAPK8 TAGTSFMMTPYVVTR 
MTOR  DLELAVPGTYDPNQPIIR 
MTOR IQSIAPSLQVITSK 
MTOR LFDAPEAPLPSR 
MTOR LTESLDFTDYASR 
MTOR  TDSYSAGQSVEILDGVELGEPAHK 
MTOR TGTTVPESIHSFIGDGLVKPEALNK 
MTOR  GTTVPESIHSFIGDGLVKPEALNKK 
MTOR TRTDSYSAGQSVEILDGVELGEPAHK 
MTOR  VLGLLGALDPYK 
PTEN  AQEALDFYGEVR 
PTEN  GVTIPSQR 
PTEN  IYNL(camC)AER 
PTEN  IYSSNSGPTR 
PTEN  NHLDYRPVALLFHK 
RAF1  DSSYYWEIEASEVMLSTR 
RAF1  GLQPE(camC)(camC)AVFR 
RAF1  GYASPDLSK 
RAF1  STSTPNVHMVSTTLPVDSR 
RAF1  VVDPTPEQFQAFR 
RASGRF1  LLYGEPPKSPR 
RASGRF1  NSLDYAK 
RASGRF1  SLELLFASGQNNK 
RPS6KA1  GFSFVATGLMEDDGKPR 
RPTOR  ALETIGANLQK 
RPTOR SLIVAGLGDGSIR 
RPTOR SYN(camC)TPVSSPR 
RPTOR  VLDTSSLTQSAPASPTNK 
RPTOR  VLNSIAYK 
STAT3 
FI(camC)VTPTT(camC)SNTIDLPMSP
R 
STAT3 Y(camC)RPESQEHPEADPGSAAPYLK 
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Matrix-assisted Laser Desorption Ionization Mass Spectrometry (MALDI-MS). MALDI-
MS (4700, Sciex) was used to examine synthetic and stable isotope-labeled peptides. An 
aliquot of each peptide (500 fmol) was deposited with α-cyano-4-hydroxycinnamic acid (10 
mg/ml in aqueous 60% ACN) on the MALDI target. Mass spectra were acquired in positive ion 
mode using laser power 2,400-3,000 arbitrary units (a.u.) to examine isotope incorporation and 
detect any incomplete amino acid coupling steps or failure to remove protecting groups. 
Tandem mass spectra were acquired using 3,600 a.u. laser power for sequence verification and 
identification of any contaminants. 
 
 Peptide Infusion for Assay Workup.  Electrospray ionization on a triple quadrupole mass 
spectrometer (TSQ Vantage or Quantiva, Thermo) interfaced with a nano-electrospray source, 
was used to analyze synthetic light and stable isotope-labeled peptides. Peptides were 
prepared as 1 µM solutions in aqueous 30% ACN with 0.1% FA and infused for one minute into 
the instrument at 0.300 µL/min. Mass spectra were acquired in positive ion mode using a spray 
voltage of 2,400 in order to determine charge state distribution and verify results from MALDI-
MS analysis. Product ion spectra were acquired in centroid mode with enough collision energy 
(CE) to fragment the parent ion to < 20% of the base peak observed in the spectrum. CE 
optimization was performed for fragment ions with m/z larger than the parent ion or the top five 
ion signals if not enough high m/z transitions were observed. CE optimization was performed at 
this point for some peptides. This experiment generated a list of CE values specific to each 
transition.  
 
Skyline Targeted Method Assembly and Refinement  
Automated Collision Energy Optimization and iRT. All data processing, targeted method 
editing, and method refinement were done using the open source software, Skyline.106, 161 We 
created a spectral library from LC-MS/MS data acquired on the QExactive Plus (Thermo) to use 
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in the Skyline document. Peptide retention times were mapped using Skyline’s iRT107 function, 
which takes “benchmark” peptide RTs from a standard mix and assigns each peptide a value 
between 0-100 as their assigned relative retention time. This way, any adjustment to scheduling 
windows could be adjusted by simply running the standard peptide mix. In this case, the Pierce 
Retention Time Calibrator peptide mix was used to generate relative RTs for the RAS peptide 
panel. In addition, CE optimization can be automated using Skyline.2 First, peptides were 
mapped to scheduled 6 to 8 min windows and an iRT library was generated. Once target 
scheduling was complete, high-throughput CE optimization was facilitated by Skyline to 
generate a collision energy library. In the end, the targeted assay Skyline document contains all 
resources necessary for targeted quantification. This repository includes a spectral library (as a 
reference for transition ratios/rankings), relative retention time database, and optimized 
transition CE library (per transition). The fragment ion spectrum (Figure 16A) and CE 
optimization (Figure 16B) for IPLENLQIIR from EGFR are provided as an example. 
 
LC-MRM Method Scheduling. Skyline also has a visualization tools to assist with 
multiplex analysis acquisition window scheduling (Figure 16C). The plot indicates how many 
transitions are being monitored concurrently at any RT across the gradient. The cut-off is 
determined by the speed of instrument acquisition, peak width, and quality of data desired. The 
TSQ Quantiva is capable of monitoring up to 800 concurrent transitions, but at the cost of data 
quality; either the number of points across the peak or sensitivity will be reduced. To avoid this, 
we selected 300 concurrent transitions as the maximum, which is specified by the dotted line. 
This cut off was determined using equations 1 and 2 for the following calculation: 
 
 
 
57 
Equation 1:  	

 
	
 =       
Equation 2: !"  = #$%&& '()% × +,(-./ 012,// +%34 
56 789 = 20 / ;  =>""  =  10 )/ ; 5	
 @	 56 ≥ 7   
 	

 
	
 = CDE 
 
The maximum number of transitions to acquire at least 7 points across a 20 ms peak with a 10 
ms dwell time is 286. Based on the Skyline scheduling plot, 8 min RT windows was selected for 
the multiplex LC-MRM method. Also, to further improve data quality and allow for RT 
fluctuations based on ambient temperature, windows were widened and dwell time increased for 
the most early and late eluting peptides.  
 
Standard Peptide Master Mix Formulation 
Quantitative assay grade peptide stocks (New England Peptide) were received as 1 mM 
solutions in aqueous 30% ACN and 0.1% FA, which solubilizes most peptides, and stored at -80 
oC. A few hydrophobic peptides were dissolved in other solvents, including DMSO and 
isopropanol, if they could not be dissolved in the standard buffer. Next, light (MM1) and heavy 
(MM2) “master mix” peptide stocks each containing 117 peptides were formulated and aliquots 
made for all characterization and validation experiments. Peptides were thawed on ice, vortexed 
and centrifuged, briefly before mixing equal amounts (60 µL) of each in a 15 mL conical tube 
(Falcon) to generate 8.55 µM solutions. The solutions were then diluted and mixed at a 1:1 ratio 
in aqueous 2% ACN, 0.1 % FA with 5 fmol/µL PRTC peptides and 25 fmol per peptide was 
areas were quantified and peptides with ratios deviating ± 20% from 1 were adjusted. This was 
necessary for < 15% of all peptides. The majority of these peptides had been previously flagged 
for solubility issues. Diluted solutions were also analyzed to verify that there was no cross 
contamination between injected for LC-MRM analysis to QC the solutions. Peak areas were
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Figure 16. Example of Skyline Process to Refine Targeted Method. Images exported from 
Skyline that show the spectra from LC-MS/MS data with matched peaks and their observed m/z 
values and ranking of fragment ions for automated method development (A). Collision energy 
optimization data is shown for IPLENLQIIR (B), with the optimal CE found at the apex of the peak 
found in the inset graph selected for fragmentation. This information is stored in a database that 
can be shared and used for all exported transition lists. Skyline allows visualization of the number 
of concurrent transitions monitored over time, based on specified scheduling windows (C). The 
dotted line is at 300 concurrent transitions, which is the maximum desired.   
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quantified and peptides with ratios deviating ± 20% from 1 were adjusted. This was necessary 
for < 15% of all peptides. The majority of these peptides had been previously flagged for 
solubility issues. Diluted solutions were also analyzed to verify that there was no cross 
contamination between the light and heavy mixes. After adjustments were made, the final 
master mix solutions (MM1 and MM2) contained a concentration of 8.011 µM per peptide and 
aliquots were made with a Repeater Pipette (Eppendorf). A small subset of peptides (Table 5) 
did not perform as well as the others. To ensure that there would be enough points at the low 
end of the response curves and to reduce variability of the standard spiked peptide for improved 
quantification, a supplemental peptide mix was made to increase their concentrations. 
Protein Peptide 
MM2 Fold 
Increase 
Poor 
Solubility 
(+/-) 
Acidic Other 
AKT1 FFAGIVWQHVYEK 10x + –   
AKT2 LLPPFKPQVTSEVDTR 2x – – Signal Splitting 
ARAF DSGYYWEVPPSEVQLLK 2x – +  
ARAF NLGYRDSGYYWEVPPSEVQLLK 2x – + Signal Splitting, Late RT 
CCND1 A(camC)QEQIEALLESSLR 2x – + Signal Splitting, Late RT 
CCND1 FLSLEPVKK 10x – – Signal Splitting, Early RT 
CDH2 SAAPHPGDIGDFINEGLK 10x – + Late RT 
EGFR GSHQISLDNPDYQQDFFPK 2x – +  
EGFR 
YSSDPTGALTEDSIDDTFLPVPEYINQSV
PK 
10x – + Purity <80% 
ERBB2 GTPTAENPEYLGLDVPV 2x – ++  
FOS GSSSNEPSSDSLSSPTLLAL 2x – ++ Purity < 80% 
MK01 SQQLSNDHI(camC)YFLYQILR 10x + – Purity < 90% 
MTOR TGTTVPESIHSFIGDGLVKPEALNKK 2x – – Signal Splitting 
 
 
Table 5. Peptides Requiring Higher Concentrations – MM1* and MM2*. 
60 
Liquid Chromatography –Multiple Reaction Monitoring Mass 
Spectrometry 
Peptides were separated by ultra-high pressure 
reverse phase liquid chromatography using nanoflow (300 
nL/min flow rate) on an Ultimate 3000 RSLCnano system 
(Dionex/Thermo).  
Beginning with the lowest concentration sample, 5 
to 6.5 µL injections were loaded onto a nano trap column 
(Acclaim PepMap, 100 µm ID x 2 cm length) packed with 5 
µm C18 particles with 100 Å pores. After peptides were 
loaded for 7.5 min using the loading buffer (aqueous 1.5% 
ACN, 0.1% FA), peptides were then separated on a C18 
analytical column (Acclaim PepMap RSLC, 75 µM ID x 25 cm length) packed with 2 µm 
particles with 100 Å pores using a 60 min gradient ramping described in Table 6, with B solvent 
(90% ACN, 0.1% FA) and A solvent (2% ACN, 0.1% FA). Following separation, peptides were 
analyzed by nanoelectrospray ionization (ESI) MRM-MS using 2,200 spray voltage into the ion 
transfer tube heated to 275 °C (TSQ Quantiva, Thermo). Transitions were monitored using a 
minimum of 10 ms scan time per transition (Appendix D). Q1 and Q3 mass resolutions were 
set to 0.4 and 0.7, respectively, around the specified precursor and fragment ion m/z value and 
the collision cell (q2) CID pressure was 2 mTorr (using Argon gas).  
 
LC-MRM Assay Characterization Experiments 
All characterization experiments were prepared and analyzed following the CPTAC 
guidelines previously outlined. Resulting assay metrics (e.g. LOD, LLOQ) were calculated 
following assay portal instructions.58, 160 Experiments were carried out to the quality necessary 
for submission to the NCI assay portal (assays.cancer.gov). 
Time 
(min) 
B Solvent (%) 
0 2 
7.5 2 
8.5 6.5 
50 26.5 
58 55 
58.5 90 
63 95 
64 2 
82 2 
Table 6. LC-MRM Gradient for 
RAS Protein Quantification 
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 Calibration Curve – CPTAC Experiment One. The background matrix digest (Table 4) 
was used for creating a reverse calibration curve. The eight-point response curve was prepared 
by diluting the SIS-peptide mix, MM2, with the supplemental peptide mix (MM2*) while spiking 
the light peptide mix, MM1 (with supplemental MM1*) at a constant amount added at the 
specified fold-changes listed in Table 5. The concentrations, all of which are given in fmol/µg 
digested protein, for each point at the 1x amount were: 1000, 200, 40, 8, 2, 0.5, 0.2, and 0.08 
fmol/µg and the light peptides were spiked in at the constant concentration of 10 fmol/µg. Each 
curve replicate was analyzed on a different day, for a total of three days. A 10x solution 
corresponding to each curve point was diluted from three different stock solution concentrations 
prepared independently of the calibration curve. The purpose of this approach was to avoid 
propagation of error introduced by serial dilution, also called regression bias, which has been 
shown to significantly impact clinical results if not minimized or corrected.162-164 Peptide mixes 
were diluted into background matrix to form the 10x points. The light peptide was spiked into the 
background matrix, aliquot and stored at -80 oC until analysis. Each day, an aliquot of the 10x 
stocks and background matrix with light spiked peptide were thawed, prepared, and added to 
individual autosampler vials. Blank samples were made by adding equivalent volumes of 
background. Blank samples were injected before and after each complete replicate curve 
analysis to determine the baseline noise measurement and sample carryover.  
 
 Mini-validation of Repeatability – CPTAC Experiment Two. Based on the LLOQ values 
determined by the first experiment, three concentrations spanning the working range of the 
assay were selected for high, medium, and low concentration samples. Because there are so 
many analytes in the panel (n = 117), concentrations were determined for the group of peptides 
as a whole, with the exception of the peptides in the supplemental master mixes (MM1*, MM2*). 
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Samples were analyzed by LC-MRM in triplicate each day for five days. The high, medium, and 
low sample concentrations were 100, 7.5, and 0.75 fmol/µg for the 1x peptides. High, medium, 
and low samples were injected in a random order, with injection of an extra blank when moving 
from a higher to a lower concentration sample. 
 
Reproducible Endogenous Target Detection.  Multiple aliquots (n = 5 – 6) of the same 
sample, the reference lysate (Table 4), were digested for five days following the digestion 
protocol described. The distinction between this approach and experiment two is that the 
reproducibility of the entire workflow, from digestion to analysis, is evaluated, whereas the 
reproducibility of the digestion is not a factor in experiment two. Samples were injected once 
and assay variability determined as described for experiment two. LC-MRM analysis also took 
place on separate days. Prior to sample clean up, 20 fmol of SIS peptides (MM2) with addition 
of the supplemental mix (MM2*) were added to the samples. Each replicate consisted of 
digesting 550 µg of the reference lysate. Prior to freezing and lyophilizing, 50 µg was separated 
and dried by vacuum centrifugation (SpeedVac, Thermo).  
 
Data Analysis and Statistical Calculations  
 LC-MRM Assay Characterization Data Analysis. For characterization experiments, the 
ratios between SIS and light peptides were calculated to generate the peptide response ratio. 
Using the ratios calculated from triplicate LC-MRM measurements, the average, standard 
deviation, and coefficient of variation (% CV) were calculated for each peptide amount. 
Standard error bars representing ± 1 standard deviation were added to each data point. Data 
points with a CV greater than 20% were removed from regression calculations. Assay linearity 
was determined by fitting r to a power equation (y = Axn), where n must fall between 0.95 and 
1.05. Alternatively, a linear regression with an R2 ≥ 0.995 was also considered linear. A CV (%) 
of greater than 20% was used to determine the assay’s lower limit of quantification (LLOQ).  
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Results from experiment two were used to determine the overall assay variability: intra-assay 
variability was calculated by determining the CV for the three replicates for each of the five 
days, inter-assay variability was calculated by determining the CV for each replicate across all 
five days (e.g. across all first injections, second injections, etc.), and the total assay variability 
was estimated using the sum of squares. 
 
 Analysis of Cell Line Screen. Cell line expression data was assessed manually to 
remove fragment ions or peptides that had poor peak shape or contained background 
interference. Results exported from Skyline, following manual interrogation, contained dot 
product ratios comparing the light and heavy fragment ions, peptide light to heavy ratios, along 
with light and heavy peak area values. Peptides that had a dot product ratio of less than 0.7 in 
all cell lines were removed from the dataset. Peptides that had at least 3 fragment ions with 
reproducible ion ratios were considered to be quantifiable, peptides where low abundance 
fragment ions dropped out and only 1 or 2 could be measured were labeled as detected, and 
the remaining were not detected.  
 
Statistical Summary and Calculations. All raw datasets were manually evaluated and 
processed in Skyline, then analyzed using R116 in R Studio.115 Data summary statistics and 
calculations utilized the R packages reshape,119 purrr,165 and dplyr,118 and graphs were 
generated using ggplot2.117 Datasets are uploaded to Panorama110 and will be made publically 
available on Panorama and the NCI Assay Portal (https://assays.cancer.gov) following 
publication. 
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Results and Discussion  
Development of an Optimized Multiplexed LC-MRM Assay Targeting a Panel of RAS Signaling 
Proteins 
 We have developed a multiplexed assay capable of quantifying expression of 30 
proteins relevant to RAS signaling by LC-MRM MS analysis targeting 117 surrogate peptide 
markers.166-167 For this assay, the standard in-solution trypsin digestion followed by SIS peptide 
spiked at a known concentration (Figure 17A) was used for absolute quantification, as 
described previously.28, 32, 36-37 LC-MRM method assembly and refinement tools available in 
Skyline were utilized to optimize numerous parameters, including analyte transition selection, 
retention time scheduling, and transition specific CE values. The chromatography parameters 
were also tuned to maximize separation of these specific peptide targets across the acquisition 
time and to optimize signal and reproducibility of early and late eluting peptides, which are 
known to be challenging for LC-MS analysis (Figure 17B). Tuning the LC-MRM assay to the 
specific targets improves the sensitivity and reproducibility of multiplexed quantification of 
proteins.  
CE optimization of such a large peptide panel with precursor mass to charge (m/z) 
values spanning from m/z 371.9 to m/z 1223.5 facilitated generation of customized CE 
regression equations that can be utilized for any future LC-MRM analyses on our TSQ Quantiva 
(Figure 18A).  In summary, automated CE optimization was performed for 694 transitions from 
145 precursors, which correspond to 107 peptides (Figure 18B). Ten peptides were added to 
the panel at a later time and had CEs optimized manually (described in Methods); therefore, 
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they were not included in generating the optimized equation. Additionally, the panel had a 
cohort of triply charged precursors (n = 47) of sufficient size to derive a greatly improved CE 
regression equation. Previous to this, the default equation provided for the Quantiva in Skyline 
was used, which was: y = 0.044x + 3.314 (Figure 18B), where x is the m/z value for the triply 
charged precursor. The default equation compared to empirically generated equation result in 
vastly different CEs, becoming more pronounced as the precursor m/z increases. For example, 
the precursor selected for the ARAF peptide, NLGYRDSGYYWEVPPSEVQLLK, is m/z 871.77 
for the triply protonated ion. The original equation results in a CE of 41.7 V compared to 26.1 V 
calculated from the derived equation, y = 0.0218x + 7.0893. This will create a completely 
different spectrum, with the increased CE over-fragmenting the peptide resulting in fewer high 
Figure 17. Workflow and Optimized Gradient for Multiplexed LC-MRM Quantification of RAS 
Proteins. (A) The assay workflow for absolute quantification using SIS peptide dilution into tryptic 
digest followed by LC-MRM on the TSQ Quantiva (Thermo). Peptide separation has been optimized 
with strong signal maintained at both the beginning and end of the elution profile, which can be seen 
on the TIC exported from Skyline (B). 
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m/z fragments and more small fragments, which is undesirable. Accurate CE prediction is 
necessary for initial assay assembly as this can impact which charge state and fragments will 
be monitored for the peptide. If incorrect, the selection of inferior precursor and fragments with a 
predicted CE that deviates substantially from the optimized CE will negatively impact the assay 
sensitivity for downstream applications.  
 
RAS Signaling Protein Assay Characterization 
 The optimized method for multiplexed LC-MRM monitoring of the 117 peptides was used 
for analytical characterization as described in the Methods section above. All assay metrics, 
including linearity, sensitivity, and precision, are reported for each individual peptide, but the 
experiments and LC-MRM analysis are carried out with the multiplexed method for use as a 
Figure 18. Collision Energy Optimization on Peptides from RAS Panel Generates Improved CE 
Predictions. The cohort of peptide surrogates from the RAS protein panel (n = 107), which spanned a 
range from m/z 371.87 to m/z 1223.55, had CEs optimized by the automated tools built into Skyline.2 
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single quantitative assay. Downstream users of the assay will be able to use each assay 
individually or as a single assay depending on their purpose.  
 
Experiment 1 – Response Curve. The first experiment of the assay characterization 
consisted of a reverse response curve, which had eight points covering more than four orders of 
Figure 19. Response Curves for All AKT1 Peptides. Representative data (A) are shown for the 
reverse response curves for the five peptide surrogate markers selected for quantification of AKT1. 
The table below contains the summary results from assay characterization experiment one. Example 
extracted ion chromatograms exported from Skyline of the light (left) at 10 fmol/µg and the LLOQ 
(right) at 80 amol/µg. The x and y axes are in log scale and each point consists of the mean with ± SD 
for error bars (n = 3). 
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magnitude (80 amol/µg to 1000 fmol/µg) with the SIS peptide varying and the light peptide 
spiked in at a constant amount. A pooled cell line protein digest was used as the background 
matrix, which served two purposes: to mimic the matrix of unknown samples (e.g. cell lines and 
ultimately tumor tissues) where the assay will be implemented and as a carrier for the peptides 
to prevent loss via non-specific binding to plastics. The linear dynamic range, lower limit of 
quantification, and lower limit of detection for each peptide were evaluated for each peptide. 
After filtering out curve points that had CVs ≥ 20%, linear regression models and R2 values were 
calculated (Table 7). Overall, sub-femtomole per microgram of protein LLOQs were achieved 
across nearly five orders of magnitude. Representative response curves for all AKT1 peptides 
and corresponding summary results are provided; the resulting LLOQs are from 0.8 fmol/µg to 
80 amol/µg (Figure 19A). SLLSGLLK had the most impressive sensitivity (Figure 19B) and 
because signal was detectable to the lowest curve concentration, it is likely a lower LLOQ could 
be achieved. The example EICs demonstrates that even at the LLOQ concentration of 80 amol/ 
µg, the relationship between the three monitored fragment ions is maintained with negligible 
interference from background noise.   
Table 7. Complete Peptide Summary Results from Response Curves 
 
Protein Peptide m y-int R2 
Points 
(n) 
AKT1 FFAGIVWQHVYEK 1.546 0.011 0.9999 9 
AKT1 FYGAEIVSALDYLHSEK 1.175 0.210 0.9994 8 
AKT1 RPHFPQFSYSASGTA 1.219 0.330 0.9996 8 
AKT1 SLLSGLLK 0.854 -0.009 1.0000 8 
AKT1 TF[camC]GTPEYLAPEVLEDNDYGR 1.014 0.282 0.9995 7 
AKT2 EGISDGATMK 0.862 0.196 0.9999 8 
AKT2 FYGAEIVSALEYLHSR 1.118 0.051 0.9996 6 
AKT2 LLPPFKPQVTSEVDTR 1.095 0.060 1.0000 8 
AKT2 SLLAGLLK 0.884 0.018 1.0000 8 
AKT2 THFPQFSYSASIR 0.960 0.271 0.9995 8 
AKT2 THFPQFSYSASIRE 1.145 0.343 0.9989 9 
AKT3 DEVAHTLTESR 1.253 0.151 1.0000 8 
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Table 7. Continued 
Protein Peptide m y-int R2 
Points 
(n) 
AKT3 EGITDAATMK 0.791 0.234 0.9999 8 
AKT3 FYGAEIVSALDYLHSGK 1.152 0.017 0.9998 8 
AKT3 RPHFPQFSYSASGR 0.890 0.289 0.9997 8 
AKT3 RPHFPQFSYSASGRE 0.730 0.087 1.0000 8 
AKT3 TDGSFIGYK 0.907 0.217 0.9999 8 
AKTS1 LNTSDFQK 0.896 0.796 0.9976 8 
      
ARAF DSGYYWEVPPSEVQLLK 1.193 0.292 0.9993 8 
ARAF GLNQD[camC][camC]VVYR 0.970 0.119 1.0000 8 
ARAF IGTGSFGTVFR 0.949 -0.060 0.9999 8 
ARAF NLGYRDSGYYWEVPPSEVQLLK 0.877 0.482 0.9980 8 
ARAF TQADELPA[camC]LLSAAR 1.285 0.281 0.9995 9 
ARAF VSQPTAEQAQAFK 1.165 0.115 1.0000 9 
BRAF AGFQTEDFSLYA[camC]ASPK 1.022 0.366 0.9992 7 
BRAF GDGGSTTGLSATPPASLPGSLTNVK 0.954 1.071 0.9980 5 
BRAF GLIPE[camC][camC]AVYR 1.080 0.074 1.0000 8 
BRAF RDSSDDWEIPDGQITVGQR 1.055 0.232 0.9996 8 
BRAF SNNIFLHEDLTVK 0.883 0.126 0.9999 7 
CADH1 GLDARPEVTR 1.048 0.283 0.9998 8 
CADH1 GQVPENEANVVITTLK 0.961 0.260 0.9998 6 
CADH1 NDVAPTLMSVPR 0.747 -0.025 0.9999 9 
CADH1 NTGVISVVTTGLDR 2.102 0.730 0.9997 9 
CADH1 TAYFSLDTR 1.178 0.227 0.9999 8 
CADH2 GPFPQELVR 0.992 0.138 1.0000 9 
CADH2 IDPVNGQITTIAVLDR 0.777 -0.118 0.9999 5 
CADH2 LNGDFAQLNLK 0.993 0.041 1.0000 8 
CADH2 LSDPANWLK 1.009 0.046 1.0000 8 
CADH2 SAAPHPGDIGDFINEGLK 1.407 -0.222 1.0000 8 
CCND1 A[camC]QEQIEALLESSLR 0.932 0.212 0.9993 8 
CCND1 AEET[camC]APSVSYFK 0.886 0.004 1.0000 7 
CCND1 AYPDANLLNDR 0.778 0.343 0.9996 7 
CCND1 FLSLEPVKK 1.028 0.057 1.0000 8 
CCND1 VIK[camC]DPD[camC]LR 0.799 0.193 0.9999 8 
CTNB1 RTSMGGTQQQFVEGVR 0.718 0.039 1.0000 8 
CTNB1 TSMGGTQQQFVEGVR 0.692 -0.021 0.9999 9 
EGFR GSHQISLDNPDYQQDFFPK 0.925 0.085 0.9999 8 
EGFR GSTAENAEYLR 0.854 0.152 0.9999 9 
EGFR IPLENLQIIR 1.007 0.016 1.0000 8 
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Table 7. Continued 
Protein Peptide m y-int R2 
Points 
(n) 
EGFR NLQEILHGAVR 1.014 0.051 1.0000 7 
EGFR YSSDPTGALTEDSIDDTFLPVPEYINQSVPK 1.389 0.660 0.9960 9 
EIF2A SDKSPDLAPTPAPQSTPR 0.986 0.171 0.9999 8 
EIF2A SPDLAPTPAPQSTPR 0.922 0.095 1.0000 8 
ERBB2 ELVSEFSR 0.824 0.108 1.0000 9 
ERBB2 GIWIPDGENVK 1.232 0.052 1.0000 8 
ERBB2 GTPTAENPEYLGLDVPV 1.021 0.206 0.9998 6 
ERBB2 LLDIDETEYHADGGK 1.147 -0.150 0.9999 6 
ERBB3 ANDALQVLGLLFSLAR 2.763 -2.083 0.9993 6 
ERBB3 GDSAYHSQR 1.016 0.025 1.0000 7 
ERBB3 LTFQLEPNPHTK 1.107 0.053 1.0000 8 
ERBB3 SLEATDSAFDNPDYWHSR 1.106 -0.050 1.0000 9 
ERBB3 YLERGESIEPLDPSEK 0.885 -0.056 0.9999 9 
FOS APHPFGVPAPSAGAYSR 0.947 -0.081 0.9999 9 
FOS GSSSNEPSSDSLSSPTLLAL 0.823 0.359 0.9992 6 
FOS LEFILAAHR 1.042 0.169 0.9999 8 
FOS SALQTEIANLLK 0.545 3.981 0.9697 4 
FOS TEPFDDFLFPASSR 1.056 0.256 0.9996 7 
FOXO3 AVSMDNSNK 0.669 0.510 0.9993 6 
FOXO3 AVSMDNSNKYTK 0.784 0.554 0.9987 8 
GSK3B LLEYTPTAR 0.900 0.174 1.0000 7 
GSK3B QTLPVIYVK 0.894 0.189 1.0000 6 
GSK3B TPPEAIAL[camC]SR 0.889 0.125 1.0000 8 
GSK3B TTSFAES[camC]KPVQQPSAFGSMK 0.993 -0.020 1.0000 7 
GSK3B VIGNGSFGVVYQAK 0.928 0.088 0.9999 9 
KS6A1 GFSFVATGLMEDDGKPR 0.811 0.306 0.9992 8 
MK01 VADPDHDHTGFLTEYVATR 0.955 0.186 0.9998 8 
MK03 ALDLLDR 0.919 0.342 0.9999 7 
MK03 GQPFDVGPR 1.126 0.233 0.9999 9 
MK03 IADPEHDHTGFLTEYVATR 1.068 0.481 0.9993 7 
MK03 NYLQSLPSK 1.057 0.169 0.9999 8 
MK03 SQQLSNDHI[camC]YFLYQILR 0.680 -0.271 0.9964 2 
MK08 TAGTSFMMTPYVVTR 1.063 0.068 1.0000 8 
MK14 HTDDEMTGYVATR 0.818 0.094 1.0000 6 
MP2K1 IPEQILGK 0.888 0.224 0.9999 7 
MP2K1 ISELGAGNGGVVFK 0.741 0.282 0.9993 9 
MP2K1 L[camC]DFGVSGQLIDSMANSFVGTR 1.175 1.972 0.9959 5 
MP2K1 VSHKPSGLVMAR 1.020 0.226 0.9999 8 
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Table 7. Continued 
Protein Peptide m y-int R2 
Points 
(n) 
MTOR DLELAVPGTYDPNQPIIR 1.232 0.265 0.9994 8 
MTOR IQSIAPSLQVITSK 0.823 0.024 1.0000 8 
MTOR LFDAPEAPLPSR 0.958 0.002 1.0000 8 
MTOR LTESLDFTDYASR 0.824 0.187 0.9995 8 
MTOR TDSYSAGQSVEILDGVELGEPAHK 1.072 0.199 0.9997 8 
MTOR TGTTVPESIHSFIGDGLVKPEALNK 1.200 -0.040 1.0000 9 
MTOR TGTTVPESIHSFIGDGLVKPEALNKK 0.944 0.046 0.9999 9 
MTOR TRTDSYSAGQSVEILDGVELGEPAHK 0.992 0.099 0.9998 8 
MTOR VLGLLGALDPYK 1.301 0.198 0.9996 8 
PTEN AQEALDFYGEVR 1.057 0.254 0.9994 9 
PTEN GVTIPSQR 0.851 0.150 0.9999 8 
PTEN IYNL[camC]AER 0.856 0.171 0.9999 8 
PTEN IYSSNSGPTR 0.758 0.165 0.9999 7 
PTEN NHLDYRPVALLFHK 0.975 0.098 1.0000 7 
RAF1 DSSYYWEIEASEVMLSTR 0.613 -0.135 0.9996 5 
RAF1 GLQPE[camC][camC]AVFR 1.168 0.066 1.0000 9 
RAF1 GYASPDLSK 0.816 0.143 0.9999 9 
RAF1 STSTPNVHMVSTTLPVDSR 0.939 -0.008 1.0000 8 
RAF1 VVDPTPEQFQAFR 1.134 0.176 0.9999 7 
RGRF1 LLYGEPPKSPR 0.946 0.283 0.9999 6 
RGRF1 NSLDYAK 0.793 0.201 0.9999 8 
RGRF1 SLELLFASGQNNK 0.932 0.095 0.9999 8 
RPTOR ALETIGANLQK 0.999 0.138 1.0000 9 
RPTOR SLIVAGLGDGSIR 0.876 0.045 1.0000 8 
RPTOR SYN[camC]TPVSSPR 0.800 0.175 0.9999 8 
RPTOR VLDTSSLTQSAPASPTNK 1.028 -0.024 1.0000 8 
RPTOR VLNSIAYK 0.808 0.250 0.9997 9 
STAT3 FI[camC]VTPTT[camC]SNTIDLPMSPR 0.916 0.215 0.9997 7 
STAT3 Y[camC]RPESQEHPEADPGSAAPYLK 1.126 0.049 1.0000 9 
 
Experiment 2 – Mini-Validation of Assay Repeatability of LC-MRM RAS Assay Panel.  
Next, we examined the assay variability both within day, or intra-assay, and between 
day, or inter-assay, and used that information to estimate the total assay variability. Because 
this is a “mini” validation of repeat replicates for 5 days and not the traditional 20-25 days for full 
assay validation, these results are estimates of the actual assay variability. This analysis was 
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carried out at three different concentrations which were selected based on results from the 
response curves. Because all the peptides are contained in one mixture, plus the supplemental 
mix for peptides with lower signal, the values selected for the low, medium, and high 
concentrations are shared amongst all peptides in their respective groups (Table 8). The 
following concentrations were used for the low, medium, and high points for the “1x” amount: 
0.75, 7.5, and 100 fmol/µg.  The high value was kept relatively low compared to the response 
curve because it is expected that most of the responses for endogenous analytes will not be 
higher without sample enrichment. 
 
Representative results demonstrate strong agreement between the repeat injections 
(triplicate measurements for 5 days, termed a 5 x 3 validation) of all concentrations from the five 
AKT1 peptides (Figure 20). The boxplots for each concentration per peptide have very small 
interquartile ranges, consistent with the calculated intra- and inter- assay CVs. All peptides had 
Peptide Group SIS Spike 
(fmol/ µg) 
Avg 
Intra CV 
(%) 
Avg 
Inter CV 
(%) 
Total 
Assay CV 
(%) 
FFAGIVWQHVYEK Low 7.5 2.79 5.92 6.54 
FFAGIVWQHVYEK Med 75 1.43 3.07 3.39 
FFAGIVWQHVYEK High 1000 1.08 3.06 3.24 
FYGAEIVSALDYLHSEK Low 0.75 8.15 14.21 16.38 
FYGAEIVSALDYLHSEK Med 7.5 4.19 10.83 11.61 
FYGAEIVSALDYLHSEK High 100 2.88 4.36 5.23 
RPHFPQFSYSASGTA Low 0.75 6.54 6.73 9.39 
RPHFPQFSYSASGTA Med 7.5 5.75 6.39 8.60 
RPHFPQFSYSASGTA High 100 2.83 4.33 5.18 
SLLSGLLK Low 0.75 2.35 4.16 4.78 
SLLSGLLK Med 7.5 2.59 3.30 4.19 
SLLSGLLK High 100 1.69 3.13 3.56 
TF[camC]GTPEYLAPEVLEDNDYGR Low 0.75 13.21 10.97 17.17 
TF[camC]GTPEYLAPEVLEDNDYGR Med 7.5 3.26 6.93 7.66 
TF[camC]GTPEYLAPEVLEDNDYGR High 100 1.96 5.23 5.59 
Table 8. LC-MRM Assay Variability Summary for AKT1 Peptides. 
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a total CV (calculated by the sum of squares) below 20%, which is the cut off for validation of the 
Figure 20. Mini-Validation of Repeatability Results for AKT1 Target Peptides. Representative 
results from the mini-validation experiment are displayed. The boxplots are generated from the 
repeated measurements (n = 15), which are triplicate analyses on five different days.  
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assay within the experiment range (0.75 to 100 fmol). All except the 0.75 fmol/µg (low) 
concentration from the “TFC” peptide had total CVs < 15%, which is the recommended cut-off  
for MS-based clinical assay.168 The average estimate of the total assay CV for the five AKT1 
peptides is 7.5%. Our results are quite promising and CVs < 10% are likely necessary for real 
endogenous measurement reproducibility. This experiment is done by spiking peptides into the 
background matrix digest, so the variability estimate does not include sample digestion, which is 
a major source of variability for peptide-based assays.169-170  
Summary of Characterization Experiments for Multiplexed LC-MRM Quantification of 
RAS Signaling Proteins. Data filtering in Skyline resulted in removal of all transitions that did not 
maintain consistent ion ratios. After this, all response ratios were calculated from at least two 
transitions, with the majority from three or more. This is a benefit of including 4-6 transitions per 
precursor, particularly if the sample preparation includes no enrichment. Every sample will 
contain a different composition of background peptides, resulting in unpredictable signal 
interference. Monitoring more transitions improves assay robustness due to flexibility of ion 
selection for quantification. Further filtering was done for the curve datasets to remove all points 
that had a CV above 20%. Next, peptides with less than 5 data points (the blank plus 4 
concentrations), which are identified by red font in Table 7, were identified as poor performing. 
The distribution of points per curve was used as a metric to assess the quality of the whole 
assay panel response curve results (Figure 21A). The maximum number possible was 9, which 
includes all concentrations and the blank measurement. Considering that the blank often 
includes variability due to background noise, peptide response curves with both 8 and 9 points, 
generally did not have any curve points removed. Therefore, we conclude that exceptional 
sensitivity as low as 80 amol/µg can be achieved for up to 84 out of the 117 target peptides, or 
71.8%; these are surrogate markers for 28 out of 30 RAS proteins in the multiplexed assay.  
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Next, the distributions of within day, 
(intra-) between day (inter-), and total assay 
variability were evaluated (Figure 21B). As 
expected, the distribution of within day 
variability was shifted to lower inter-assay CVs 
with less than 3% of the concentration 
exceeding the 20% cut-off. The between day 
variability distribution shifted slightly, but 
regardless, the majority of inter-assay CVs fell 
below 5%. As expected, the calculated total 
assay CVs were greater than the intra- and 
inter-assay CVs alone, with only 4.3% of the 
CVs across all peptides and concentrations 
had total assay variability ≥ 20%. Based on 
these assay characterization experiments, six 
peptides (Figure 21C) failed analytical assay 
characterization and validation. Upon 
examining these peptides, certain 
characteristics and trends stand out. The 
ERBB3 “ANDAL” peptide elutes last, with a RT 
of 62.5 min and the average of all six peptide’s 
RTs is 57.4 min. Two of these were in the 
supplemental peptide mix, which was a 
preliminary indicator of less than desirable 
analytical performance. Another two, “LCDGF” 
and “DSSYY,” contain a methionine, which has 
Figure 21. Evaluation of All Peptides’ 
Analytical Characterization. (A) Distribution of 
points included in response curves after filtering 
(CV > 20%, n = 112). The maximum number of 
point per curve is 9 and includes the 8 
concentrations plus the blank measurement. (B) 
Histograms of inter-, intra-, and total CVs (%) for 
all peptides with CV < 20% to visualize lower 
end distribution. The table (C) lists all peptides 
that failed assay characterization (fewer than 5 
points for curve, variability (CV) exceeded 20% 
for more than one of the high, medium, and low 
repeatability samples.  
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reduced analytical performance due to variable oxidation events. The remaining peptide, 
IDPVN, had substantially better performance than the others in the poor performing group, but 
failure to meet the CV cut-offs for the low concentrations resulted in 5 calibration curve points 
and acceptable variability observed in the high and medium repeatability samples. Results 
indicate that perhaps the IDPVN peptide would have benefited from inclusion in the 
supplemental peptide mix so it could be characterized with higher concentrations. Fortunately, 
the peptides are from proteins that have multiple other peptides that did generate highly 
sensitive assays which were successfully validated in these experiments. In conclusion, we 
have developed and characterized a highly multiplexed LC-MRM assay panel capable of 
quantifying 112 peptides as proxies for expression of 30 RAS signaling proteins in a single LC-
MRM run from 1 µg of total protein with LLOQs below 100 amol/µg.  
 
Biological Demonstration in Cell Line Models  
 Utility of the newly developed LC-MRM assay targeting RAS signaling proteins is 
demonstrated in two examples. First, a cell line screen looking at the ability of the assay to 
quantify endogenous expression will be described. Next, the multiplexed assay is applied to 
melanoma and colorectal cancer (CRC) cell lines to quantify changes in endogenous 
expression of the targets following treatment with the BRAF inhibitor, Vemurafenib. These 
systems were chosen because they are well characterized, enabling comparisons of LC-MRM 
quantification to what has been described in the literature using traditional cancer biology 
methods (e.g. Western blots). 
 
 Differential Expression of RAS Signaling Proteins in KRAS mutant Pancreatic and Lung 
Cancer Cell Lines. Four cell lines were tryptically digested and endogenous expression of 
peptides important for RAS signaling were quantified by LC-MRM. Two cell lines, AsPC-1 and 
BxPC-3 are pancreatic cancer and the other two, H2122 and H2444, are NSCLC cell lines and 
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with the exception of BxPC-3 (WT), all harbor KRAS mutations. AsPC-1, H2122, and H2444 all 
have mutations in codon 12, which are G12D, G12V, and G12C, respectively. In the initial 
screening, 44 peptides corresponding to 20 proteins were quantified from 1 µg of protein digest  
(Figure 22). Certain features stand out, including significantly increased amounts of the β-
catenin peptide, TSMGGTQQQFVEGVR, in the KRAS wt cell line BxPC-3. BxPC-3 has an 
epithelial phenotype and high expression of β-catenin compared to AsPC-1, which is more 
mesenchymal, consistent with previous data shown in the literature.171 H2122 appears to have 
lower expression of EGFR, which can be seen by quantification of GSTAE, IPLEN, and NLQEI 
peptides. Three GSKβ peptides all consistently show higher expression in H2444 compared to 
the other three cell lines, along with CDH2 or N-cadherin. Interestingly, H2122 had opposite 
cadherin expression: CDH2 was low while CDH1 or E-cadherin was high. This experiment 
Figure 22. Endogenous Detection of RAS Signaling Proteins in a Panel of Pancreatic and 
NSCLC cell lines. LC-MRM quantification from SIS dilution for absolute quantification in the RAS 
mutant (+1 WT) cell lines. Peptides are organized by protein and pink cell lines are pancreatic, while 
blue are NSCLC. 44 peptides from the following proteins are shown:  AKT1*, AKT1S1*, AKT2, AKT3*, 
ARAF, BRAF*, CCND1, CDH1, CDH2, CTNNB1, EGFR, GSK3B, MAP2K1, MAPK1*, MAPK3, MTOR, 
PTEN*, RAF1*, RPTOR*, STAT3*.  
*Indicates only one peptide was detectable.  
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demonstrates that the LC-MRM assay has sufficient sensitivity to detect differences between 
these four cell lines for profiling endogenous expression. When differences were observed, the 
increase or decrease was consistent amongst multiple peptides per protein. 
Multiplexed LC-MRM Quantification of Protein Expression Changes in Melanoma and 
Colorectal Cancer Cell Lines Treated with BRAF Inhibitor. Next, we wanted to demonstrate the 
utility of LC-MRM quantification of changes in endogenous analytes following kinase inhibitor 
treatment because this application will be most relevant to biologists. Melanoma and CRC cell 
lines with different BRAF and RAS mutations were treated with a BRAF inhibitor (BRAFi), 
PLX4720 or the vehicle control (DMSO), for 3 hours, which will show immediate response to 
treatment before feedback loop signaling ensues. Cell line information relevant to the study is 
shown in Table 9. The melanoma cell lines and signaling changes are well characterized with 
known markers (e.g. phosphorylated ERK).172 BRAF mutant lines, like A375, are initially 
sensitive to BRAFi, while NRAS mutant lines, like SKMEL2 are resistant. Interestingly, CRC cell 
lines harboring BRAF mutations are not sensitive to BRAFi. Our results should match what is 
known, validating the assay, and perhaps show something interesting, warranting further 
investigation. 
We quantified 57 out of 117 unmodified peptide targets from 24 cancer signaling 
proteins in at least 1 of 4 cell lines with 98.6% of CVs below the 20% cut-off (Figure 23).  The 
majority of measurements were at sub-fmol per µg protein levels (Figure 23A) confirming that a 
highly sensitive assay is necessary. Characterization experiments identified LLOQs down to 80 
amol/µg for many targets. The range of values quantified in each cell line shows that for all 
conditions, >75% of the values were greater than 100 amol, therefore the vast majority of 
measurements will be in the quantifiable range, as opposed to simply detected or not detected. 
These peptide specific values can be averaged to generate a higher confidence protein 
concentration. 
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Cancer Type Cell Line Mutation Status BRAFi Sensitivity 
Melanoma A375 BRAF V600E Sensitive 
SKMEL2 NRAS Q61R Resistant 
Colorectal HT-29 BRAF V600E Resistant 
HCT-116 KRAS G13D Resistant 
 
By quantifying proteins with multiple peptides, caveats of protein quantification using 
peptide surrogate markers are reduced. This allows for removal of outlier peptides, which may 
not agree with the group due to unknown post-translationally modifications or mutations to 
reduce the impact of random outliers. Without multiple peptides per protein, outlier identification 
wouldn’t be possible; therefore, analysis of multiple peptides is necessary for generation of 
accurate results to support downstream biological and clinical applications. This approach was 
performed to calculate the average fold changes of each protein after BRAFi treatment (Figure 
24). Peptides with known phosphorylation sites were removed, if possible, resulting in 1-4 
peptides per protein. Results show very few changes, as expected for endogenous protein 
expression levels following short term treatment. Most proteins have negligible response to 
BRAFi. Error bars are larger, indicating a reduction in precision, but improvements on accuracy 
and measurement robustness were gained. A couple proteins do stand out as being potentially 
differently regulated by BRAFi treatment: CCND1 or cyclin D1 in both BRAF V600E cell lines  
(A375 and HT29) are significantly decreased, observed increase in A375 N-cadherin (CADH2), 
and increase in ERBB2/HER2 levels. 
Table 9. Melanoma and Colorectal Cancer Cell Line Information 
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 Comparisons of vehicle in DMSO and BRAFi treated cell lines can be compared side by 
side similar to western blots (WB), but with absolute quantification with validated measurement 
linearity. Separating out the treatments and peptides can be used for a different perspective  
(Figure 25).  LC-MRM quantification of established markers for BRAFi response can be 
compared to Western blots of the same samples. To demonstrate this, results from the 
B A 
 
Figure 23. Global Summary of Quantified Peptides in Cell Line Models Following BRAFi 
Treatment. (A) Quantification of RAS pathway proteins in four cell lines before and after treatment 
resulted in datasets spanning a similar range, which is a QC metric for overall data consistency. The 
y-axis maximum was set to 1 µg, which removed 18 out of 434 outlier data points from the figure. 
Each data point is an average of three injections. (B) Boxplots show the variability (CV) of quantified 
protein amounts in each condition. 428 out of 434 measurements have a CV > 20%. The red dotted 
line is at 0.1 fmol, which is near the LLOQ for many targets (A) and at 20% CV (B). 
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expression LC-MRM and another RAS signaling panel targeting phosphorylation sites are 
compared to Western blots (Figure 26). The BRAFi sensitive melanoma cell line, A375, shows 
the canonical ERK1/2 (MK03/01) decrease in phosphorylation, which matches the Western blot 
(Figure 26 A, B). The BRAFi resistant cell line, SKMEL2, has the opposite response to BRAFi 
treatment. There is an increase in phosphorylated ERK following 3 h BRAFi treatment, which is 
consistent in the WBs and LC-MRM quantification (Figure 26C, D). In the resistant cell line, 
SKMEL2, there is a small decrease in total ERK. This can be seen by LC-MRM quantification of 
MK01 (ERK2) peptide, VADPDHDHTGFLTEYVATR. While the degree of downregulation in 
phosphorylated ERK is different between the two quantification methods, the directions of 
changes are consistent. This technique can be used to elucidate drug resistance mechanisms, 
Figure 24. RAS Signaling Proteins Measured in Cell Line Models After Short Term BRAFi 
Treatment. Peptide level measurements were averaged (n = 1-4) to generate protein level 
quantification. Fold changes of BRAFi Tx (PLX) were calculated. Standard error bars are ± SD. The 
black dotted line at y = 1 signifies no change following treatment. Those that are above are 
increasing and below decreasing.  
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such as BRAFi resistance, identify prognostic markers of therapeutic response, and to support  
drug development through target identification. The examples shown in this chapter  
demonstrate uses for LC-MRM assays developed for RAS signaling proteins and applications to 
translational cancer research.   
 
*Sensitive 
 
Figure 25. Absolute Quantification of CCND1 in 
Melanoma and CRC Cell Lines Treated with BRAFi. 
Peptide level measurements were quantified by one-point 
calibration to calculate the amount of protein (fmol/ug) in. 
Fold changes of BRAFi Tx (PLX) were calculated. Bar 
graphs plot the mean ± SD (n = 3).  
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Figure 26. Comparison of LC-MRM Quantification to Western Blots of BRAFi Response 
Markers in Melanoma Cell Lines.  A375 and SKMEL2 melanoma cell lines were treated with BRAFi 
(PLX4720) for 3 h. (A) Results of Western blotting (WB) for total and phospho ERK for the two 
melanoma lines before and after treatment for the time point corresponding to the LC-MRM analysis, 
provided by Matt Holderfield (NCI-FNL). The WBs show both ERK1 and ERK2. The phospho sites are 
listed as T202/Y204. (B) Peptide level LC-MRM measurements were quantified by one-point 
calibration to calculate the amount of protein (fmol/ug) in. Bar graphs plot the mean ± SD (n = 3).  
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Conclusions and Future Directions 
 To support translational cancer research efforts and the advancement of companion 
biomarker diagnostics, we have developed LC-MRM assays to quantitatively measure 
expression of selected RAS signaling proteins. We have also provided a detailed description of 
assay development using open source tools; this includes Skyline2, 106-107, 161 for method 
assembly and refinement, Panorama110 for data sharing, and R in R Studio115 along with 
Tidyverse173 packages for data analysis. Upon completion, assays will be shared with the 
research community on the CPTAC assay portal (http://assays.cancer.gov),160 where this 
resource can be used individually for specific protein quantification or as the panel presented as 
a highly multiplexed assay interrogating the RAS signal transduction network. Feasibility has 
been demonstrated in cell line models in order to identify signaling changes that confer BRAF 
inhibitor resistance and biomarkers of sensitivity to treatment. This analytical LC-MRM panel 
could support meaningful development of new therapeutic options for patients afflicted with 
RAS-mutant cancers, leading to improved patient outcomes. 
 As alluded to in the last figure, a complementary multiplexed LC-MRM assay has been 
developed for phosphorylated peptides from the RAS proteins in the expression panel. We will 
apply the same in-depth characterization outlined in this dissertation. Next, the panel of cell 
lines or treatment models can be expanded until endogenous detection of all peptides has been 
achieved. In addition, the study described is a part of a large-scale multi-site study to develop, 
validate, and harmonize immuno-affinity LC-MRM assays specific for a subset of the targets 
described here. The inter-laboratory study is ongoing and beyond the scope of this dissertation, 
but the end goal will be to compare quantification between different laboratories to examine 
assay portability. Harmonization across multiple laboratories as an essential step for clinical 
implementation of assays intended for clinical use as an in-vitro diagnostic.159, 174 More 
importantly, however, would be to validate the assays for use in tumor tissues as quantification 
of proteins in resected tumors is a greater challenge.175 Ideally, assay feasibility must be 
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demonstrated in both fresh frozen tissues and formalin-fixed paraffin embedded (FFPE) tissues 
because these methods, particularly the latter, are the most common protocols used. 
Challenges with protein quantification from FFPE tissues are well described, and methods for 
proteomic analysis of these bio samples have been described.176-178 The immune-affinity LC-
MRM methodology is used to overcome some of these sample issues to enrich for the desired 
target peptides. 
The most commonly used method of protein quantification in molecular biology is the 
antibody-based Western blot. This method is laborious and antibodies can be costly and 
specificity issues have been described as rampant.179 LC-MRM for multiplexed quantification 
offers several improvements over traditional immunoassays, like WB and ELISA.180 We have 
demonstrated that with the RAS signaling protein assay panel, up to 30 proteins can be 
quantified and endogenous detection for 24 of these proteins has been observed in four cell 
lines. This is dependent on endogenous expression and the number could be increased by 
screening more cell lines or administering treatment that results in increases in proteins not yet 
observed endogenously. Following sample preparation, which includes proteolytic digestion with 
either no enrichment or automated phosphopeptide enrichment when needed, LC-MRM 
analysis takes about 90 minutes per run to quantify all targets with a high degree of 
reproducibility. Immuno-blotting for all those proteins in a cohort of 20 samples would be an 
onerous task and a large amount of protein run on multiple gels would be necessary. In 
addition, LC-MRM provides improved quantification over WBs and other immunoassays through 
improved linear range, reproducibility, specificity, reagent availability, and variability in antibody 
batch quality. Initial instrument costs and set up can be barriers for more widespread adoption 
of LC-MRM to improve protein quantification in cancer research. One caveat of LC-MRM 
analysis is the high work requirement up front for assay development and characterization, 
which could prevent increased use. However, this will become less of a barrier as more assays 
are made available to the research community and this study supports that effort.  
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CHAPTER FOUR 
PERSONALIZED DETECTION AND MASS SPECTROMETRY QUANTIFICATION OF 
MULTIPLE MYELOMA TUMOR BURDEN 
 
Introduction 
Multiple Myeloma and Monoclonal Immunoglobulin Development  
Multiple Myeloma (MM), a devastating hematological malignancy formed by clonal 
expansion of plasma cells in the bone marrow (Figure 27), remains fatal due to persistence of 
minimal residual disease (MRD) following treatment. This disease typically has an initial 
response to therapy and temporary 
remission, followed by an aggressive 
and refractory disease relapse.181 Over 
the past decade, the introduction of 
new, less toxic therapies has increased 
median overall survival to six years.182 
These recent improvements in 
therapeutic strategies have resulted in 
unprecedented depths of response and 
correlative improvements in patient 
outcomes; however, responses are not 
quantifiable using current clinical 
methods.183-184 As we continue to 
improve therapeutic options and move 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Presentation and Characteristics of 
Multiple Myeloma. Arrow indicates the bone lesion 
from the outgrowth of myeloma cells. MM is 
characterized by secretion of an intact Ig or free light 
chains, which are found in the blood or urine. 
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closer to a cure, development and assessment of tools with improved sensitivity in detecting 
and quantifying MRD to guide treatment decisions will be quintessential to achieving improved 
patient outcomes.184-185 
 
VDJ Recombination to Produce Immunoglobulins. MM formed by a clonal expansion of 
plasma cells, creates its own disease-specific biomarker through secretion of a monoclonal 
immunoglobulin, called the M-protein.183, 186 This disease biomarker is produced through normal 
Figure 28. VDJ Recombination Throughout B-Cell Development Leads to Creation of Unique 
Immunoglobulins. The process of somatic recombination of germline DNA segments from the 
variable (V), diversity (D), and joining (J) loci leads to formation of the heavy chain Ig region and 
recombination of the V and J gene segments leads to formation of the light chain Ig region. Nucleotide 
insertions in joint regions and somatic hypermutation during plasma cell development, leads to unique 
heavy and light chain sequences, which are spliced to the C region, translated, and paired together to 
form a complete Ig. 
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VDJ recombination, which occurs throughout B-cell development before completion at the 
plasma cell stage (Figure 28). Immunoglobulins (Ig), which are produced by B lymphocytes and 
presented on the surface or secreted, are comprised of a heavy and light chain. Each chain 
originates from separate sets of Ig genes found on different chromosomes. The variable region 
is formed during B cell development by combining one segment from each of the three segment 
groups: variable (V), diversity (D), and joining (J). In this process, conserved DNA sequences 
flanking each V, D, or J gene segments guide germline DNA fragmentation and rearrangement 
in a highly regulated process known as somatic recombination. First, one D and one J segment 
are joined together, and then a V segment is rearranged to form the full VDJ sequence for the 
heavy chain, which is termed the variable, or V-region. When each of the three segments is 
joined together, random nucleotides are inserted at the V-D and D-J junctions to fill in gaps 
created by cleavage of DNA during the rearrangement process. The same process is used for 
light chain variable region rearrangement, except light chains contain only V and J segments.  
This process leads to a diverse immunoglobulin repertoire due to the number of possible 
combinations of segments and the random process of nucleotide insertion at the joints. Human 
heavy chain DNA contains 65 VH, 27 DH, and 6 JH gene segments, resulting in 13,770 possible 
variable region sequences.187 Combined with the 320 possible light chain variable region 
sequences, over 4 million unique Igs can be formed. The nucleotide insertion process at the 
joint regions introduces even further diversity of the final sequences. Once the B cell is mature 
and the Ig is expressed, the V regions are further modified by somatic hypermutation once 
exposed to an antigen to increase affinity.187-188 After this whole process, the memory B cell, or 
plasma cell, produces a unique Ig specific to the antigen that caused activation; this is the stage 
at which MM develops (Figure 29A). Because MM tumors are an abnormal clonal outgrowth of 
one plasma cell, which normally each produce a unique Ig, they secrete an excess of one type, 
termed monoclonal immunoglobulin, or M-protein (Figure 29B).186 The amount of secreted M-
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protein in serum increases in response to tumor growth, resulting in an ideal disease biomarker 
to monitor MM progression.189 
 
 
Disease Monitoring and Minimal Residual Disease Detection 
Current Clinical M-Protein Monitoring Methods. Clinical techniques for M-protein 
monitoring include serum and urine protein electrophoresis (SPEP/UPEP) and immunofixation 
electrophoresis (IFE), which have limited sensitivity.190-191 An increasing number of studies 
indicate the correlation between depth of response and improved patient outcomes, suggesting 
that achieving complete response (CR) is necessary for maximizing long-term survival.185, 192-193 
Currently, a multitude of techniques are used in the clinic to evaluate patient disease burden by 
serial measurement of the M-protein. SPEP/UPEP detects the disease-specific biomarker as a 
discrete band, which is used to estimate the amount of M-protein secreted by tumor cells. M-
protein quantification of the highly expressed Igs (IgG, IgA, and IgM) by SPEP is limited (≥ 0.1 
g/dl), however, because detection is not possible below normal Ig levels of the background 
Figure 29. Clonal Outgrowth of a Normal Plasma Cell Leads to Production of a Multiple 
Myeloma Biomarker. Plasma cells secrete unique Igs that form the normal diverse Ig repertoire in 
every human. In MM patients, a clonal population of myeloma cells secretes a monoclonal Ig, creating 
a disease specific biomarker. 
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repertoire and quant of rare Igs (IgD and IgE) and light-chain only disease cannot accurately be 
assessed.  To complement these results, immunofixation electrophoresis (IFE) is used to 
identify the monoclonal Ig type, followed by nephelometric quantitation of total Ig expression and 
serum-free light chains are also used for patient monitoring.194-195 
 
Minimal Residual Disease Detection Methods. At the present time, the detection of 
minimal residual disease is limited by the applied technology. With the advent of therapies 
achieving deeper responses and the potential for curing MM on the horizon, development and 
assessment of tools with improved sensitivity in quantifying MRD to guide treatment decisions 
are necessary.184-185 New  methods for personalized detection of MRD are actively being 
pursued and examples include quantitative PCR using patient-specific primers to amplify DNA 
corresponding to the M-protein196 , multi-parameter flow cytometry to quantify the number of 
tumor cells197, and RNA-seq of the Ig heavy chain from plasma cells as a deep sequencing 
method for disease monitoring.192 A major caveat of current MRD detection methods using MM 
cells is the requirement of a quality bone marrow aspirate, which is an invasive, sometimes 
painful, procedure that may not accurately represent disease burden due to challenges related 
to localized sampling.184 To avoid placing additional burden on the patient, minimally invasive, 
systemic monitoring techniques (blood or urine) provide an advantage over current, invasive 
MRD detection. 
 
Mass Spectrometry to Monitor Minimal Residual Disease. Because levels of circulating-
tumor DNA are very low for this disease due to being housed in the bone marrow, MS, rather 
than NGS, has emerged as the ideal platform to quantify this protein biomarker in serum or 
urine. In addition, newly-approved therapeutic monoclonal antibodies (mAbs), which are 
typically humanized IgG-kappa proteins, can interfere with SPEP and IFE assays by producing 
a false-positive M-spike.198 Detection of the mAb can be interpreted as an incomplete response 
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or a new clonal outgrowth, resulting in the inability to assess patient outcome with molecular 
methods, unnecessary follow-up testing, or have the potential for misinterpretation as 
recurrence or relapse in IgG-kappa disease patients, impacting clinical decision making.199 MAb 
interference can also impact CR rates for determining response to therapy in clinical trials, 
indicating a need for a different clinical endpoint or a new detection method for determination of 
efficacy. MS is the ideal tool to improve disease monitoring in MM patients, particularly in the 
context of patients treated with therapeutic mAbs.200-201 Multiplexed LC-MRM assays targeting 
constant region peptides have been developed to quantify all classes of immunoglobulin; 
analytical performance is comparable to nephelometry.202 Significant efforts to quantify these 
patient-specific biomarkers have also been made by researchers at the Mayo clinic and others 
on multiple MS platforms. LC-MS/MS and LC-MRM have been used to quantify patient-specific 
tryptic peptides corresponding to the variable region of the M-protein.202-205 These studies 
demonstrate that limits of detection can be improved by at least 100 times using MS 
quantification, but their low-throughput nature limits clinical implementation.  
 
MALDI M-Protein Monitoring. To improve throughput of M-protein monitoring, a method 
termed miRAMM (monoclonal Ig rapid accurate mass measurement) was developed to quantify 
nanobody-enriched, intact M-protein light chains by microLC-TOF MS by using their unique 
molecular masses. M-protein monitoring in serum of patients in CR using miRAMM has shown 
that patients whose M-protein did not decrease in serial measurements had progression-free 
survivals of 17.9 months compared to 51.6 months for those that decreased.206 Intact light chain 
measurements have also been translated to a chromatography-free matrix assisted laser 
desorption/ionization (MALDI)-TOF MS platform, also called MASS-FIX, to improve assay 
robustness and throughput.207-208 MASS-FIX has been validated in clinical labs in multiple 
settings that have demonstrated its ability to perform measurements in <1 min that is capable of 
replacing five different clinical laboratory tests (SPEP, UPEP, IFE of both serum and urine, and 
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serum free light chain), which could lead to significant cost-savings. Applicability has also been 
showing in different plasma cell diseases, such as amyloidosis.209 Recent widespread clinical 
adoption of MALDI-TOF MS for bacterial identification has paved the way for clinical 
implementation of MASS-FIX for M-protein quantification in plasma cell disorders.210 These 
studies highlight the challenges of translating MS-based protein biomarker assays to routine 
clinical implementation by meeting the demands of the clinical lab and how to achieve this 
through generating an affordable, high-throughput, analytically robust M-protein monitoring 
platform. 
 
Study Overview 
Currently, clinical treatment decisions are made based on semi-quantitative results from 
multiple tests.  An increasing number of studies indicate the correlation between depth of 
response and improved patient outcomes, suggesting that achieving complete response is 
necessary for long-term survival.185, 192-193, 211 Using a proteogenomics approach, peptide-based, 
LC-MRM assays personalized to each patient’s diseased Ig to improve quantification of MM 
tumor burden, which could be a valuable tool for MRD assessment in the development of new 
inhibitors and determining responses in clinical trials (Figure 30). If this assay is translated to 
the clinical lab, it could change the paradigm for patient evaluation and clinical decision-making, 
increasing the ability of clinicians to continue first line therapy to achieve deeper responses, or 
to intervene at an earlier time point upon disease recurrence.  Additionally, each assay for 
patient Ig evaluation is a single test that results in quantitative readouts on all Ig classes of both 
heavy and light chain, potentially simplifying the analytical process of MM tumor evaluation. 
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Materials and Methods 
All chemicals and HPLC solvents used in 
the following experiments were purchased from 
Sigma-Aldrich and Honeywell Burdick & Jackson, 
respectively, unless otherwise specified. 
 
Patient Serum Collection and Storage 
De-identified MM patient serum samples 
were collected following the protocol approved by 
the University of South Florida Institutional Review 
Board (see Appendix E). All patients included in 
the study have consented to participation in 
Moffitt Cancer Center’s Total Cancer Care (TCC) 
protocol, allowing access to banked samples, 
along with lab and pathology records. To ensure 
no additional burden was placed on patients, 
aliquots of excess sera were collected following 
standard clinical testing (as the samples would be discarded as waste otherwise). Blood was 
collected in serum separator tubes allowed to clot, then centrifuged. Serum samples were 
refrigerated until pickup (< 2 weeks), then stored at -80o C until analysis.  
Serum collection has been ongoing from 2014 to present for 64 patients divided into two 
cohorts: newly diagnosed or relapsing who are beginning treatment and patients in remission 
that are being monitored for relapse. A total of 560 serum samples have been banked, thus far. 
Some patients have up to 32 longitudinal samples, while others have only 1, with the median 
being 7 samples accrued. For each longitudinal sample the clinical lab results (SPEP, IFE, 
SFLC assay, and Ig quantification), sample transfer date (not PHI), historical and current 
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Figure 30. Workflow for Personalized 
Detection of MM Tumor Burden. RNA-
sequencing of CD138+ cells from patient 
bone marrow is used to generate the M-
protein sequence following translation from 
RNA. Trypsin peptides are selected from the 
Ig variable region and peptide standards are 
synthesized for biomarker assay 
development. LC-MRM assays will be used 
for longitudinal assessment of patient disease 
burden. 
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treatment, response at the time of blood draw, and time from last treatment have all been 
recorded (see Appendix F).  
 In this study, personalized LC-MRM assays have been developed and characterized for 
10 patients. Of these, three are from the remission being monitored for relapse cohort, five are 
newly diagnosed or beginning a second round of treatment, and two fit into neither category, but 
were of interest for monitoring (one IgE, lambda and one IgG, lambda that evolved into light 
chain only disease). These patients cover several elements of the spectrum of the MM patient 
population and the basic patient information can be found in Table 10.  
Bone marrow aspirates have been collected during standard patient work-up, either at 
time of diagnosis, relapse, or first presentation at Moffitt Cancer Center. Plasma cells (CD138+) 
were isolated by flow cytometry; aliquots of 0.3 to 2.5 million purified CD138+ cells were then 
cryopreserved as frozen pellets until requested. Two marrows were collected at residual 
disease stage (low disease burden), one of which contained unpurified, bulk marrow cells due to 
insufficient plasma cell numbers (Table 10).  
 
Plasma Cell Immunoglobulin Variable Region Amplification and RNA-sequencing 
 RNA was extracted from ≥ 300,000 CD138+ cells (Invitrogen, TRIzol) per the 
manufacturer’s instructions, followed by amplification of the variable region using 5’- rapid 
amplification of cDNA ends (Clontech, SMARTer 5’-RACE) with class specific primers212, a PCR 
based method to amplify regions with only one primer.212 All RNA sample preparation was 
carried out using RNAse free plastics and reagents in a biological fume hood cleaned with 0.1% 
SDS and 10% bleach 15 min prior to minimize RNase contamination. The concentration of RNA 
was determined (Thermo, NanoDrop) and half to all, depending on concentration, of the total 
RNA was used for the cDNA synthesis by SMARTer Reverse Transcriptase. Total RNA inputs 
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varied from 0.1471 to 2.4 µg. To test the quality of the extracted RNA, 100 ng were separated 
by electrophoresis on a 1% agarose gel with Ethidium Bromide using 75 V for 45 min. 
Ribosomal (28S and 18S) and transfer RNA band definition versus lane smearing were 
qualitatively assessed to estimate level of RNA degradation. 
 
 
Gene Target Primer Sequences (5' to 3') Tm (oC) 
*IgA TAGTGCTTCACGTGGCATGTCACGGACTTGCC 67.5 
*IgG TCTTGTCCACCTTGGTGTTGCTGGGCTTGTG 66.8 
*IgD CGGTGTGCTGGACCACGCATTTGTACTCGCC 68.4 
IgM CTCGCACAGGACTTCCTTCCCGACTCCA 67.9 
IgE ACTGTGGTCTCTGAGCTTGGCCCTCTCTTACCG 66 
IgK TCCTGCTCTGTGACACTCTCCTGGGAGTTACC 65.9 
IgL GTCTTCTCCACGGTGCTCCCTTCATGCGTGAC 67.4 
*Found in the literature.212 
Ig class specific primers were custom designed in house or found in the literature 
(indicated in Table 11) and adjusted to have similar melting temperatures (Tm) to enable 
multiplexing (ordered from Integrated DNA Technologies). For the 5’-RACE PCR reaction, 
primers were the reverse complement of the constant region and those with multiple isoforms, 
IgG1-4, for example, could all be amplified with one primer targeting a conserved sequence. 
The resulting cDNA product was diluted depending on the initial input amount. Using a generic 
primer with the Ig class specific primers, touchdown PCR was carried out using a thermocycler 
(Bio-Rad). The PCR product was purified and concentrated using the NucleoSpin Gel and PCR 
Clean-up kit (Clontech) before submission to the Molecular Genomics Core. PCR amplicons 
were prepared for multiplexed massively parallel next-generation sequencing (NGS) following 
the manufacturer library prep protocol (Encore Complete Library System, NuGEN). The Ig 
variable region amplicons underwent NGS on a MiSeq (Illumina), which generated ≥ 1 million 
Table 11. List of Primers Used for 5'-RACE PCR for Ig Variable Region Amplification Before 
Sequencing. 
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150-nucleotide paired-end reads per sample. Demultiplexing and data quality evaluation was 
performed using the CASAVA (Illumina).  
Next, de novo sequence assembly to generate a list of full length RNA sequences, or 
contigs, is done using Trinity,213-214 followed by identification of full length immunoglobulin 
rearrangements. All sequences are aligned to contigs using Bowtie,215 and contigs are matched 
to the human reference genome (NCBI) using BLAT and IgBLAST.216 The Ig rearrangement is 
then confirmed using IMGT/V-Quest217 and the VDJ junction is assessed by 
IMGT/JunctionAnalysis,218 which are tools developed and maintained by the international 
ImMunoGeneTics information system® (IMGT®). The dominant immunoglobulin variable region 
nucleotide sequence (generally >95% of all sequencing reads even in the most 
challenging/least pure samples) is then translated to amino acids in silico using TransDecoder 
(http://transdecoder.sourceforge.net). A list of potential VRPs is generated by in silico trypsin 
digestion of each patient’s predicted Ig variable region. 
 
Serum Sample Preparation for Mass Spectrometry Analysis 
 A small aliquot of serum (e.g. 10 µL) was diluted 1:4 into aqueous 80 mM ammonium 
bicarbonate (ambic), which was formulated with HPLC-grade water. To denature and solubilize 
serum proteins, the volume was doubled by trifluoroethanol (TFE) for a final concentration of 
50% TFE with 32 mM ambic. The samples were then reduced using tris(2-
carboxyethyl)phosphine (TCEP) at a final concentration of 2.5 mM, which was incubated for 30 
min at 37 oC and alkylated using 25 mM iodoacetamide (IAM) at room temperature in the dark 
for 30 mins. This process ensures that disulfide bonds are cleaved and capped to prevent new 
disulfide bond formation to ensure effective and reproducible digestion of the Ig heavy and light 
chains. The samples are then diluted to 7.5% TFE with aqueous 30 mM ambic and a volume 
containing 0.75 µL of serum is aliquoted into each well of a 96-well plate (Protein LoBind 500 µL 
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deep well plate, Eppendorf). Next, samples are digested at 37 oC with a 1 to 30 ratio of trypsin 
(Worthington) to serum volume for either 4 h or overnight. With each sample digestion, a pooled 
and filtered normal serum sample (Off the Clot Human Serum, Golden West Diagnostics) was 
used as a control reference as a quality control metric (QC). Stable-isotope labeled peptides 
were spiked into each sample, and then they were acidified with 0.5% Formic Acid (FA). 
Digested samples were dried in the 96-well plate using 
vacuum centrifugation (Thermo,  
 SpeedVac Concentrator) and resuspended in 60 µL of 
aqueous 2% ACN, 0.1% FA. The peptides were left to 
resolubilize for at least 30 min and were stored at 4 oC 
until LC-MRM analysis.  
 
Liquid Chromatography – Multiple Reaction Monitoring 
Mass Spectrometry 
  The prepared sample plate was placed into the 
refrigerated autosampler of the ultra-high pressure liquid 
chromatography system (Dionex Ultimate 3000 
RSLCnano, Thermo), which had been manually reconfigured to use only the loading pump for 
higher flow rate (400 µL/min) analytical LC separations. The optimized, multi-step gradient is 
described in Table 12. Peptide separation was achieved with a two-solvent system consisting of 
aqueous “A” solvent, 1% ACN with 0.1% FA, and organic “B” solvent, 90% ACN with 0.1% FA. 
Solvent flow was diverted to waste for the first 1.5 min and again at 7 min to prevent source 
contamination from salts, lipids, and undigestable protein. Peptides were separated on a 10 cm 
C18 reversed phase column with a 2.1 mm internal diameter, packed with 2.6 µm narrow pore 
(80 Å) particles (Accucore, Thermo) kept in a column compartment at 30 oC. Next, peptides 
Time 
(min) 
B Solvent 
(%) 
Flow Rate 
(µL/min) 
0 2 400 
0.4 2 400 
0.5 8 400 
4.25 24 400 
4.9 50 400 
5 90 400 
5.5 90 400 
5.75 92 500 
6.75 92 525 
6.85 2 525 
8.85 2 525 
9 2 400 
9.5 2 400 
Table 12. Gradient for Ig Peptide 
Separation 
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were ionized in a heated electrospray ionization source (HESI) in positive polarity for MRM 
analysis on a triple-quadrupole MS (TSQ Vantage, Thermo). All instrument parameters were 
manually tuned using the TSQ tune software (Thermo). The source maintained a vaporizer 
temperature of 375 oC and a spray voltage of 4000 V with the ion transfer tube at 305 oC. The 
ion sweep, sheath, and auxiliary gas pressures were 0.5, 40, and 12 psi, respectively. The mass 
selection resolution for Q1 was 0.4 and 0.7 for Q3 with a collision gas pressure of 1.5 mTorr for 
precursor fragmentation in q2. Other details regarding the MRM acquisition method can be 
found in transition lists in Appendix G. 
 
LC-MRM Target Selection and Test for Variable Region Peptide Uniqueness 
 We began with the subclass specific Ig constant region peptides that had been 
characterized in the lab previously,202 with a few new peptides for improved quantification of Ig 
classes. Albumin was monitored for digestion QC, and it serves a secondary purpose as a 
potential prognostic factor in MM as it can evaluate how imbalanced the blood protein 
population becomes with high levels of the monoclonal immunoglobulin. A peptide 
corresponding to conserved portions of the Ig variable region (Heavy, Kappa, and Lambda) 
were also selected as non-specific VRPs. All putative tryptic peptides identified by in silico 
digestion of the patient sequenced variable region, for both heavy and light chain, were 
screened for in that patient’s serum. If peptides are identified in the patient serum, their 
uniqueness in the antibody repertoire was assessed. To determine if the peptides are unique to 
each patient’s M-protein, a cohort of >83 serum samples202 was screened using LC-MRM. This 
patient population was used as a proxy for the each patient’s background Ig repertoire to 
facilitate selection of the most unique VRPs. If no unique peptides were identified, the VRP with 
lowest signal intensity and fewest observations in the patient cohort were selected. Peptides 
were also assessed for MRM feasibility, assessing the following considerations: 6-18 AAs, 
contains Pro, while avoiding M and C containing peptides, cleavage sites flanked by additional 
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Lys (e.g. “KK”) or acidic residues (D/E), and possible glycosylation sites (NXT/NXS). However, it 
was not always possible to follow these recommendations, so these rules are considered when 
evaluating each patient’s variable region sequence and prioritizing specific peptides.  
Unlabeled (light) and stable isotope-labeled standard (SIS) peptides were synthesized in 
house using standard FMOC chemistry (Symphony, Protein Technologies), purified by semi-
prep reversed phase HPLC (Dionex Ultimate 3000, Thermo), analyzed with MALDI MS and 
MS/MS (4700, Applied Biosystems), and quantified by amino acid analysis at the Texas A&M 
University Protein Chemistry Laboratory (AminoQuant, Hewlett Packard) prior to assay 
development.  
All peptides selected for assay development are listed in Table 13; the underlined AA 
contains the heavy labels (13C and 15N), and one peptide has an AA substitution instead of a 
heavy label (A  G).202 
 
LC-MRM Assay Optimization and Characterization 
 LC-MRM method parameters, such as gradient and flow rate, were optimized prior to 
sample analysis. Optimization was performed by running different methods on the reference 
control serum with flow rates from 300 – 500 µL/min in 50 µL/min increments. Various gradients 
with 1-3 steps were tested to maximize binding and separation of Ig peptides, many of which 
are on both ends of the hydrophobicity spectrum (e.g. highly hydrophilic or hydrophobic). In 
addition, injection amount was optimized by looking at the peptide response. Peptide saturation 
and background noise levels were used to select 0.25 µL of starting serum on column per LC-
MRM injection. 
After peptide synthesis and determining product purity and concentration, each peptide 
was characterized as described in Chapter 3. Briefly, this strategy included direct infusion ESI-
MS and MS/MS to identify dominant precursor and fragment ions for quantification  
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Type Protein Peptide Used for Quantification 
Constant 
Region 
IgA1 TPLTATLSK 
IgA2 D(A)SGATFTWTPSSGK* 
IgG1 GPSVFPLAPSSK 
IgG2 GLPAPIEK 
IgG3 WYVDGVEVHNAK 
IgG4 GLPSSIEK 
IgG5 DGFFGNPR 
IgD EPAAQAPVK 
IgE DFTPPTVK 
Kappa VDNALQSGNSQESVTEQDSK 
Lambda YAASSYLSLTPEQWK 
QC Albumin LVNEVTEFAK 
Conserved 
Variable Region 
Kappa VRP ATGIPAR 
Heavy VRP VAGESLK 
Heavy VRP YYADSVK 
Lambda VRP SGTSASLAISGLR 
Patient Specific 
Variable Region 
Pt 100 (IgA) LEQSGPEVK 
Pt 100 (Kappa) ASQSVTTNLAWYQQKPGQAPR 
Pt 110 SNIGSNTVTWYR 
Pt 105 (IgA) DSLYLQMNSLR 
Pt 105 FSGSNSNSGNTATLSISR 
Pt 102 LSGPVFGGGTK 
Pt 101 (IgA) NSLHLQISGLR 
Pt 101 FANTATLTIR 
Pt 11,12 VTIT(camC)QATQDISK 
Pt 135 (IgG) DPPYPTNWHR 
Pt 135 (Kappa) ASPGIDNLLAWYR 
Pt 127 (IgG) ALTFGGGTK 
Pt 127 (Kappa) NTLSLQMNSLR 
Pt 23 (IgA) GLEWVGYISNIGR 
Pt 23 (Kappa) LLIYEASK 
Pt 24 (IgA) ASGYTLTK 
Pt 24 (Kappa) DSGVPDR 
Pt 3,26 (IgE) LMIYDVSNRPSGVSNR 
Pt 3, 26 QAPGQSLEWMGWINPGNGHTK 
Table 13. Summary of Peptides Used for Myeloma Patient Ig Quantification 
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and collision  energy optimization. For each peptide, the dominant precursor and 3-5 fragment 
ions were selected for quantification and if applicable, the minor charge state was monitored as 
well. Peptide RTs were mapped using Skyline’s iRT.107 Ig CRPs were used as the benchmark 
peptides to map patient-specific VRP’s RTs. Guidelines established by CPTAC (available on 
http://assays.cancer.gov) were followed for peptide characterization,160 including Experiment 1 
(response curve), Experiment 2 (repeatability), and Experiment 5 (reproducibility of endogenous 
analyte detection). Experiment 5 is a “mini” version of the traditional assay validation 
experiments performed in the clinical chemistry lab. Stability experiments were done using 
serum samples that had endured multiple freeze-thaw cycles and digested samples that had 
been stored in the autosampler or refrigerator (4 oC) for specified lengths of time (from 1 day to 
3 weeks).  
 
Trypsin Digestion Kinetics and Recovery 
 To correct for variability in proteolytic digestion and other batch effects, a standard 
isotope labeled protein was spiked into reference control samples prior to digestion. In general, 
SILuMAb (Sigma), a commercially available IgG Kappa SIL protein, was spiked into the serum 
prior to digestion at a concentration of either 2 mg/mL (High) or 0.5 mg/mL (Low), which are 
concentrations surrounding the SPEP LOD of 1 mg/mL. SIS peptides were spiked in after 
digestion as described above. Time courses were performed for a subset of VRPs (and CRPs) 
using double labeled peptides or peptides with a single AA change to calculate digestion 
recovery of endogenous peptides as well as SILuMAb peptides. The following equations (1-3) 
were used to calculate and correct for digestion recovery: 
FG- 1:  #(I%/.(,- J%1,K%2L =  MNOPQR0S +%T.(U% J%/T,-/%VM#,QS&% PWJ+ J%/T,-/%V   
FG- 2:  W,22%1.(,- X31.,2 (WX) =   1M#(I%/.(,- J%1,K%2LV  
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FG- 3:  J%1,K%2L W,22%1.(,- =    WX × MF-U,I%-,Q/ \J+ J%/T,-/%VMNON \J+ J%/T,-/%V   
 
LC-MRM Immunoglobulin Quantification 
 The SIS peptides, which match selected surrogate peptides from the endogenous 
protein were spiked into each sample were used for absolute quantification of the total protein, 
as previously described.28, 37 Amounts of peptide spiked into samples were determined by 
estimating the expected endogenous concentration in healthy controls, with the exception of 
very low abundance analytes like IgE. For VRPs, spiked SIS used was around the SPEP limit of 
detection (100 mg/dL). Similar to experiments described in Chapter 3, this method includes SIS 
peptide dilution into the patient sample and in general, single-point calibration was used. In 
some cases, where it has been indicated, a “mini” calibration curve with a low, medium, and 
high concentration were used for quantification in addition to the spiked SIS. These samples 
had light VRPs spiked into the reference control serum, along with the same concentration of 
SIS spiked as the patient samples being analyzed in the batch processed. Each batch also 
included blank samples of the reference control serum. After establishing the assay error in the 
characterization experiments, patient samples are only measured by single injection, as is 
routinely done with many clinical measurements. Each well contains enough serum digest for 3 
injections and repeat analysis is performed only if QCs indicate a technical error occurred. 
 
Clinical Measurements 
 All clinical measurements were performed in the Clinical Chemistry lab by qualified and 
certified staff under the supervision of Kaaron Benson, MD. Clinical tests to measure the M-
protein included capillary SPEP190 quantification and IFE191 to identify monoclonal Ig heavy and 
light chain classes. Individual Ig quant (IgG, IgA, and IgM) are measured on a Cobas 501 
system (Roche Diagnostics) and serum free light chain (FLC) assay,219 which is used to monitor 
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light chain disease is done on the SPA analyzer with the kit produced by the Binding Site. Bone 
marrow analysis includes 8-panel flow cytometry and immunohistochemistry (IHC) to confirm < 
5% plasma cell involvement. These results are used for patient staging and response to 
therapy, which are determined using the guidelines provided by the International Myeloma 
Working Group.220 
 
Data Analysis 
All processing of raw MS data files was carried out using Skyline, as previously 
described106 and assay characterization experiment calculations (e.g. dynamic range, LLOQ, 
LLOD, inter- and intra-assay variability) are performed the same as described in Chapter 3. 
Each ion signal was manually reviewed to ensure correct peak peaking by the software 
algorithm. Integration of all transitions was forced to ensure background measurements were 
made for downstream statistical analysis. Transition ratios of endogenous analyte compared to 
the standard were evaluated and transitions with interference were removed. Consistency of 
transition ratios across samples was ensured for reliable quantification. A minimum of two 
transitions were used for quantification of each peptide. Following data processing in Skyline, all 
analysis and graph generation was performed in R,115 as described in Chapter 2. Confidence 
intervals (95%) for measurements were calculated using the SE established in characterization 
experiment 5. Outliers were removed from dataset if they were identified by statistical testing 
(Grubbs test for outliers). 
Peptide responses were calculated as a ratio of endogenous peak area to corresponding 
spiked in SIS peptide. The amount injected on column was back calculated to the concentration 
in the sample; an example for IgG heavy chain is provided below as Equation 4: 
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FG- 4:  W,-1%-.23.(,- ,^ R − +2,.%(- (- N%2Q) N3)T&%
=   +%T.(U% J%/T,-/% J3.(, × 1 (-`%1.(,-0.25 cP /%2Q)  ×  
d c),& eWP  NON (-`%1.%Uf × 
1 ),&
10g c),&  ×
1 ),& OIh
2 ),& eW ×  
146,000 I
1 ),& OIh   
 
Similar calculations were performed for all class of Ig using class specific molecular weights. 
Light chain measurements were calculated using a 1 to 1 molar ratio and estimating a MW of 
22,500 g/mol. Total LC measurements from LC-MRM quantification were compared to SFLC 
clinical measurements. All MRM M-protein quantification results were compared to SPEP 
clinical measurements to determine correlations between the methods. Individual assay 
parameters are statistically evaluated using p-values calculated from a student’s paired t-test.   
 
Results & Discussion for Immunoglobulin Measurements 
Rapid Amplification of cDNA Ends and NGS Elucidates Patient Specific M-Protein Variable 
Region Sequence 
 A PCR based approach, 5’RACE, was used to generate variable region amplicons, 
which were then sequenced (Figure 31A). This information was used to predict patient specific 
VRPs and direct LC-MRM assay development. The genomic and bioinformatics workflows 
developed for this project have proven to be robust and effective with a success rate greater 
than 90%. Only 3 out of 40 samples sequenced did not generate a clear variable region 
sequence from a clonal Ig population. For a minority of sequencing results, a full length Ig 
variable region was not identified. However, because we are using surrogate peptide markers 
for quantification, it is not necessary to have the full sequence. If the amino acid sequence 
contained the constant region part complementary to the RACE primer, peptides were selected 
from the partial variable region and screened in the patient serum; VRPs were selected for 
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assay characterization for all but one patient, even if multiple or partial sequences were 
identified (patient not included in the study). RNA is easily degraded if contaminated and with 
samples isolated from a patient and extensively handled during sample processing, the quality 
of starting material could often compromised. For the majority of samples, the RNA quality was 
poor and may not have been acceptable for RNA-seq. RACE amplification can “rescue” these 
samples by amplifying the non-degraded copies. It also minimizes the cost of sequencing and 
the time necessary for the bioinformatics analyses, which are extremely important factors when 
considering clinical implementation.  
Two patient PCR products are shown for IgA and kappa LC as an example (Figure 
31A). All produced a band except patient 23 kappa LC; however, PCR was repeated using 
more cDNA template and more round of PCR. The sequence was analyzed using IMGT/V-
Quest221, which identifies the closest V, D, and J gene and allele matches in their databases, 
specifies the percentage of matching bases and generates the junction AAs218 (Figure 31B). On 
average, each patient variable region had ~90% uniqueness due to somatic hyper mutation and 
class switching during Ig development. Patient 100 variable region AAs are displayed in a 
standardized IMGT 2D graphical representation using the IMGT Colliers de Perles tool.1, 222 The 
figure (Figure 31C) is created based on variable region sequence rules and specific conserved 
AAs/motifs (shown in red). Heavy and light chain RNA and AA sequences from 40 RNA 
samples have been compiled to in-house databases for future use.  
 
LC-MRM Screen of Serum from Patient Population Leads to Identification of Most Unique VRPs 
 Next, tryptic VRPs were predicted from the translated M-protein variable region 
sequence using in silico tryptic digestion, which cleaves on the C-terminal side of K and R; 
example results for patient 101 will be described. The following peptides were identified in 
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patient 101’s HC (IgA) and screened for expression in the patient’s serum: GFAMDLGLR, 
LT(camC)TASGFSFSR, YSMTWVR, NSLHLQISGLR, and AEDTAVYY(camC)AR (Figure 
32A,B). All but one of the peptides (GFAMDLGLR were found in the patient serum with varying 
levels of intensity. Possible common Ig PTMs that could impact VRP detection include 
glycosylation, oxidation (as perhaps in the case of the GFAMDLGLR peptide), and deamidation. 
Errors introduced by PCR and in sequencing could also prevent detection and peptide chemical 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. Unique Variable Region Sequences Identified from RNA-seq of RACE Products. (A) 
100 ng of PCR products that were sequenced are separated by electrophoresis on a 1% agarose 
gel (EtBr) using 75 V (45 min) for both heavy and light chain. The ladder is on the far left and bands 
go from 1000 to 100 bps in 100 bp increments. Each patient has a lane for the heavy chain (IgA) 
and light chain (κ). Example results from IMGT V-Quest (B) indicate the closest gene and allele 
matches for Pt 100, IgA and the junction sequence. The amino acids and structure of the variable 
region sequence in the representative table is shown as a 2-D schematic with the CDR regions 
indicated1 (C). 
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properties impact how well it performs in LC-MRM leading to variability in signal across 
peptides.  The screening provided information regarding LC-MRM amenability, with the best 
performance from AEDTAVYYCAR and NSLHLQISGLR. The most important factor for VRP 
peptide selection is their uniqueness amongst the Ig VRP background repertoire. To determine 
if the peptide is unique to each patient’s M-protein, a cohort of 83 serum samples202 is screened 
using LC-MRM (Figure 32C). Peptides were observed with varying degrees of uniqueness. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32.  Patient 101 (IgA/λ) M-protein VRP Selection and Uniqueness Screen.  AA sequence 
for the heavy chain variable region translated from RNA-seq results (A). The underlined tryptic peptide 
sequences (V1-5) were selected for LC-MRM verification in serum (B). LC-MRM screening in serum 
digest of a patient population, n = 83 (C). Patient 101 is in the red box on the far right. The inset table 
summarized total observations for each VRP. Underlined AAs signify changes compared to the 
closest match in the IMGT Ig database. *VRP selected for assay development. 
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While AEDTAVYYCAR had the best signal, it was the least unique peptide, observed a total of 
49 out of 83 times. The inset table (Figure 32C) summarizes the observations across all 
samples.  
Interestingly, the VRPs that contained variants compared to any sequence found in the 
IMGT database were not observed above baseline noise in any of the comparator samples (n = 
83), while the two that were identified in the database were not unique in our dataset. This 
remained true for other patients, demonstrating that publically available datasets may be 
sufficient for assessing peptide uniqueness. This step in the initial assay development is very 
time consuming and labor intensive, therefore replacement with an automatable step was 
necessary for clinical implementation. With the recent successes in cancer immunotherapies, 
there has been in increased interest in sequencing of B-cell repertoires leading to newly 
published publically available datasets. We’ve capitalized on this and downloaded the spectral 
library available the data repository, MassIVE (Mass Spectrometry Interactive Virtual 
Environment, v 1.3.0, massive.ucsd.edu), which is part of the NIH-funded Center for 
Computational Mass Spectrometry. In addition to data storage, there are a variety of tools 
available for data reanalysis. As a part of this, they have combined 30 TB of data to generate a 
vast spectral library containing over 1 million peptides from 19, 611 proteins. We’ve combined 
this with other Ig variable region specific datasets223-225, including in depth LC-MS/MS analysis 
of a polyclonal antibody mixture searched against a customized antibody database called 
Abscan226, a NIST spectral library created from characterization of a mAb reference material227, 
and a dataset we generated by performing de novo database searching in PEAKS228-229 on 
tryptic peptides from light and heavy chain gel bands of the patients used for the uniqueness 
screening. This spectral library can be directly imported into Skyline, making the screen for 
peptide expression in the patient serum and uniqueness test simultaneous and further 
streamlining our workflow. 
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Patient Variable Region Sequencing Workflow is Effective for Bulk Marrows taken at Residual 
Disease Stage  
Ideally, assays are developed for myeloma patients with bone marrow aspirates taken 
when they received their initial diagnosis and had high disease burden. This means the marrow 
will be dominated by malignant plasma cells. This outcome is not always the case, however 
because patients often transfer from other locations or a lack of bio-banking of excess marrow 
for research. We hypothesized that the amplification and bioinformatics pipeline developed 
would be capable of identifying the rearranged monoclonal Ig sequence. We identified two 
patients (110 and 127) who had marrows taken at residual disease stage, which means they 
had less than 5% plasma cell involvement in the marrow as verified by immunohistochemistry 
(IHC) and flow cytometry (Figure X). The banked sample for patient 110 was not only taken at 
residual disease, but was also a non-purified bulk marrow aspirate. This means the MM cells 
were a minority of the total cells in the sample (with an unknown amount of other plasma cells) 
and could provide an example of the robustness of our sequencing workflow. RNA-seq results 
for patient 127 (marrow 5776) resulted in heavy and light chain sequences that were generated 
from 91.3% and 97.6%, respectively. Patient 110 had lambda LC disease and impressively, the 
sequence identified (marrow 5855) resulted from 99.9% of the reads. 
 The IHC corresponding to patient 127 marrow aspirate and the clinical SPEP data 
indicating the time point when taken, which predates the patient’s enrollment in this study are 
shown (Figure 33 A, B). This led to productive IgG and kappa variable region sequences with 
putative VRPs underlined (Figure 33C). Three out of the four peptides were observed and 
follow the same trend as the matched SPEP M-protein quantification (Figure 33 B, D). The 
ALTFGGGTK peptide in purple (Figure 33C) and circled in red (Figure 33D) was selected for 
quantification of patient 127 kappa LC and went through in depth characterization. 
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Characterization of Highly Sensitive, Patient Specific LC-MRM Assays 
 Once the VRP peptides from the heavy and light chains have been selected, light and 
SIS peptides were synthesized and concentrations established as previously described.32-33, 230 
Following the same steps in Chapter 3, assay characterization was performed to define the 
VRP assay dynamic linear range, LLOQ, and inter- and intra-assay variability. This data is 
Figure 33. RNA-seq of Variable Region Amplicon from Patient 127 Residual Disease Bone 
Marrow Aspirate Identifies VRPs for Personalized LC-MRM Quantification. 
Representative IHC from the marrow used for RNA extraction, RACE amplification, and RNA-seq 
(A) and the time point at which the marrow was taken, indicated by the red arrow are shown. The 
kappa sequence (C) and LC-MRM screening (D) with three samples following the SPEP trend (B) 
indicate workflow robustness.  
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patient- and peptide-specific and therefore done for each VRP. For select peptides, additional 
experiments were performed, including digestion kinetics, carryover assessment, stability 
through freeze-thaw cycles and storage at 4 oC. Representative characterization experiments 
will be described. 
 Example curves are shown in Figure 34 for M-protein VRPs from specific to patients 
127 and 23. Because the curves are generated across many orders of magnitude, power 
equations were selected to reduce the impact of the higher curve points in skewing the results. 
The data is considered to be linear if the exponent (n) in the derived equation falls between 0.95 
and 1.05, since an exponent of 1 would equal a linear equation. For example, n is 1.0151 for the 
patient 127 Kappa peptide, ALTFGGGK, resulting in a range of linearity across > 4 orders of 
magnitude, from 5 fmol to 100 pmol (Figure 34B). The assay characterization results from the 
first experiment are summarized in Table 14. 
 All peptides have slopes that are within 20% of 1, indicating an insignificant bias from 
matrix effects or curve preparation and R2 values > 0.995. Carry over was assessed by injecting 
a blank sample after the highest curve point of 100 pmol and ranged from < 0.005% to 0.5%. 
While this seems negligible, because the assay linear range is so high, that could be 
problematic for a low concentration sample being injected after a high concentration. The high  
Patient Peptide LLOD 
(fmol inj) 
M Protein 
LLOD  
(mg/dL) 
Light 
Chain 
LLOD  
(mg/L) 
LLOQ 
(fmol) 
M Protein 
LLOQ 
(mg/dL) 
Light 
Chain 
LLOQ 
(mg/L) 
Pt 127, IgG NTLSLQMNSLR 10 0.6 ND 25 1.5 NA 
Pt 127, Kappa ALTFGGGTK < 1 fmol 0.06 0.09 5 0.3 0.45 
Pt 23, IgA GLEWVGYISNIGR 3 0.18 ND 10 0.6 NA 
Pt 23, Kappa LLIYEASK 1.1 0.066 0.1 45 2.7 4.05 
Table 14. Summary of Patient 127 and 23 VRP Response Curve Results 
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Figure 34. Patient 127 and 23 VRP Response Curves Determine Assay Dynamic Range, LLOD, 
and LLOQ. Reverse calibration curves were generated using SIS peptides spiked in from 5 fmol to 100 
pmol on column using 100 fmol of light peptide to generated response ratios. The top two curves 
correspond to patient 127 IgG HC (A) and Kappa LC (B). Whereas the bottom two are from patient 23 
IgA HC (C) and Kappa LC (D). Each graph has a power equation (red) which is used to determine linear 
range and a linear regression equation (black), which is used to calculate the LLOD and LLOQs.  
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carryover (0.5%) was calculated for NTLSLQMNSLR and GLEWVGYISNIGR, both of which are 
very hydrophobic. For these peptides, we reduced the carry over by implementing a high 
organic (50% Methanol, 40% Acetonitrile) wash every few samples. The high point of 100 pmol 
corresponds to a 6 g/dL M-spike, which is a rare occurrence. If a sample in this range is 
injected, the high organic wash can be used between the injections to reduce carryover and the 
low sample analysis repeated. Because this represents < 0.1% of the samples, we do not for  
 see this presenting a problem with clinical measurements, but routine cleaning and vigilance for 
highly hydrophobic peptides will be helpful. The LOD for SPEP measurements of M-protein are 
0.1 g/dL or 100 mg/dL. The personalized LC-MRM assays demonstrate a 50-300 fold 
improvement in sensitivity and improved quantitative capability at lower values compared to 
current clinical M-protein measurements. Serum FLC assay can measure as low as 0.6 and 1.3 
mg/L for kappa and lambda LC, respectively; comparison to VRP quant by LC-MRM indicates 
comparable or a small improvement over serum FLC assay. To fully elucidate whether LC-MRM 
is more sensitive than the FLC assay, this study would require more patients with FLC disease.  
Next, repeatability experiments were performed to establish the inter- and intra-assay 
precision (% CVs). High, medium, and low sample were prepared based on the LLOQs 
Patient, Ig Peptide 
M-Spike 
(mg/dL) 
Intra-Assay 
Avg CV (%) 
Inter-Assay 
Avg CV (%) 
Total Assay 
CV (%) 
Pt127, IgG NTLSLQMNSLR 
3 9.19 16.40 18.79 
72 4.17 7.47 8.56 
3000 3.81 18.49 18.88 
Pt127, 
Kappa 
ALTFGGGTK 
0.9 6.35 17.99 19.07 
21.6 2.01 6.98 7.27 
3000 3.52 10.65 11.21 
      
Pt23, IgA GLEWVGYISNIGR 
1.8 4.43 43.15 43.38 
36 2.40 25.67 25.78 
3000 5.70 60.26 60.53 
Pt23, 
Kappa 
LLIYEASK 
3.6 2.71 11.39 11.71 
72 1.46 7.10 7.24 
3000 0.96 9.38 9.43 
Table 15. Summary of Patient 127 and 23 VRP Within and Between Day Assay 
Variability 
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determined by the response curve; results are summarized in Table 15 below. The low 
concentration for the repeatability experiment is considered the validated LLOQ; these values 
are as low as 0.9 mg/dL. While the SPEP LOD is 100 mg/dL, the LLOQ ranges from ~200 to 
500 mg/dL depending on the lab and Ig isotype,194, 231 meaning VRP LC-MRM assays are up to 
500-fold more sensitive in our data acquired to date. Not only is sensitivity improved, but M-
protein quantification by LC-MRM of VRPs has a dramatic improvement in linear range at both  
ends of the spectrum. SPEP has been shown to overestimate serum Ig concentrations below 
500 mg/dL and underestimate when concentrations are > 3000 mg/dL.190, 232 In summary, 
precise and sensitive quantification of monoclonal Igs with LLOQ’s as low as 0.3 mg/dL and 
0.45 mg/L have been achieved, with linearity maintained to at least 6000 mg/dL and possibly 
higher.  
 Between day assay repeatability (CV < 20%) was not achieved for patient 23’s heavy 
chain VRP, GLEWVGYISNIGR. The reason for this was explored and peptide stability of 
multiple AAs, including tryptophan (W), tyrosine (Y), and asparagine (N) are likely the cause. 
Deamidation of Asp is one of the most common modifications observed in serum proteins and 
Igs in particular, multiple oxidations and losses leading to up to eight modifications of Trp have 
been observed, and single or double oxidation is possible for Tyr.233-234 Based on our results 
and evidence in the literature, it is advisable to avoid selection of peptides containing W, Y, N, 
Q, and M, if possible; instability of these amino acids becomes particularly problematic when 
more than one is present. For the quantification of patient 23’s M-protein, the LC peptide, 
LLIYEASK was used. We also observed improvements in the LLOQ upon removing the y7 
transition, which had interference and was impacting results at low concentrations (Figure 35A-
C). The extracted ion chromatograms (EIC) initially included the three fragment ions selected for  
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quantification. The light peptides across the top were used as the standards for the reverse 
calibration curve. The y6 fragment is dominant and the ratio between fragment ions should be 
maintained in the heavy EICs below. Background interference that was apparent in the lower 
curve points E-I reduced the assay’s dynamic range. The lowest point “I”, which corresponds to 
the EICs had an expected response ratio of 0.09; however, the observed ratio was 0.19 
resulting in a 113% mean bias (Figure 35A). Removal of y7 resulted in complete agreement 
between transition response ratios of 0.09, which was a perfect match to the expected response 
ratio (Figure 35B). The discrepancy between the ratios of y7 versus y5 and y6 and their onset at 
lower curve points E-I was observed (Figure 35C). Quantification with the two remaining 
transitions yielded a LLOQ of 0.54 mg/dL, which is a 5-fold improvement in sensitivity.  
Longitudinal Patient Analysis 
Figure 35. Impact of Ion Fragment Ratio Evaluation and Filtering of Patient 23 Light Chain VRP. 
Extracted ion chromatograms from LLIYEASK were exported from Skyline (A,B). Data are from curve 
point “I”, which is a spike amount of 0.54 mg/dL. The left panels (A) are peaks from light (top) and 
heavy (bottom) with fragment ions y5-y7. The light peak is the standard (constant spike level) while 
heavy was varied. The response ratio is between panels in red. The right panels (B) are the same 
peaks, but after removal of y7. The response ratio for each transition monitored for the lower curve 
points E-F, with D for comparison. 
117 
 Patient assay development and characterization are done in parallel and the entire 
process can be completed in about thirty days. While this may seem like a lengthy time, these 
assays are not necessary for patients to begin treatment; because these biomarkers are 
idiotypic proteins, their function, or lack of, is not useful to stratify patients for therapy selection. 
For the vast majority of patients, assay workup is only necessary once. Most changes observed 
in the patient population are an intact immunoglobulin switching to sFLC disease. Sometimes 
this occurs as a survival mechanism upon drug treatment to reduce the workload of the 
myeloma cell.235 For this reason, it is important to monitor both chains to look for discrepancies 
in the quantification as indication of a disease change. 
 In-depth characterization steps and representative data have been described. Now, 
longitudinal patient measurements can be taken and established assay variability used for the 
measurement error. We can be confident the value generated for patient measurements will fall 
in the 95% confidence interval, therefore longitudinal patient data will be from single 
measurements unless a repeat analysis was necessary for technical reasons.  
Longitudinal serum sample measurements for two patients, one IgG/κ with 6 time points 
and the other λLC only with 15 measurements are presented in Figure 36. In each case, LC-
MRM was used to quantify the monoclonal Ig in excess sera remaining from clinical chemistry 
tests using patient-specific SIS VRPs as surrogates for the protein to achieve absolute 
quantification. Each patient’s biomarker indicates a different trend, but each is increasing 
substantially from the previous data collection and both patients passed shortly thereafter. The 
correlation between LC-MRM to capillary SPEP quantification of patient 127’s intact M-protein is 
strong, with an R2 of 0.998 (Figure 36C). The correlation of LC-MRM versus the sFLC (Binding 
Site) assay is not as strong, with an R2 of 0.853 (Figure 36D), but that appears to be due to a 
single point, which is the second to last in the longitudinal plot (1004 mg/L sFLC assay versus 
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Figure 36. Longitudinal LC-MRM Measurements of Patients 127 and 110 and Comparison to 
Current Clinical Methods. Longitudinal plots with days from first sample collected on the x axis 
and absolute quantification of the M-spike (A) for Patient 127 and the monoclonal LC (B) using 
patient-specific surrogate VRPs. Digestion recovery was corrected for using batch processed 
SILuMAb. Monoclonal Ig LC-MRM quantification is compared to the relevant clinical assay. SPEP 
quantification (C) and Binding Site sFLC Assay quantification  (D) are on their respective x-axes 
with LC-MRM quantification on the y-axis in both panels (C, D). Patient 127, n = 6 and patient 
110, (B) n = 15, (D) n = 12.  
  
A B 
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2615 mg/L LC-MRM). The final three measurements for patient 110 are within 40 days of one 
another; this makes the continuous increasing trend for the LC-MRM Ig results more believable, 
as opposed to a dip in Ig serum concentration observed by the sFLC assay (Figure 36B, D). 
Batch to batch variability in assay reagents has been cited as a source of variability in the sFLC 
assay, with up to 45% variance between batches.236-237 In addition, if there are any sample 
issues with aggregation, protein degradation, or over-abundance of kappa LC, this assay can 
inaccurately quantify the amount of lambda LC. Despite criticism of peptide-based protein 
quantification, this strategy does remove the reliance on intact, stable proteins for quantification, 
which increases assay robustness. Aggregation and partial degradation are generally not issues 
for measurements of peptides from enzymatically digested proteins. 
 
Conclusions and Future Direction 
Personalized LC-MRM assays have been developed using de novo RNA sequencing to 
define unique candidate biomarkers to quantify Multiple Myeloma patient tumor burden. We 
have demonstrated up to a 500-fold increase in sensitivity compared to clinical methods; 
however, assay performance is patient- and peptide-specific. We are able to detect the 
diseased Ig at the MRD stage in both RNA-seq from bone marrow and VRP measurements in 
serum. The sensitivity and specificity improvements indicate this may be a valuable tool for 
MRD assessment in the development of new inhibitors and determining responses in clinical 
trials. If translated to the clinical lab, it could change the paradigm for patient evaluation and 
clinical decision-making, increasing the ability of clinicians to continue first line therapy to 
achieve deeper responses or to intervene at an earlier time point upon disease recurrence.   
We have reduced the cost and time necessary to implement the assay by implementing 
5’ RACE amplification, improving its translational potential. At each step of the initial assay 
workup, improvements were implemented to improve clinical applicability. We made every effort 
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to improve assay robustness while maintaining simplicity, and all sample preparation were 
designed for implementation on an automated platform.   
Also, in the event that a patient enters the clinic in with low tumor burden, preliminary 
results indicate that assays can be developed with unpurified bone marrow aspirates collected 
at residual disease stage.  Currently, additional tests must be used to monitor light chain 
disease and rare MM cases, including IgD and IgE.  This personalized assay is a single test that 
results in quantitative readouts on all immunoglobulin classes of both heavy and light chain, 
potentially simplifying the analytical process for evaluation of MM tumor burden. Taken together, 
personalized LC-MRM assays could have a very positive impact on improving patient outcomes. 
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APPENDIX B: 
ACTIVITY-BASED PROTEIN PROFILING PRECURSOR LIST FOR PRM ON Q EXACTIVE 
 
Mass [m/z] Species 
CS 
[z] 
Start 
[min] 
End 
[min] 
NCE 
493.7683 SSAAPPPPPR 2 15 23 30 
713.7402 DLKPANIFISTEDLVLK 3 15.26 23.26 30 
1056.60118 DLKPANIFISTEDLVLK 2 15.26 23.26 30 
1305.158307 YLQDDTSDPTYTSSLGGKIPVR 2 15.26 23.26 30 
528.283254 KGEQQNR 2 15.47 23.47 30 
496.286748 HVLTSIGEK 2 15.76 23.76 30 
533.332466 SHFIVALKVLFK 3 16.84 24.84 30 
536.31148 EKTDRVK 2 16.88 24.88 30 
451.283477 DIPVPKPK 2 17.87 25.87 30 
498.801083 VKAAQAGR 2 17.89 25.89 30 
506.79854 REDKLR 2 17.96 25.96 30 
631.359827 AGAHLQGGAKR 2 19 23 30 
468.589599 KAHRTEFYR 3 20.73 28.73 30 
462.283224 KKPLWLEFK 3 20.89 28.89 30 
561.306729 DHQKLER 2 21.02 29.02 30 
1065.250454 WIEAGPVVLKHPASEAEIQPQTQVTLR 3 21.03 29.03 30 
422.73636 IGDYAGIK 2 21.15 29.15 30 
566.315 DLKPENLLYATPAPDAPLK 4 21.16 29.16 30 
754.75 DLKPENLLYATPAPDAPLK 3 21.16 29.16 30 
1131.622644 DLKPENLLYATPAPDAPLK 2 21.16 29.16 30 
580.363516 HEIKLPVK 2 21.24 29.24 30 
566.294857 RLCEHKYGNAPR 3 21.34 29.34 30 
479.800217 ILSSKSK 2 23.55 34 30 
532.365527 VKIPVAIK 2 24.54 32.54 30 
538.838671 KGHPLLVAVKILRPDATK 4 24.69 32.69 30 
595.334098 TSVAVKTCK 2 25.52 33.52 30 
521.976577 KTGHVIAVKQMR 3 26.07 34.07 30 
762.414465 EYHAEGGKVPIK 2 26.73 34.73 30 
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525.828255 VMLVKHK 2 26.93 34.93 30 
695.832445 TASEFDSAIAQDK 2 27.36 35.36 30 
498.316034 ITKNVPK 2 27.65 35.65 30 
519.299602 HKIISIFSGTEK 3 27.84 35.84 30 
513.777156 DLKPENLLCMGPELVK 4 28.01 36.01 30 
628.996477 DVKPHNVMIDHQQK 3 28.18 36.18 30 
492.817356 VAVKMLK 2 28.29 34 30 
1113.269408 QLASALSYLEDKDLVHGNVCTKNLLLAR 3 28.53 36.53 30 
473.297645 LYAVKR 2 28.67 36.67 30 
589.839677 VWAGKFFK 2 28.71 36.71 30 
586.800329 SAAGAFGPELSR 2 28.97 36.97 30 
480.287277 GNFAKVK 2 29.14 37.14 30 
484.306001 NLKIQR 2 29.35 37.35 30 
681.028611 ITDFGLSKEAIDHDKR 3 29.39 37.39 30 
699.904888 DLKLENIMVK 2 29.85 37.85 30 
651.364389 EAVAICKGFLTKHPGK 3 30.1 38.1 30 
505.323859 TGAKLPVK 2 30.29 38.29 30 
554.653039 NRETHEIVALKR 3 29 37 30 
656.3726 ALKLNSNEAR 2 30.98 38.98 30 
581.676961 ARDGTTFPLSLKLK 3 34 42 30 
507.312438 VAVKCIK 2 31.21 39.21 30 
740.935368 YAAVKIHQLNK 2 31.22 39.22 30 
770.874847 NTCTSVYTKDR 2 31.37 39.37 30 
547.823169 KLHMELK 2 31.85 39.85 30 
470.813127 VAVKSLK 2 32.02 40.02 30 
713.372266 FYDSNTVKQK 2 32.39 40.39 30 
644.857741 HYAMKVLSK 2 32.47 40.47 30 
530.644716 GSAHLVALKCIPK 3 32.73 40.73 30 
542.97864 WISQDKEVAVKK 3 32.81 40.81 30 
488.302927 TYVIKR 2 32.82 40.82 30 
530.300916 NKEFVAR 2 32.88 40.88 30 
506.957294 HVPSGQIMAVKR 3 32.9 40.9 30 
468.927112 LDGCIYAIKR 3 28 36 30 
705.056612 VRFPSHFSSDLKDLLR 3 29 38 30 
606.851304 KIHRDIKAGNILLNTEGHAK 4 33.1 41.1 30 
546.848033 GGKGLLPVR 2 31 40 30 
522.305144 IAIKSCR 2 33.76 41.76 30 
681.721007 DIKGDNVLINTFSGLLK 3 34.07 42.07 30 
681.721007 DLKPENILLDEIGHIK 3 34.07 42.07 30 
526.832383 GNLVAVKR 2 34.07 42.07 30 
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468.803094 GGKIPIR 2 34.2 42.2 30 
491.809531 IAKMPVK 2 34.32 42.32 30 
482.78437 FFQKAK 2 34.51 42.51 30 
603.827494 ISDFGTSKR 2 36 45 30 
754.951018 YVAVKIHQLNK 2 34.82 42.82 30 
828.943784 EASSTQDTGKLPVK 2 34.96 42.96 30 
656.033362 DLKAENLLLDAEANIK 3 38 46 30 
464.902854 VDDCNYAIKR 3 37 47 30 
554.317544 DLKVENILLHDR 3 36.11 44.11 30 
773.895577 ELGQSGVDTYLQTK 2 36.16 44.16 30 
774.452809 EVAIKIIDKTQLNPSSLQK 3 36.19 44.19 30 
612.395347 SQVALKIIR 2 36.51 44.51 30 
566.329673 TIGKGNFAK 2 38 44 30 
628.348928 WQKTGNAVR 2 37.18 45.18 30 
628.090685 TDREIKVTLVFEHVDQDLR 4 37.31 45.31 30 
575.328221 KLQLELNQEREK 3 37.64 45.64 30 
573.81693 LGDFGASKR 2 40 48 30 
600.336722 LRADNTLVAVKSCR 3 40 48 30 
609.335487 AAGIGKDFKENPNLR 3 38.43 46.43 30 
541.645661 IAIKEIPERDSR 3 38.69 46.69 30 
491.81841 LKVEAVK 2 36 46 30 
518.029471 DLKPENIMLNHQGHVK 4 38.72 46.72 30 
628.846319 KGGCAMLPVK 2 39.17 47.17 30 
618.347504 DVKPENFLVGRPGTK 3 40 50 30 
680.848427 KIYSGDYYR 2 39.51 47.51 30 
542.829309 QGAKFPIK 2 42 48.27 30 
704.054937 KIRLESEEEGVPSTAIR 3 42 50 30 
587.995525 WKGQYDVAVKMIK 3 40.54 48.54 30 
580.837331 LGDYGLAKK 2 43 51 30 
682.377017 DLKLDNLLLDTEGYVK 3 41.75 49.75 30 
686.392479 IQCAIKSLSR 2 41.96 49.96 30 
725.144963 KYSLTVAVKTLKEDTMEVEEFLK 4 41.98 49.98 30 
558.325982 GLILVGGYGTR 2 41.99 49.99 30 
553.645661 DLKPENLILDHR 3 42.01 50.01 30 
554.863683 VAIKIVNR 2 42.13 50.13 30 
664.851501 DFKENPNLR 2 48 54 30 
765.408857 ADNTLVAVKSCR 2 42.51 50.51 30 
554.863683 VAVKILNR 2 42.59 50.59 30 
492.968076 LKGAVLAAVSSHK 3 42.62 50.62 30 
541.358233 VVAIKSIR 2 42.9 50.9 30 
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558.362985 LYAVKVVK 2 42.95 50.95 30 
616.871705 ALYATKTLR 2 43.04 51.04 30 
612.389731 TIAPALVSKK 2 43.32 51.32 30 
656.886498 EVVAIKCVAK 2 46 54 30 
753.050186 YIKYNSNSGFVRDDNIR 3 43.39 51.39 30 
636.860283 HYAMKVLSK 2 43.43 51.43 30 
521.033911 DLKPENILLDDHGHIR 4 43.65 51.65 30 
550.657678 SVKASHILISVDGK 3 42 50 30 
742.732807 NLIPMDPNGLSDPYVKLK 3 44.16 52.16 30 
777.42155 KHFNTGPKPNSTAAGVSVIATTALDKER 4 44.77 52.77 30 
966.524192 KYSLTVAVKTLKEDTMEVEEFLK 3 44.77 52.77 30 
534.344792 VAVKVIDK 2 42 50 30 
534.362985 VAIKIISK 2 44.81 52.81 30 
801.411503 GILFVGSGVSGGEEGAR 2 44.83 52.83 30 
574.34902 IYAMKVVK 2 44.89 52.89 30 
591.858263 DVAVKVIDK 2 46 63 30 
681.69675 LTDFGLSKESIDHEKK 3 45.11 53.11 30 
713.740178 DLKPANLFINTEDLVLK 3 45.14 53.14 30 
605.873913 DVAIKIIDK 2 48 56 30 
554.347866 VPADLLKR 2 47 55 30 
680.403369 GVYQISKQIK 2 45.68 53.68 30 
814.024517 KLIHLEIKPAIR 2 45.76 53.76 30 
822.430647 YIKYNSNSGFVR 2 45.86 53.86 30 
688.332187 MYAMKYMNK 2 45.86 53.86 30 
676.365112 LTDFGLSKEAIDHEKK 3 45.97 53.97 30 
540.813659 FTSKFVR 2 46.4 54.4 30 
612.881738 EVAIKIIDK 2 46.46 56 30 
559.343738 FVAMKVVK 2 46.59 54.59 30 
902.939664 TIDAGCKPYMAPER 2 53 59 30 
622.034926 DLKPANLLISASGQLK 3 46.95 54.95 30 
701.394125 LKMEKEKEGFPITSLR 3 46.95 54.95 30 
707.395182 DLKPENLLLDEKNNIR 3 50 58 30 
470.302927 KDVLLR 2 47.36 55.36 30 
598.866088 DVAIKVIDK 2 53 60 30 
620.34754 DIKPGNIMR 2 47.66 55.66 30 
711.919384 DVKPSNVLINK 2 47.66 55.66 30 
694.353876 KIYNGDYYR 2 48.05 56.05 30 
550.844959 GFNKVVLK 2 48.07 56.07 30 
548.366059 LVAIKSIR 2 48.18 56.18 30 
486.96081 EYAIKILEKR 3 48.56 56.56 30 
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558.842416 LLGKGTFGK 2 48.66 56.66 30 
606.380851 LVAIKCIAK 2 49 56 30 
654.89792 DLKPSNIVVK 2 48.98 56.98 30 
645.35705 TMKIAICTR 2 49.01 57.01 30 
835.446271 VSDFGLTKEASSTQDTGKLPVK 3 53 59 30 
723.409183 SKNIFLTQNGK 2 52 60 30 
612.871174 KVEAPFIPK 2 49.45 57.45 30 
785.424507 DVKPSNMLVNTR 2 50 60 30 
694.382331 DLKPHNILISMPNAHGK 3 50.02 58.02 30 
766.44068 EVAVKIIDKTQLNSSSLQK 3 51.04 59.04 30 
487.9887 VKIPVAIKELR 3 51.86 59.86 30 
628.344997 DIKPGNIMR 2 52.4 60.4 30 
706.706592 LMTGDTYTAHAGAKFPIK 3 53.93 61.93 30 
653.887158 KVWAGKFFK 2 53.98 61.98 30 
829.772095 IGDFGLTKAIETDKEYYTVK 3 54.1 62.1 30 
783.403349 LIKDDEYNPCQGSKFPIK 3 54.1 62.1 30 
653.866954 GGYGKVFQVR 2 54.46 62.46 30 
645.358627 LSKGDGLEFK 2 57 63 30 
515.289011 DIKPDNILIDRDGHIK 4 54.67 62.67 30 
706.388251 TVDGPSGKLWR 2 57 63 30 
882.480534 TSTQEYAAKIINTK 2 57 63 30 
790.438137 LGLPGDEVDNKVK 2 55.19 63.19 30 
945.525807 DIKAGNILLNTEGHAK 2 55.45 63.45 30 
608.331854 QELNKTVWEVPQR 3 55.65 63.65 30 
769.438472 DVKPSNILVNSR 2 59 66 30 
521.029137 DLKPENILLDDNMNIK 4 55.82 63.82 30 
642.389731 EVFAGKIVPK 2 55.82 63.82 30 
725.900659 YFEGVSPKSLK 2 55.91 63.91 30 
506.532541 DLKPANILLDEHGHVR 4 55.91 63.91 30 
669.927012 LLQSAKTILR 2 54 62 30 
688.357573 KPTMYPEWK 2 56.51 64.51 30 
498.801809 LTILEELR 2 56.53 64.53 30 
682.390262 GAFGKVYLGQK 2 56.54 64.54 30 
617.897723 IPVAIKELR 2 56.72 64.72 30 
591.86388 SLDVVGKIR 2 56.73 64.73 30 
584.876259 APVAIKVFK 2 57.07 65.07 30 
598.361504 DIKGANILR 2 57.38 65.38 30 
669.362825 DLKPENIMLSSQGHIK 3 57.42 65.42 30 
662.378804 HKAEEVFYAVKVLQK 3 60 67 30 
786.084673 VIEDDPEAVYTTTGGKIPVR 3 57.79 65.79 30 
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627.351137 DVKPENFLIGRPGNK 3 57.81 65.81 30 
646.392273 FYAVKVLQK 2 57.84 65.84 30 
960.033465 DIKAANVLLSEHGEVK 2 57.85 65.85 30 
541.29474 QTHEKWQDILK 3 57.92 65.92 30 
530.811116 AIGKGSFGK 2 57.95 65.95 30 
650.341923 YSFGATCVKK 2 57.96 65.96 30 
778.387587 LAYNENDNTYYAMKVLSK 3 57.98 65.98 30 
800.437417 DTGHVYAMKILR 2 58.03 66.03 30 
835.154651 DTVTIHSVGGTITILPTKTKPK 3 57 63 30 
660.70307 DIKPGNLLVNSNCVLK 3 58.24 66.24 30 
696.393336 LGSGKFGQVFR 2 58.27 66.27 30 
654.418488 EIPVAIKTLK 2 5456 68 30 
661.37383 DLKPANVFLDGKQNVK 3 59 67 30 
671.717485 DLKPSNVLLDPELHVK 3 58 68 30 
660.874779 GKFGNVYLAR 2 59.26 67.26 30 
671.362602 DLKAENLLLDADMNIK 3 57 65 30 
635.35818 DIKGANILLTDNGHVK 3 59.5 67.5 30 
644.358068 DIKPSNLLVGEDGHIK 3 60.12 68.12 30 
740.105855 IQSIAPSLQVITSKQRPR 3 57 64 30 
695.405353 HEIKLPVKWTAPEAIR 3 62 71 30 
636.380851 LFAVKCIPK 2 60 67 30 
572.315147 VDTHALYAMKTLR 3 60.97 68.97 30 
574.34902 TFAMKILK 2 61.15 69.15 30 
996.4984 IQKSSNFGYITSCYK 2 61.25 69.25 30 
629.400098 GTFGKVILVK 2 61.33 69.33 30 
535.352617 TVAIKTLK 2 56 64 30 
714.405586 DMKAANVLITR 2 66 72 30 
807.930745 AIQFLHQDSPSLIHGDIKSSNVLLDER 4 61.67 69.67 30 
645.029952 DLKSPNVLVTHTDAVK 3 61.67 69.67 30 
766.928894 EAVAICKGFLTK 2 64 72 30 
635.897723 QKKIFSK 2 61.7 69.7 30 
653.007036 DLKPENLLFDEYHK 3 62.01 70.01 30 
726.450851 DVAVKVIDKLR 2 62.05 70.05 30 
922.019826 IPTGQEYAAKIINTK 2 64 71 30 
828.448514 DIKCSNILLNNR 2 65 73 30 
635.686185 DIKGANILLTDHGDVK 3 62 71 30 
554.384251 LVALKVIR 2 62.66 70.66 30 
811.469241 VKVLGSGAFGTVYK 2 62.7 70.7 30 
779.124692 EVAIKIIDKTQLNPTSLQK 3 63.59 71.59 30 
895.473221 YIHSMSLVHMDIKPSNIFISR 3 63.87 71.87 30 
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1051.560044 QEDGGVYSSSGLKQIPIK 2 63.91 71.91 30 
643.403172 GTFGKVILVR 2 64.13 72.13 30 
864.777909 FLEDDTSDPTYTSALGGKIPIR 3 63 70 30 
810.969605 DLKPQNLLINEK 2 64.7 72.7 30 
1161.940457 SPGQPIQVVYVPSHLYHMVFELFKNAMR 3 64.7 72.7 30 
786.744428 VLEDDPEATYTTSGGKIPIR 3 64.76 72.76 30 
615.028217 ILKSLHHPNIVGYR 3 64.83 72.83 30 
657.885444 VMVMKELIR 2 64 75 30 
668.690942 DLKPENVLLDAHMNAK 3 65.65 73.65 30 
767.918526 LSDFGLCTGLKK 2 65.84 73.84 30 
818.477066 IKVLGSGAFGTVYK 2 66.05 74.05 30 
803.441014 IGQGTFGEVFKAR 2 66.1 74.1 30 
868.777909 FLEDDPSDPTYTSSLGGKIPIR 3 68 75 30 
839.486847 VQVAVKHLHIHTPLLDSERK 3 65 73 30 
629.866954 VQVAVKHLHIHTPLLDSERK 4 65 73 30 
728.433812 VSGDLVALKMVK 2 65 72 30 
761.969408 TIVLQEIIGKGR 2 66.37 74.37 30 
722.750855 VAIKIIDKTQLDEENLK 3 70 78 30 
821.47472 ETSVLAAAKVIDTK 2 66.82 74.82 30 
629.957576 DMYDKEYYSVHNK 3 66.82 74.82 30 
523.797674 AKEDFLK 2 66.82 74.82 30 
682.88227 IGKGSFGEVFK 2 67.58 75.58 30 
566.998935 DKVSGDLVALKMVK 3 67.59 75.59 30 
984.044029 DIKGQNVLLTENAEVK 2 67.61 75.61 30 
938.514974 VAIKTLKPGTMSPEAFLQEAQVMK 3 68.18 76.18 30 
938.520216 LVKIGDFGLAKAVPEGHEYYRVR 3 68.19 76.19 30 
626.392805 SVPVAVKSLR 2 68.19 76.19 30 
627.395013 DVAVAIKTLK 2 68.19 76.19 30 
646.373718 DLKPQNILVTSSGQIK 3 65 75 30 
698.419551 NLLQVDLTKR 2 68.38 76.38 30 
760.94339 DLKPENLLVQR 2 73 78 30 
761.435398 DLKPENILLDR 2 72 80 30 
760.451382 DLKPQNLLINR 2 71 79 30 
678.903536 EIQNLKLFR 2 68.87 76.87 30 
919.043301 DIKPGNLLLTTGGTLK 2 72 82 30 
1230.342685 YLNEIKPPIIHYDLKPGNILLVNGTACGEIK 3 69.24 77.24 30 
676.916644 IGDLGLATLKR 2 69.26 77.26 30 
904.468024 IIHTDIKPENILMCVDDAYVR 3 72 80 30 
824.972679 DLKPQNLLINER 2 69.76 79 30 
833.498529 NVNTGELAAIKVIK 2 68 75 30 
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825.956694 DIKPENLLLDER 2 69.85 77.85 30 
701.906276 ISDFGLSKALR 2 69.99 77.99 30 
765.935565 DLKTQNVFLTR 2 75 83 30 
1301.984903 DLKPTNILLGDEGQPVLMDLGSMNQACIHVEGSR 3 70.76 78.76 30 
923.825871 YSLTVAVKTLKEDTMEVEEFLK 3 70.76 78.76 30 
811.941044 DVKPDNILLDER 2 70.86 78.86 30 
934.030391 DLKPENILVTSGGTVK 2 74 82 30 
707.358205 FYIMMCKPK 2 71.18 79.18 30 
948.525472 DIKAANVLLSEQGDVK 2 76 84 30 
804.453787 DLKPQNLLIDDK 2 75 83 30 
604.031404 SKLTENLVALKEIR 3 75 82 30 
719.740401 IGHYVLGDTLGVGTFGKVK 3 71.67 79.67 30 
708.057847 QVLGLGVNGKVLECFHR 3 71.8 79.8 30 
672.040851 DIKPDNVLLDVNGHIR 3 70 78 30 
740.430115 DIKPSNILLDR 2 75 83 30 
811.95362 DLKPENLLLDEK 2 72.42 80.42 30 
824.49646 GLWIPEGEKVKIPVAIKELR 3 72.54 80.54 30 
687.040516 DLKPENILLDEEGHIK 3 72.86 80.86 30 
793.440157 VAIKTVNEAASMR 2 73.12 81.12 30 
723.879736 KIGCGNFGELR 2 72 83 30 
947.523264 DIKGANILINDAGEVR 2 75 83 30 
946.546208 DIKAGNILLTEPGQVK 2 75 83 30 
905.454516 VFKVDNEDIYESR 2 73.45 81.45 30 
773.910898 SSEKQALMSELK 2 73.45 81.45 30 
784.474523 DLKSSNILILQK 2 74 85 30 
783.940513 DIKPDNLLLDSK 2 76 84 30 
599.359521 SKLTDNLVALKEIR 3 72 82 30 
727.711059 DIKPENLLVYEHQDGSK 3 73.79 81.79 30 
911.009458 DLKPENIVLQDVGGK 2 72 80 30 
694.712511 DLKSNNIFLHEDLTVK 3 73.81 81.81 30 
640.382325 DLKTSNLLLSHAGILK 3 74.14 82.14 30 
916.523067 DLKPQNILLSNPAGR 2 77 85 30 
672.612051 KVDYTKNINPNWSVNIKGGTSR 4 74.6 82.6 30 
550.991892 AACLLDGVPVALKK 3 74.74 82.74 30 
742.417008 DVKPENFLIGR 2 78 86 30 
864.952255 MLDVLEYIHENEYVHGDIKAANLLLGYK 4 90 105 30 
659.699437 DLKPDNLLVTSMGHIK 3 75.74 83.74 30 
756.924666 DLKPANVFLDGK 2 80 86 30 
559.334647 VLGTGAYGKVFLVR 3 76.02 84.02 30 
747.731571 YVLDDQYVSSVGTKFPVK 3 76.62 84.62 30 
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982.033996 DLKPENIVLQQGEQR 2 76.82 84.82 30 
662.900994 NTNQIVAIKK 2 76.82 84.82 30 
768.953423 DLKPENLLLASK 2 80 88 30 
1028.255205 AIHKETGQIVAIKQVPVESDLQEIIK 3 74 83 30 
790.972147 LTDNLVALKEIR 2 77.21 85.21 30 
532.315364 WQGNDIVVKVLK 3 77.71 85.71 30 
730.429584 KSLAYVDNILK 2 77.71 85.71 30 
915.012001 ETGQQFAVKIVDVAK 2 78.36 86.36 30 
891.989057 DVKGANLLIDSTGQR 2 74 84 30 
659.397864 DIKPENLLLGLKGELK 3 78.92 86.92 30 
869.781542 FLEENSSDPTYTSSLGGKIPIR 3 79.32 87.32 30 
1044.867787 LTHTDLKPENILFVQSDYTEAYNPK 3 76 85 30 
639.686185 DIKPSNLLLGDDGHVK 3 79.75 87.75 30 
786.936916 DLKVSNLLMTDK 2 79.84 87.84 30 
751.020465 KDVILQDDDVECTMTEK 3 79.85 87.85 30 
664.371321 DLKPDNLLITSMGHIK 3 79.98 87.98 30 
665.049123 DLKAENLLLDANLNIK 3 80.16 88.16 30 
925.043301 DVKAGNILLSEPGLVK 2 82 90 30 
1221.629186 DLKPSNILYVDESGNPESIR 2 84 92 30 
766.100992 IHRDIKAGNILLNTEGHAK 3 81.36 89.36 30 
684.365112 DLKPVNIFLDSDDHVK 3 85 92 30 
781.423976 EKFLQEALTMR 2 81.54 89.54 30 
699.747951 VMASKKKPLWLEFK 3 81.55 89.55 30 
830.950881 DLKPENVVFFEK 2 81.81 89.81 30 
839.0881 DLKPSNILYVDESGNPECLR 3 84 93 30 
1258.128496 DLKPSNILYVDESGNPECLR 2 82.09 90.09 30 
838.000708 VLGQGSFGKVFLVK 2 82.34 90.34 30 
703.044261 DLKPENILLDDYGHIR 3 77 85 30 
982.064765 DLKPQNLLINTEGAIK 2 82.61 90.61 30 
1021.05354 DLKPSNLLINTTCDLK 2 86 94 30 
967.516143 NIVHCDLKPENVLLASADPFPQVK 3 82.81 90.81 30 
681.013862 DLKPSNLAVNEDCELK 3 85 93 30 
681.038119 DLKPSNLLLNTTCDLK 3 86 94 30 
1033.037358 DLKPSNIFFTMDDVVK 2 86 94 30 
737.430115 HILTGKEVAVKIIDKTQLNSSSLQK 4 82.88 90.88 30 
907.512168 FLSGLELVKQGAEAR 2 82.98 90.98 30 
1005.527831 TVSVAVKCLKPDVLSQPEAMDDFIR 3 83.78 91.78 30 
1358.372427 IMSSAKRPLWLNWENPDIMSELLFQNNEIIFK 3 86 96 30 
1019.031139 IMSSAKRPLWLNWENPDIMSELLFQNNEIIFK 4 86 96 30 
991.202441 YSVKVLPWLSPEVLQQNLQGYDAK 3 84.59 92.59 30 
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681.362825 DMKSNNIFLHEGLTVK 3 84.77 92.77 30 
683.0309 DLKSPNMLITYDDVVK 3 84.78 92.78 30 
1024.042641 DLKSPNMLITYDDVVK 2 84.78 92.78 30 
665.031075 DLKPDNLLVTSMGHIK 3 81 89 30 
976.0195 DLKPANILVMGEGPER 2 90 98 30 
968.022043 DLKPANILVMGEGPER 2 85.18 93.18 30 
996.062222 DLKPNNLLLDENGVLK 2 86.83 94.83 30 
969.981863 ISMADVKFSFQCPGR 2 87.18 95.18 30 
692.731906 DLKPQNLLINERGELK 3 87.78 95.78 30 
843.477263 DLKPSNIFLVDTK 2 88.01 96.01 30 
1038.09098 DIKPQNLLVDPDTAVLK 2 88.06 96.06 30 
883.458182 DLKSNNILLLQPIESDDMEHK 3 88.86 96.86 30 
658.385847 DLKPDNLLITSLGHIK 3 87 94 30 
710.091545 LSVIHRDVKPSNVLINK 3 89.32 97.32 30 
935.045844 DIKPANVFITATGVVK 2 89.38 97.38 30 
927.52019 DVKGNNILLTTEGGVK 2 89.46 97.46 30 
849.480704 QIAQEIIKGMGYLHAKGIVHK 3 86 94 30 
1105.598114 NLIPMDPNGLSDPYVKLK 2 89.58 97.58 30 
947.038216 DIKPENLLLGSAGELK 2 89.63 97.63 30 
758.442691 DGTTFPLSLKLK 2 89.78 97.78 30 
1014.537723 DLKAENLLLDADMNIK 2 57 65 30 
676.6942  3 90.13 98.13 30 
1007.043506 DIKCSNILLNNSGQIK 2 93 100 30 
920.46556 YEIVGNLGEGTFGKVVECLDHAR 3 90.43 98.43 30 
815.437083 DVKPDNFLMGLGK 2 91.75 99.75 30 
934.514974 VAVKTLKPGTMSVQAFLEEANLMK 3 91.85 99.85 30 
697.068295 DIKPQNLLLDPDTAVLK 3 95 103 30 
631.038559 DVKPSNVLINALGQVK 3 93.42 101.42 30 
1101.059876 YVLDDQYTSSSGAKFPVK 2 93.46 101.46 30 
772.122623 VLLSEFRPSGELFAIKALK 3 93.96 101.96 30 
836.447982 DIKPDNFLMGIGR 2 96 105 30 
731.141484 DLKPENILLDSQGHIVLTDFGLCK 4 94.2 102.2 30 
751.453059 DIKTLNIFLTK 2 96.06 104.06 30 
751.932491 DIKSQNIFLTK 2 98 106 30 
925.126655 FFSSKTTAAHSLVGTPYYMSPER 3 97.25 105.25 30 
673.379037 TMVDKLLSSR 2 97.89 105.89 30 
1031.088771 GGPNIITLADIVKDPVSR 2 97.95 105.95 30 
941.163041 EGAKFPIKWTAPEAINFGCFTIK 3 98.3 106.3 30 
901.008927 ITDFGLAKLLGAEEK 2 98.63 106.63 30 
937.043301 DIKGANIFLTSSGLIK 2 98.96 106.96 30 
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995.524949 LADFGVAGQLTDTMAKR 2 99.52 107.52 30 
1317.241643 ETGQIVAIKQVPVESDLQEIIK 2 100.2 108.2 30 
828.13 IIHRDLKPENIVLQQGEQR 3 100.2 108.2 30 
1241.698071 IIHRDLKPENIVLQQGEQR 2 100.24 108.24 30 
747.91411 HAQSGTIMAVKR 2 101.22 109.22 30 
864.954566 TGQLAAIKVMDVTGDEEEEIKQEINMLKK 4 101.36 109.36 30 
632.038447 DIKGANLLLTLQGDVK 3 101 112 30 
973.035673 DIKSANILLDEAFTAK 2 102.26 110.26 30 
672.3772 DIKPDNILIDLDGHIK 3 103.58 114 30 
1008.062222 DIKPDNILIDLDGHIK 2 103.58 114 30 
999.501671 DLKPSNVAVNEDCELR 2 106 114 30 
998.207421 TGDLFAIKVFNNISFLRPVDVQMR 3 103.83 114 30 
717.394125 QKVIGAGEFGEVYKGMLK 3 104.26 112.26 30 
752.41562 CALKLLYDSPK 2 105.86 115 30 
1028.56988 DLKLGNLFLNEDLEVK 2 106 114 30 
965.038216 DLKAGNILFTLDGDIK 2 106 114 30 
647.687309 DLKAGNVLMTLEGDIR 3 106 114 30 
972.598243 DLKPPNLLLVAGGTVLK 2 106 114 30 
499.323859 SKNILVK 2 106 114 30 
962.057411 ENRVLHFWTLKKR 2 106 114 30 
1074.094585 DLKPGNILITGPDSQGLGR 2 104 114 30 
992.506306 VCQGTSNKLTQLGTFEDHFLSLQR 3 106 114 30 
1006.011872 DLKPGNLAVNEDCELK 2 106 114 30 
957.856343 VAIKTLKPGTMMPEAFLQEAQIMK 3 106 114 30 
1085.635357 EGAKFPIK 1 106 114 30 
1041.548622 DLKPSNLLVNENCELK 2 106 114 30 
1201.628207 DVKAGNILLGEDGSVQIADFGVSAFLATGGDITR 3 106 114 30 
623.041023 VLGVIDKVLLVMDTR 3 106 114 30 
871.463207 NKEER 1 106 114 30 
879.484565 DVKPDNFLMGLGKK 2 106 114 30 
472.302618 FILKVRPAFK 3 106 114 30 
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APPENDIX C: 
PEPTIDE CHARACTERIZATION REPORT FOR EGFR PEPTIDE – IPENLQIIR 
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MALDI MS Peptide Report for Stable Isotope-Labeled 
IPLENLQIIR from EGFR_HUMAN
Mass Spectrum of C-terminal Arg (+10) Labeled IPLENLQIIR:
Tandem Mass Spectrum of C-terminal Arg (+10) Labeled IPLENLQIIR: 
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• Isotope Incorporation: >98%
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Matrix-assisted laser desorption ionization mass spectrometry (4700, Sciex) was used to examine 
synthetic and stable isotope-labeled peptides.  An aliquot of each peptide (500 fmol) was deposited with 
a-cyano-4-hydroxycinnamic acid (10 mg/ml in 60% ACN) on the MALDI target.  Mass spectra were 
acquired in positive ion mode using laser power 2,550 a.u. to examine isotope incorporation and detect 
any incomplete amino acid coupling steps or failure to remove protecting groups.  Tandem mass spectra 
are acquired using 3,500 a.u. laser power for sequence verification and identification of any contaminants.
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Infusion Assay Workup for Stable Isotope-Labeled 
IPLENLQIIR from EGFR_HUMAN
MS of C-term Arg (+10) Labeled IPLENLQIIR:
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Collision Energy Optimization for doubly charged ion, 609.83 m/z:
Electrospray ionization using a triple quadrupole mass 
spectrometer (TSQ Vantage, Thermo) was used to 
analyze synthetic and stable isotope-labeled peptides. 
Peptides were prepared as 1 µM solutions in 30% ACN, 
0.1% Formic Acid and directly infused for one minute into 
the instrument at 0.300 µL/min. Mass spectra were 
acquired in positive ion mode using a spray voltage of 
2,400 in order to determine charge state distribution and 
verify modifications identified in MALDI-MS analysis. 
Product ion spectra were acquired in centroid mode using 
a collision energy (CE) sufficient to fragment the parent ion 
to <20% (specified below). CE optimization was performed 
for fragment ions with m/z larger than parent ion or the top 
five ion signals (if not enough high transitions exist).
Methods:
[M + 2H]+2
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APPENDIX D: 
MRM TRANSITION LIST FOR RAS SIGNALING TARGET PANEL ON QUANTIVA 
 
Compound 
Start 
Time 
(min) 
End 
Time 
(min) 
Precursor 
(m/z) 
Product 
(m/z) 
Collision 
Energy 
(V) 
Dwell 
Time 
(ms) 
AC[+57.0]QEQIEALLESSLR (heavy)(+3) 53.92 59.92 586.297 714.402 17.9 16 
AC[+57.0]QEQIEALLESSLR (heavy)(+3) 53.92 59.92 586.297 601.3179 16.6 16 
AC[+57.0]QEQIEALLESSLR (heavy)(+3) 53.92 59.92 586.297 472.2753 16.6 16 
AC[+57.0]QEQIEALLESSLR (heavy)(+3) 53.92 59.92 586.297 385.2433 15.3 16 
AC[+57.0]QEQIEALLESSLR (heavy)(+3) 53.92 59.92 586.297 930.3986 16.6 16 
AC[+57.0]QEQIEALLESSLR(+3) 53.92 59.92 582.961 704.3937 17.9 16 
AC[+57.0]QEQIEALLESSLR(+3) 53.92 59.92 582.961 591.3097 16.6 16 
AC[+57.0]QEQIEALLESSLR(+3) 53.92 59.92 582.961 462.2671 16.6 16 
AC[+57.0]QEQIEALLESSLR(+3) 53.92 59.92 582.961 375.235 15.3 16 
AC[+57.0]QEQIEALLESSLR(+3) 53.92 59.92 582.961 930.3986 16.6 16 
AEETC[+57.0]APSVSYFK (heavy)(+2) 31.8 37.8 748.844 1167.559 24.2 16 
AEETC[+57.0]APSVSYFK (heavy)(+2) 31.8 37.8 748.844 1066.512 24.2 16 
AEETC[+57.0]APSVSYFK (heavy)(+2) 31.8 37.8 748.844 906.4811 24.2 16 
AEETC[+57.0]APSVSYFK (heavy)(+2) 31.8 37.8 748.844 835.444 24.2 16 
AEETC[+57.0]APSVSYFK (heavy)(+2) 31.8 37.8 748.844 552.2908 24.2 16 
AEETC[+57.0]APSVSYFK(+2) 31.8 37.8 744.837 1159.545 24.2 16 
AEETC[+57.0]APSVSYFK(+2) 31.8 37.8 744.837 1058.498 24.2 16 
AEETC[+57.0]APSVSYFK(+2) 31.8 37.8 744.837 898.4669 24.2 16 
AEETC[+57.0]APSVSYFK(+2) 31.8 37.8 744.837 827.4298 24.2 16 
AEETC[+57.0]APSVSYFK(+2) 31.8 37.8 744.837 544.2766 24.2 16 
AGFQTEDFSLYAC[+57.0]ASPK 
(heavy)(+2) 
45.65 51.65 950.437 1496.682 31.1 16 
AGFQTEDFSLYAC[+57.0]ASPK 
(heavy)(+2) 
45.65 51.65 950.437 1266.591 31.1 16 
AGFQTEDFSLYAC[+57.0]ASPK 
(heavy)(+2) 
45.65 51.65 950.437 1004.496 29.8 16 
AGFQTEDFSLYAC[+57.0]ASPK 
(heavy)(+2) 
45.65 51.65 950.437 804.38 28.5 16 
AGFQTEDFSLYAC[+57.0]ASPK 
(heavy)(+2) 
45.65 51.65 950.437 641.3167 29.8 16 
AGFQTEDFSLYAC[+57.0]ASPK(+2) 45.65 51.65 946.43 1488.668 31.1 16 
AGFQTEDFSLYAC[+57.0]ASPK(+2) 45.65 51.65 946.43 1258.577 31.1 16 
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AGFQTEDFSLYAC[+57.0]ASPK(+2) 45.65 51.65 946.43 996.4819 29.8 16 
AGFQTEDFSLYAC[+57.0]ASPK(+2) 45.65 51.65 946.43 796.3658 28.5 16 
AGFQTEDFSLYAC[+57.0]ASPK(+2) 45.65 51.65 946.43 633.3025 29.8 16 
ALDLLDR (heavy)(+2) 33.75 39.75 413.238 754.4333 15.8 14 
ALDLLDR (heavy)(+2) 33.75 39.75 413.238 641.3492 14 14 
ALDLLDR (heavy)(+2) 33.75 39.75 413.238 526.3223 17.9 14 
ALDLLDR (heavy)(+2) 33.75 39.75 413.238 300.1554 15.3 14 
ALDLLDR(+2) 33.75 39.75 408.234 744.425 15.8 14 
ALDLLDR(+2) 33.75 39.75 408.234 631.341 14 14 
ALDLLDR(+2) 33.75 39.75 408.234 516.314 17.9 14 
ALDLLDR(+2) 33.75 39.75 408.234 300.1554 15.3 14 
ALETIGANLQK (heavy)(+2) 27.59 33.59 583.336 981.5455 19.8 16 
ALETIGANLQK (heavy)(+2) 27.59 33.59 583.336 852.5029 19.8 16 
ALETIGANLQK (heavy)(+2) 27.59 33.59 583.336 751.4552 19.8 16 
ALETIGANLQK (heavy)(+2) 27.59 33.59 583.336 638.3711 18.5 16 
ALETIGANLQK(+2) 27.59 33.59 579.329 973.5313 19.8 16 
ALETIGANLQK(+2) 27.59 33.59 579.329 844.4887 19.8 16 
ALETIGANLQK(+2) 27.59 33.59 579.329 743.441 19.8 16 
ALETIGANLQK(+2) 27.59 33.59 579.329 630.357 18.5 16 
ANDALQVLGLLFSLAR (heavy)(+2) 58.75 64.75 855.992 1226.749 30.5 20 
ANDALQVLGLLFSLAR (heavy)(+2) 58.75 64.75 855.992 1098.691 29.2 20 
ANDALQVLGLLFSLAR (heavy)(+2) 58.75 64.75 855.992 999.6225 29.2 20 
ANDALQVLGLLFSLAR (heavy)(+2) 58.75 64.75 855.992 886.5384 27.9 20 
ANDALQVLGLLFSLAR (heavy)(+2) 58.75 64.75 855.992 716.4329 30 20 
ANDALQVLGLLFSLAR(+2) 58.75 64.75 850.988 1216.741 30.5 20 
ANDALQVLGLLFSLAR(+2) 58.75 64.75 850.988 1088.683 29.2 20 
ANDALQVLGLLFSLAR(+2) 58.75 64.75 850.988 989.6142 29.2 20 
ANDALQVLGLLFSLAR(+2) 58.75 64.75 850.988 876.5302 27.9 20 
ANDALQVLGLLFSLAR(+2) 58.75 64.75 850.988 706.4246 30 20 
APHPFGVPAPSAGAYSR (heavy)(+3) 29.28 35.28 564.622 818.4031 19.9 16 
APHPFGVPAPSAGAYSR (heavy)(+3) 29.28 35.28 564.622 563.2812 17.3 16 
APHPFGVPAPSAGAYSR (heavy)(+3) 29.28 35.28 564.622 409.7052 17.3 16 
APHPFGVPAPSAGAYSR (heavy)(+3) 29.28 35.28 564.622 706.3671 19.9 16 
APHPFGVPAPSAGAYSR(+3) 29.28 35.28 561.286 808.3948 19.9 16 
APHPFGVPAPSAGAYSR(+3) 29.28 35.28 561.286 553.2729 17.3 16 
APHPFGVPAPSAGAYSR(+3) 29.28 35.28 561.286 404.701 17.3 16 
APHPFGVPAPSAGAYSR(+3) 29.28 35.28 561.286 706.3671 19.9 16 
AQEALDFYGEVR (heavy)(+2) 39.38 45.38 704.342 1079.54 24 14 
AQEALDFYGEVR (heavy)(+2) 39.38 45.38 704.342 1008.502 24 14 
AQEALDFYGEVR (heavy)(+2) 39.38 45.38 704.342 895.4184 22.7 14 
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AQEALDFYGEVR (heavy)(+2) 39.38 45.38 704.342 780.3914 27.9 14 
AQEALDFYGEVR (heavy)(+2) 39.38 45.38 704.342 633.323 22.7 14 
AQEALDFYGEVR(+2) 39.38 45.38 699.338 1069.531 24 14 
AQEALDFYGEVR(+2) 39.38 45.38 699.338 998.4942 24 14 
AQEALDFYGEVR(+2) 39.38 45.38 699.338 885.4101 22.7 14 
AQEALDFYGEVR(+2) 39.38 45.38 699.338 770.3832 27.9 14 
AQEALDFYGEVR(+2) 39.38 45.38 699.338 623.3148 22.7 14 
AVSMDNSNK (heavy)(+2) 12.3 18.3 487.228 803.3443 18.2 25 
AVSMDNSNK (heavy)(+2) 12.3 18.3 487.228 716.3123 18.2 25 
AVSMDNSNK (heavy)(+2) 12.3 18.3 487.228 585.2718 18.2 25 
AVSMDNSNK (heavy)(+2) 12.3 18.3 487.228 470.2449 18.2 25 
AVSMDNSNK(+2) 12.3 18.3 483.221 795.3301 18.2 25 
AVSMDNSNK(+2) 12.3 18.3 483.221 708.2981 18.2 25 
AVSMDNSNK(+2) 12.3 18.3 483.221 577.2576 18.2 25 
AVSMDNSNK(+2) 12.3 18.3 483.221 462.2307 18.2 25 
AVSMDNSNKYTK (heavy)(+3) 13.56 19.56 455.89 748.4079 19.5 25 
AVSMDNSNKYTK (heavy)(+3) 13.56 19.56 455.89 419.238 20.8 25 
AVSMDNSNKYTK (heavy)(+3) 13.56 19.56 455.89 598.2788 13 25 
AVSMDNSNKYTK (heavy)(+3) 13.56 19.56 455.89 554.7628 15.6 25 
AVSMDNSNKYTK (heavy)(+3) 13.56 19.56 455.89 489.2425 16.9 25 
AVSMDNSNKYTK(+3) 13.56 19.56 453.218 740.3937 19.5 25 
AVSMDNSNKYTK(+3) 13.56 19.56 453.218 411.2238 20.8 25 
AVSMDNSNKYTK(+3) 13.56 19.56 453.218 594.2717 13 25 
AVSMDNSNKYTK(+3) 13.56 19.56 453.218 550.7557 15.6 25 
AVSMDNSNKYTK(+3) 13.56 19.56 453.218 485.2354 16.9 25 
AYPDANLLNDR (heavy)(+2) 33.82 39.82 636.316 1037.525 20.3 14 
AYPDANLLNDR (heavy)(+2) 33.82 39.82 636.316 940.4722 28.1 14 
AYPDANLLNDR (heavy)(+2) 33.82 39.82 636.316 825.4453 26.8 14 
AYPDANLLNDR (heavy)(+2) 33.82 39.82 636.316 527.2812 26.8 14 
AYPDANLLNDR(+2) 33.82 39.82 631.312 1027.517 20.3 14 
AYPDANLLNDR(+2) 33.82 39.82 631.312 930.4639 28.1 14 
AYPDANLLNDR(+2) 33.82 39.82 631.312 815.437 26.8 14 
AYPDANLLNDR(+2) 33.82 39.82 631.312 517.2729 26.8 14 
DEVAHTLTESR (heavy)(+2) 17.26 23.26 634.311 924.4773 26.8 20 
DEVAHTLTESR (heavy)(+2) 17.26 23.26 634.311 853.4402 25.5 20 
DEVAHTLTESR (heavy)(+2) 17.26 23.26 634.311 716.3813 26.8 20 
DEVAHTLTESR (heavy)(+2) 17.26 23.26 634.311 615.3336 28.1 20 
DEVAHTLTESR(+2) 17.26 23.26 629.307 914.469 26.8 20 
DEVAHTLTESR(+2) 17.26 23.26 629.307 843.4319 25.5 20 
DEVAHTLTESR(+2) 17.26 23.26 629.307 706.373 26.8 20 
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DEVAHTLTESR(+2) 17.26 23.26 629.307 605.3253 28.1 20 
DIPVPKPK (heavy)(+2) 17.51 23.51 451.283 673.4487 17 20 
DIPVPKPK (heavy)(+2) 17.51 23.51 451.283 477.3275 17 20 
DLELAVPGTYDPNQPIIR (heavy)(+2) 53.02 59.02 1011.032 1380.715 29.3 20 
DLELAVPGTYDPNQPIIR (heavy)(+2) 53.02 59.02 1011.032 847.5024 42.3 20 
DLELAVPGTYDPNQPIIR (heavy)(+2) 53.02 59.02 1011.032 542.2821 30.6 20 
DLELAVPGTYDPNQPIIR (heavy)(+2) 53.02 59.02 1011.032 641.3505 29.3 20 
DLELAVPGTYDPNQPIIR(+2) 53.02 59.02 1006.028 1370.706 29.3 20 
DLELAVPGTYDPNQPIIR(+2) 53.02 59.02 1006.028 837.4941 42.3 20 
DLELAVPGTYDPNQPIIR(+2) 53.02 59.02 1006.028 542.2821 30.6 20 
DLELAVPGTYDPNQPIIR(+2) 53.02 59.02 1006.028 641.3505 29.3 20 
DSGYYWEVPPSEVQLLK (heavy)(+2) 54.2 60.2 1009.503 1117.671 34.9 20 
DSGYYWEVPPSEVQLLK (heavy)(+2) 54.2 60.2 1009.503 1018.602 34.9 20 
DSGYYWEVPPSEVQLLK (heavy)(+2) 54.2 60.2 1009.503 921.5495 34.9 20 
DSGYYWEVPPSEVQLLK (heavy)(+2) 54.2 60.2 1009.503 509.3537 34.9 20 
DSGYYWEVPPSEVQLLK(+2) 54.2 60.2 1005.496 1109.656 34.9 20 
DSGYYWEVPPSEVQLLK(+2) 54.2 60.2 1005.496 1010.588 34.9 20 
DSGYYWEVPPSEVQLLK(+2) 54.2 60.2 1005.496 913.5353 34.9 20 
DSGYYWEVPPSEVQLLK(+2) 54.2 60.2 1005.496 501.3395 34.9 20 
DSSDDWEIPDGQITVGQR (heavy)(+2) 47.97 53.97 1014.462 1080.567 32 20 
DSSDDWEIPDGQITVGQR (heavy)(+2) 47.97 53.97 1014.462 370.2073 30.7 20 
DSSDDWEIPDGQITVGQR (heavy)(+2) 47.97 53.97 1014.462 835.2741 30.7 20 
DSSDDWEIPDGQITVGQR (heavy)(+2) 47.97 53.97 1014.462 948.3581 29.4 20 
DSSDDWEIPDGQITVGQR(+2) 47.97 53.97 1009.458 1070.559 32 20 
DSSDDWEIPDGQITVGQR(+2) 47.97 53.97 1009.458 360.199 30.7 20 
DSSDDWEIPDGQITVGQR(+2) 47.97 53.97 1009.458 835.2741 30.7 20 
DSSDDWEIPDGQITVGQR(+2) 47.97 53.97 1009.458 948.3581 29.4 20 
DSSYYWEIEASEVMLSTR (heavy)(+2) 56.02 62.02 1088.492 1245.638 37.4 20 
DSSYYWEIEASEVMLSTR (heavy)(+2) 56.02 62.02 1088.492 1132.554 37.4 20 
DSSYYWEIEASEVMLSTR (heavy)(+2) 56.02 62.02 1088.492 932.4745 37.4 20 
DSSYYWEIEASEVMLSTR (heavy)(+2) 56.02 62.02 1088.492 845.4425 37.4 20 
DSSYYWEIEASEVMLSTR (heavy)(+2) 56.02 62.02 1088.492 617.3315 37.4 20 
DSSYYWEIEASEVMLSTR(+2) 56.02 62.02 1083.488 1235.63 37.4 20 
DSSYYWEIEASEVMLSTR(+2) 56.02 62.02 1083.488 1122.546 37.4 20 
DSSYYWEIEASEVMLSTR(+2) 56.02 62.02 1083.488 922.4662 37.4 20 
DSSYYWEIEASEVMLSTR(+2) 56.02 62.02 1083.488 835.4342 37.4 20 
DSSYYWEIEASEVMLSTR(+2) 56.02 62.02 1083.488 607.3232 37.4 20 
EGISDGATM[+16.0]K (heavy)(+2) 12.75 18.75 516.741 733.3276 19.1 25 
EGISDGATM[+16.0]K (heavy)(+2) 12.75 18.75 516.741 531.2687 19.1 25 
EGISDGATM[+16.0]K(+2) 12.75 18.75 512.734 725.3134 19.1 25 
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EGISDGATM[+16.0]K(+2) 12.75 18.75 512.734 523.2545 19.1 25 
EGISDGATMK (heavy)(+2) 16.62 22.62 508.744 717.3327 18.6 25 
EGISDGATMK (heavy)(+2) 16.62 22.62 508.744 630.3007 17.3 25 
EGISDGATMK (heavy)(+2) 16.62 22.62 508.744 515.2737 17.3 25 
EGISDGATMK (heavy)(+2) 16.62 22.62 508.744 387.2152 17.3 25 
EGISDGATMK(+2) 16.62 22.62 504.736 709.3185 18.6 25 
EGISDGATMK(+2) 16.62 22.62 504.736 622.2865 17.3 25 
EGISDGATMK(+2) 16.62 22.62 504.736 507.2595 17.3 25 
EGISDGATMK(+2) 16.62 22.62 504.736 379.201 17.3 25 
EGITDAATMK (heavy)(+2) 21.62 27.62 522.759 745.364 17.8 20 
EGITDAATMK (heavy)(+2) 21.62 27.62 522.759 644.3163 17.8 20 
EGITDAATMK (heavy)(+2) 21.62 27.62 522.759 529.2894 19.1 20 
EGITDAATMK (heavy)(+2) 21.62 27.62 522.759 458.2523 16.5 20 
EGITDAATMK(+2) 21.62 27.62 518.752 737.3498 17.8 20 
EGITDAATMK(+2) 21.62 27.62 518.752 636.3021 17.8 20 
EGITDAATMK(+2) 21.62 27.62 518.752 521.2752 19.1 20 
EGITDAATMK(+2) 21.62 27.62 518.752 450.2381 16.5 20 
ELASGLSFPVGFK (heavy)(+2) 50.56 56.56 680.373 789.4385 24.4 14 
ELASGLSFPVGFK (heavy)(+2) 50.56 56.56 680.373 555.3381 24.4 14 
ELGQSGVDTYLQTK (heavy)(+2) 33.99 39.99 773.895 876.4553 27.4 14 
ELGQSGVDTYLQTK (heavy)(+2) 33.99 39.99 773.895 256.1747 27.4 14 
ELVSEFSR (heavy)(+2) 27.95 33.95 488.752 734.3707 17.9 16 
ELVSEFSR (heavy)(+2) 27.95 33.95 488.752 635.3023 17.9 16 
ELVSEFSR (heavy)(+2) 27.95 33.95 488.752 548.2703 16.6 16 
ELVSEFSR (heavy)(+2) 27.95 33.95 488.752 419.2277 15.3 16 
ELVSEFSR(+2) 27.95 33.95 483.748 724.3624 17.9 16 
ELVSEFSR(+2) 27.95 33.95 483.748 625.294 17.9 16 
ELVSEFSR(+2) 27.95 33.95 483.748 538.262 16.6 16 
ELVSEFSR(+2) 27.95 33.95 483.748 409.2194 15.3 16 
FFAGIVWQHVYEK (heavy)(+2) 47.3 53.3 816.426 1266.672 29.1 20 
FFAGIVWQHVYEK (heavy)(+2) 47.3 53.3 816.426 1096.567 27.8 20 
FFAGIVWQHVYEK (heavy)(+2) 47.3 53.3 816.426 997.4981 27.8 20 
FFAGIVWQHVYEK (heavy)(+3) 47.3 53.3 544.62 997.4981 20.7 20 
FFAGIVWQHVYEK (heavy)(+3) 47.3 53.3 544.62 811.4188 20.7 20 
FFAGIVWQHVYEK (heavy)(+3) 47.3 53.3 544.62 683.3603 22 20 
FFAGIVWQHVYEK(+2) 47.3 53.3 812.419 1258.658 29.1 20 
FFAGIVWQHVYEK(+2) 47.3 53.3 812.419 1088.552 27.8 20 
FFAGIVWQHVYEK(+2) 47.3 53.3 812.419 989.4839 27.8 20 
FFAGIVWQHVYEK(+3) 47.3 53.3 541.948 989.4839 20.7 20 
FFAGIVWQHVYEK(+3) 47.3 53.3 541.948 803.4046 20.7 20 
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FFAGIVWQHVYEK(+3) 47.3 53.3 541.948 675.3461 22 20 
FIC[+57.0]VTPTTC[+57.0]SNTIDLPMSPR 
(heavy)(+2) 
48.23 54.23 1160.554 710.3893 47.4 20 
FIC[+57.0]VTPTTC[+57.0]SNTIDLPMSPR 
(heavy)(+2) 
48.23 54.23 1160.554 597.3053 35.7 20 
FIC[+57.0]VTPTTC[+57.0]SNTIDLPMSPR 
(heavy)(+2) 
48.23 54.23 1160.554 421.1904 42.2 20 
FIC[+57.0]VTPTTC[+57.0]SNTIDLPMSPR 
(heavy)(+3) 
48.23 54.23 774.038 938.5003 21.8 20 
FIC[+57.0]VTPTTC[+57.0]SNTIDLPMSPR 
(heavy)(+3) 
48.23 54.23 774.038 825.4163 20.5 20 
FIC[+57.0]VTPTTC[+57.0]SNTIDLPMSPR 
(heavy)(+3) 
48.23 54.23 774.038 710.3893 32.2 20 
FIC[+57.0]VTPTTC[+57.0]SNTIDLPMSPR 
(heavy)(+3) 
48.23 54.23 774.038 597.3053 20.5 20 
FIC[+57.0]VTPTTC[+57.0]SNTIDLPMSPR(
+2) 
48.23 54.23 1155.549 700.3811 47.4 20 
FIC[+57.0]VTPTTC[+57.0]SNTIDLPMSPR(
+2) 
48.23 54.23 1155.549 587.297 35.7 20 
FIC[+57.0]VTPTTC[+57.0]SNTIDLPMSPR(
+2) 
48.23 54.23 1155.549 421.1904 42.2 20 
FIC[+57.0]VTPTTC[+57.0]SNTIDLPMSPR(
+3) 
48.23 54.23 770.702 928.4921 21.8 20 
FIC[+57.0]VTPTTC[+57.0]SNTIDLPMSPR(
+3) 
48.23 54.23 770.702 815.408 20.5 20 
FIC[+57.0]VTPTTC[+57.0]SNTIDLPMSPR(
+3) 
48.23 54.23 770.702 700.3811 32.2 20 
FIC[+57.0]VTPTTC[+57.0]SNTIDLPMSPR(
+3) 
48.23 54.23 770.702 587.297 20.5 20 
FLSLEPVKK (heavy)(+2) 25.86 31.86 534.83 808.5018 20.8 20 
FLSLEPVKK (heavy)(+2) 25.86 31.86 534.83 721.4698 20.8 20 
FLSLEPVKK (heavy)(+2) 25.86 31.86 534.83 479.3431 26 20 
FLSLEPVKK (heavy)(+3) 25.86 31.86 356.889 721.4698 15.5 20 
FLSLEPVKK (heavy)(+3) 25.86 31.86 356.889 608.3857 14.2 20 
FLSLEPVKK (heavy)(+3) 25.86 31.86 356.889 479.3431 15.5 20 
FLSLEPVKK(+2) 25.86 31.86 530.823 800.4876 20.8 20 
FLSLEPVKK(+2) 25.86 31.86 530.823 713.4556 20.8 20 
FLSLEPVKK(+2) 25.86 31.86 530.823 471.3289 26 20 
FLSLEPVKK(+3) 25.86 31.86 354.218 713.4556 15.5 20 
FLSLEPVKK(+3) 25.86 31.86 354.218 600.3715 14.2 20 
FLSLEPVKK(+3) 25.86 31.86 354.218 471.3289 15.5 20 
FYGAEIVSALDYLHSEK (heavy)(+3) 54.16 60.16 650.662 1269.656 23.6 20 
FYGAEIVSALDYLHSEK (heavy)(+3) 54.16 60.16 650.662 1170.588 23.6 20 
FYGAEIVSALDYLHSEK (heavy)(+3) 54.16 60.16 650.662 899.4349 23.6 20 
FYGAEIVSALDYLHSEK (heavy)(+3) 54.16 60.16 650.662 784.4079 20.8 20 
FYGAEIVSALDYLHSEK(+3) 54.16 60.16 647.991 1261.642 23.6 20 
FYGAEIVSALDYLHSEK(+3) 54.16 60.16 647.991 1162.574 23.6 20 
FYGAEIVSALDYLHSEK(+3) 54.16 60.16 647.991 891.4207 23.6 20 
FYGAEIVSALDYLHSEK(+3) 54.16 60.16 647.991 776.3937 20.8 20 
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FYGAEIVSALDYLHSGK (heavy)(+3) 54.13 60.13 626.655 1098.567 23 20 
FYGAEIVSALDYLHSGK (heavy)(+3) 54.13 60.13 626.655 940.4978 23 20 
FYGAEIVSALDYLHSGK (heavy)(+3) 54.13 60.13 626.655 827.4137 23 20 
FYGAEIVSALDYLHSGK (heavy)(+3) 54.13 60.13 626.655 712.3868 24.3 20 
FYGAEIVSALDYLHSGK (heavy)(+3) 54.13 60.13 626.655 784.4139 20.3 20 
FYGAEIVSALDYLHSGK(+3) 54.13 60.13 623.984 1090.553 23 20 
FYGAEIVSALDYLHSGK(+3) 54.13 60.13 623.984 932.4836 23 20 
FYGAEIVSALDYLHSGK(+3) 54.13 60.13 623.984 819.3995 23 20 
FYGAEIVSALDYLHSGK(+3) 54.13 60.13 623.984 704.3726 24.3 20 
FYGAEIVSALDYLHSGK(+3) 54.13 60.13 623.984 780.4068 20.3 20 
FYGAEIVSALEYLHSR (heavy)(+3) 54.75 60.75 622.32 1184.63 24.1 20 
FYGAEIVSALEYLHSR (heavy)(+3) 54.75 60.75 622.32 1085.561 24.1 20 
FYGAEIVSALEYLHSR (heavy)(+3) 54.75 60.75 622.32 814.4081 24.1 20 
FYGAEIVSALEYLHSR (heavy)(+3) 54.75 60.75 622.32 685.3656 24.1 20 
FYGAEIVSALEYLHSR (heavy)(+3) 54.75 60.75 622.32 777.9111 20.2 20 
FYGAEIVSALEYLHSR(+3) 54.75 60.75 618.984 1075.553 24.1 20 
FYGAEIVSALEYLHSR(+3) 54.75 60.75 618.984 804.3999 24.1 20 
FYGAEIVSALEYLHSR(+3) 54.75 60.75 618.984 675.3573 24.1 20 
FYGAEIVSALEYLHSR(+3) 54.75 60.75 618.984 772.907 20.2 20 
GDGGSTTGLSATPPASLPGSLTNVK 
(heavy)(+3) 
41.08 47.08 765.063 1191.682 24.2 16 
GDGGSTTGLSATPPASLPGSLTNVK 
(heavy)(+3) 
41.08 47.08 765.063 823.4763 20.3 16 
GDGGSTTGLSATPPASLPGSLTNVK 
(heavy)(+3) 
41.08 47.08 765.063 469.286 30.7 16 
GDGGSTTGLSATPPASLPGSLTNVK 
(heavy)(+3) 
41.08 47.08 765.063 746.3315 19 16 
GDGGSTTGLSATPPASLPGSLTNVK 
(heavy)(+3) 
41.08 47.08 765.063 1005.448 19 16 
GDGGSTTGLSATPPASLPGSLTNVK(+3) 41.08 47.08 762.392 1183.668 24.2 16 
GDGGSTTGLSATPPASLPGSLTNVK(+3) 41.08 47.08 762.392 815.4621 20.3 16 
GDGGSTTGLSATPPASLPGSLTNVK(+3) 41.08 47.08 762.392 461.2718 30.7 16 
GDGGSTTGLSATPPASLPGSLTNVK(+3) 41.08 47.08 762.392 746.3315 19 16 
GDGGSTTGLSATPPASLPGSLTNVK(+3) 41.08 47.08 762.392 1005.448 19 16 
GDSAYHSQR (heavy)(+2) 11.65 17.65 515.732 771.3772 22.7 25 
GDSAYHSQR (heavy)(+2) 11.65 17.65 515.732 700.3401 21.4 25 
GDSAYHSQR (heavy)(+2) 11.65 17.65 515.732 537.2767 22.7 25 
GDSAYHSQR (heavy)(+2) 11.65 17.65 515.732 400.2178 24 25 
GDSAYHSQR(+2) 11.65 17.65 510.728 761.3689 22.7 25 
GDSAYHSQR(+2) 11.65 17.65 510.728 690.3318 21.4 25 
GDSAYHSQR(+2) 11.65 17.65 510.728 527.2685 22.7 25 
GDSAYHSQR(+2) 11.65 17.65 510.728 390.2096 24 25 
GFSFVATGLMEDDGKPR (heavy)(+3) 43.88 49.88 612.965 957.4334 20 16 
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GFSFVATGLMEDDGKPR (heavy)(+3) 43.88 49.88 612.965 816.8999 20 16 
GFSFVATGLMEDDGKPR (heavy)(+3) 43.88 49.88 612.965 699.8497 20 16 
GFSFVATGLMEDDGKPR (heavy)(+3) 43.88 49.88 612.965 650.3155 20 16 
GFSFVATGLMEDDGKPR(+3) 43.88 49.88 609.629 947.4251 20 16 
GFSFVATGLMEDDGKPR(+3) 43.88 49.88 609.629 811.8958 20 16 
GFSFVATGLMEDDGKPR(+3) 43.88 49.88 609.629 694.8456 20 16 
GFSFVATGLMEDDGKPR(+3) 43.88 49.88 609.629 645.3114 20 16 
GILFVGSGVSGGEEGAR (heavy)(+2) 39.79 45.79 801.411 1072.489 28.2 16 
GILFVGSGVSGGEEGAR (heavy)(+2) 39.79 45.79 801.411 772.3459 28.2 16 
GIWIPDGENVK (heavy)(+2) 39.09 45.09 618.329 1065.545 18.4 14 
GIWIPDGENVK (heavy)(+2) 39.09 45.09 618.329 879.4662 18.4 14 
GIWIPDGENVK (heavy)(+2) 39.09 45.09 618.329 766.3821 18.4 14 
GIWIPDGENVK (heavy)(+2) 39.09 45.09 618.329 554.3024 27.5 14 
GIWIPDGENVK (heavy)(+2) 39.09 45.09 618.329 357.1921 19.7 14 
GIWIPDGENVK(+2) 39.09 45.09 614.322 1057.531 18.4 14 
GIWIPDGENVK(+2) 39.09 45.09 614.322 871.452 18.4 14 
GIWIPDGENVK(+2) 39.09 45.09 614.322 758.3679 18.4 14 
GIWIPDGENVK(+2) 39.09 45.09 614.322 546.2882 27.5 14 
GIWIPDGENVK(+2) 39.09 45.09 614.322 357.1921 19.7 14 
GLDARPEVTR (heavy)(+3) 15.7 21.7 375.207 611.3387 18.6 25 
GLDARPEVTR (heavy)(+3) 15.7 21.7 375.207 514.2859 21.2 25 
GLDARPEVTR (heavy)(+3) 15.7 21.7 375.207 385.2433 19.9 25 
GLDARPEVTR(+3) 15.7 21.7 371.871 601.3304 18.6 25 
GLDARPEVTR(+3) 15.7 21.7 371.871 504.2776 21.2 25 
GLDARPEVTR(+3) 15.7 21.7 371.871 375.235 19.9 25 
GLILVGGYGTR (heavy)(+2) 38.58 44.58 558.325 719.371 20.4 14 
GLILVGGYGTR (heavy)(+2) 38.58 44.58 558.325 620.3026 20.4 14 
GLIPEC[+57.0]C[+57.0]AVYR (heavy)(+2) 35.58 41.58 674.324 1064.453 21.6 16 
GLIPEC[+57.0]C[+57.0]AVYR (heavy)(+2) 35.58 41.58 674.324 967.4 30.7 16 
GLIPEC[+57.0]C[+57.0]AVYR (heavy)(+2) 35.58 41.58 674.324 838.3574 29.4 16 
GLIPEC[+57.0]C[+57.0]AVYR (heavy)(+2) 35.58 41.58 674.324 678.3267 29.4 16 
GLIPEC[+57.0]C[+57.0]AVYR(+2) 35.58 41.58 669.32 1054.444 21.6 16 
GLIPEC[+57.0]C[+57.0]AVYR(+2) 35.58 41.58 669.32 957.3917 30.7 16 
GLIPEC[+57.0]C[+57.0]AVYR(+2) 35.58 41.58 669.32 828.3491 29.4 16 
GLIPEC[+57.0]C[+57.0]AVYR(+2) 35.58 41.58 669.32 668.3185 29.4 16 
GLNQDC[+57.0]C[+57.0]VVYR (heavy)(+2) 24.3 30.3 697.314 1109.474 23.7 20 
GLNQDC[+57.0]C[+57.0]VVYR (heavy)(+2) 24.3 30.3 697.314 981.4156 25 20 
GLNQDC[+57.0]C[+57.0]VVYR (heavy)(+2) 24.3 30.3 697.314 866.3887 26.3 20 
GLNQDC[+57.0]C[+57.0]VVYR (heavy)(+2) 24.3 30.3 697.314 706.358 27.6 20 
GLNQDC[+57.0]C[+57.0]VVYR(+2) 24.3 30.3 692.31 1099.466 23.7 20 
165 
GLNQDC[+57.0]C[+57.0]VVYR(+2) 24.3 30.3 692.31 971.4073 25 20 
GLNQDC[+57.0]C[+57.0]VVYR(+2) 24.3 30.3 692.31 856.3804 26.3 20 
GLNQDC[+57.0]C[+57.0]VVYR(+2) 24.3 30.3 692.31 696.3498 27.6 20 
GLQPEC[+57.0]C[+57.0]AVFR (heavy)(+2) 31.55 37.55 673.814 1048.458 21.6 16 
GLQPEC[+57.0]C[+57.0]AVFR (heavy)(+2) 31.55 37.55 673.814 951.4051 29.4 16 
GLQPEC[+57.0]C[+57.0]AVFR (heavy)(+2) 31.55 37.55 673.814 822.3625 28.1 16 
GLQPEC[+57.0]C[+57.0]AVFR (heavy)(+2) 31.55 37.55 673.814 299.1714 19 16 
GLQPEC[+57.0]C[+57.0]AVFR(+2) 31.55 37.55 668.81 1038.45 21.6 16 
GLQPEC[+57.0]C[+57.0]AVFR(+2) 31.55 37.55 668.81 941.3968 29.4 16 
GLQPEC[+57.0]C[+57.0]AVFR(+2) 31.55 37.55 668.81 812.3542 28.1 16 
GLQPEC[+57.0]C[+57.0]AVFR(+2) 31.55 37.55 668.81 299.1714 19 16 
GPFPQELVR (heavy)(+2) 34.85 40.85 526.791 898.502 20.5 14 
GPFPQELVR (heavy)(+2) 34.85 40.85 526.791 751.4336 20.5 14 
GPFPQELVR (heavy)(+2) 34.85 40.85 526.791 654.3809 23.1 14 
GPFPQELVR (heavy)(+2) 34.85 40.85 526.791 302.1499 17.9 14 
GPFPQELVR(+2) 34.85 40.85 521.787 888.4938 20.5 14 
GPFPQELVR(+2) 34.85 40.85 521.787 741.4254 20.5 14 
GPFPQELVR(+2) 34.85 40.85 521.787 644.3726 23.1 14 
GPFPQELVR(+2) 34.85 40.85 521.787 302.1499 17.9 14 
GQPFDVGPR (heavy)(+2) 25.62 31.62 491.752 797.418 15.4 20 
GQPFDVGPR (heavy)(+2) 25.62 31.62 491.752 700.3652 23.2 20 
GQPFDVGPR (heavy)(+2) 25.62 31.62 491.752 553.2968 21.9 20 
GQPFDVGPR (heavy)(+2) 25.62 31.62 491.752 438.2699 24.5 20 
GQPFDVGPR(+2) 25.62 31.62 486.748 787.4097 15.4 20 
GQPFDVGPR(+2) 25.62 31.62 486.748 690.357 23.2 20 
GQPFDVGPR(+2) 25.62 31.62 486.748 543.2885 21.9 20 
GQPFDVGPR(+2) 25.62 31.62 486.748 428.2616 24.5 20 
GQVPENEANVVITTLK (heavy)(+2) 41.03 47.03 860.471 1435.788 26.8 16 
GQVPENEANVVITTLK (heavy)(+2) 41.03 47.03 860.471 966.6074 32 16 
GQVPENEANVVITTLK (heavy)(+2) 41.03 47.03 860.471 682.4589 34.6 16 
GQVPENEANVVITTLK (heavy)(+2) 41.03 47.03 860.471 583.3905 34.6 16 
GQVPENEANVVITTLK(+2) 41.03 47.03 856.464 1427.774 26.8 16 
GQVPENEANVVITTLK(+2) 41.03 47.03 856.464 958.5932 32 16 
GQVPENEANVVITTLK(+2) 41.03 47.03 856.464 674.4447 34.6 16 
GQVPENEANVVITTLK(+2) 41.03 47.03 856.464 575.3763 34.6 16 
GSHQISLDNPDYQQDFFPK (heavy)(+3) 42.23 48.23 748.686 917.4607 19.8 16 
GSHQISLDNPDYQQDFFPK (heavy)(+3) 42.23 48.23 748.686 789.4021 22.4 16 
GSHQISLDNPDYQQDFFPK (heavy)(+3) 42.23 48.23 748.686 399.2482 19.8 16 
GSHQISLDNPDYQQDFFPK (heavy)(+3) 42.23 48.23 748.686 646.8055 19.8 16 
GSHQISLDNPDYQQDFFPK (heavy)(+3) 42.23 48.23 748.686 952.4483 21.1 16 
166 
GSHQISLDNPDYQQDFFPK(+3) 42.23 48.23 746.015 909.4465 19.8 16 
GSHQISLDNPDYQQDFFPK(+3) 42.23 48.23 746.015 781.3879 22.4 16 
GSHQISLDNPDYQQDFFPK(+3) 42.23 48.23 746.015 391.234 19.8 16 
GSHQISLDNPDYQQDFFPK(+3) 42.23 48.23 746.015 642.7984 19.8 16 
GSHQISLDNPDYQQDFFPK(+3) 42.23 48.23 746.015 952.4483 21.1 16 
GSSSNEPSSDSLSSPTLLAL (heavy)(+2) 54.51 60.51 978.479 1394.749 28.2 20 
GSSSNEPSSDSLSSPTLLAL (heavy)(+2) 54.51 60.51 978.479 721.4568 28.2 20 
GSSSNEPSSDSLSSPTLLAL (heavy)(+2) 54.51 60.51 978.479 634.4248 28.2 20 
GSSSNEPSSDSLSSPTLLAL (heavy)(+2) 54.51 60.51 978.479 562.2103 28.2 20 
GSSSNEPSSDSLSSPTLLAL(+2) 54.51 60.51 974.97 1387.732 28.2 20 
GSSSNEPSSDSLSSPTLLAL(+2) 54.51 60.51 974.97 714.4396 28.2 20 
GSSSNEPSSDSLSSPTLLAL(+2) 54.51 60.51 974.97 627.4076 28.2 20 
GSSSNEPSSDSLSSPTLLAL(+2) 54.51 60.51 974.97 562.2103 28.2 20 
GSTAENAEYLR (heavy)(+2) 19.37 25.37 610.792 975.477 22.1 20 
GSTAENAEYLR (heavy)(+2) 19.37 25.37 610.792 904.4398 22.1 20 
GSTAENAEYLR (heavy)(+2) 19.37 25.37 610.792 775.3972 23.4 20 
GSTAENAEYLR (heavy)(+2) 19.37 25.37 610.792 590.3172 20.8 20 
GSTAENAEYLR(+2) 19.37 25.37 605.788 965.4687 22.1 20 
GSTAENAEYLR(+2) 19.37 25.37 605.788 894.4316 22.1 20 
GSTAENAEYLR(+2) 19.37 25.37 605.788 765.389 23.4 20 
GSTAENAEYLR(+2) 19.37 25.37 605.788 580.3089 20.8 20 
GTPTAENPEYLGLDVPV (heavy)(+2) 55.28 61.28 889.447 1107.596 25.2 20 
GTPTAENPEYLGLDVPV (heavy)(+2) 55.28 61.28 889.447 320.2212 31.1 20 
GTPTAENPEYLGLDVPV (heavy)(+2) 55.28 61.28 889.447 557.2566 25.2 20 
GTPTAENPEYLGLDVPV (heavy)(+2) 55.28 61.28 889.447 671.2995 25.2 20 
GTPTAENPEYLGLDVPV (heavy)(+2) 55.28 61.28 889.447 1458.675 25.2 20 
GTPTAENPEYLGLDVPV(+2) 55.28 61.28 886.441 1101.583 25.2 20 
GTPTAENPEYLGLDVPV(+2) 55.28 61.28 886.441 314.2074 31.1 20 
GTPTAENPEYLGLDVPV(+2) 55.28 61.28 886.441 557.2566 25.2 20 
GTPTAENPEYLGLDVPV(+2) 55.28 61.28 886.441 671.2995 25.2 20 
GTPTAENPEYLGLDVPV(+2) 55.28 61.28 886.441 1458.675 25.2 20 
GVTIPSQR (heavy)(+2) 17.36 23.36 434.249 711.4023 16 20 
GVTIPSQR (heavy)(+2) 17.36 23.36 434.249 610.3547 14.7 20 
GVTIPSQR (heavy)(+2) 17.36 23.36 434.249 497.2706 16 20 
GVTIPSQR (heavy)(+2) 17.36 23.36 434.249 371.2289 12.1 20 
GVTIPSQR(+2) 17.36 23.36 429.245 701.3941 16 20 
GVTIPSQR(+2) 17.36 23.36 429.245 600.3464 14.7 20 
GVTIPSQR(+2) 17.36 23.36 429.245 487.2623 16 20 
GVTIPSQR(+2) 17.36 23.36 429.245 371.2289 12.1 20 
GYASPDLSK (heavy)(+2) 18.13 24.13 473.242 725.3919 16.1 20 
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GYASPDLSK (heavy)(+2) 18.13 24.13 473.242 654.3548 16.1 20 
GYASPDLSK (heavy)(+2) 18.13 24.13 473.242 567.3228 17.4 20 
GYASPDLSK (heavy)(+2) 18.13 24.13 473.242 221.0921 16.1 20 
GYASPDLSK(+2) 18.13 24.13 469.234 717.3777 16.1 20 
GYASPDLSK(+2) 18.13 24.13 469.234 646.3406 16.1 20 
GYASPDLSK(+2) 18.13 24.13 469.234 559.3086 17.4 20 
GYASPDLSK(+2) 18.13 24.13 469.234 221.0921 16.1 20 
HTDDEMTGYVATR (heavy)(+3) 20.55 26.55 502.557 676.3652 16.9 20 
HTDDEMTGYVATR (heavy)(+3) 20.55 26.55 502.557 619.3438 15.6 20 
HTDDEMTGYVATR (heavy)(+3) 20.55 26.55 502.557 456.2804 15.6 20 
HTDDEMTGYVATR (heavy)(+3) 20.55 26.55 502.557 598.2103 16.9 20 
HTDDEMTGYVATR (heavy)(+3) 20.55 26.55 502.557 729.2508 15.6 20 
HTDDEMTGYVATR(+3) 20.55 26.55 499.22 666.357 16.9 20 
HTDDEMTGYVATR(+3) 20.55 26.55 499.22 609.3355 15.6 20 
HTDDEMTGYVATR(+3) 20.55 26.55 499.22 446.2722 15.6 20 
HTDDEMTGYVATR(+3) 20.55 26.55 499.22 598.2103 16.9 20 
HTDDEMTGYVATR(+3) 20.55 26.55 499.22 729.2508 15.6 20 
HVLTSIGEK (heavy)(+2) 16.09 22.09 496.286 854.5073 18.5 25 
HVLTSIGEK (heavy)(+2) 16.09 22.09 496.286 755.4389 18.5 25 
IADPEHDHTGFLTEYVATR (heavy)(+3) 36.3 42.3 728.019 849.434 27 14 
IADPEHDHTGFLTEYVATR (heavy)(+3) 36.3 42.3 728.019 748.3863 28.3 14 
IADPEHDHTGFLTEYVATR (heavy)(+3) 36.3 42.3 728.019 619.3438 28.3 14 
IADPEHDHTGFLTEYVATR (heavy)(+3) 36.3 42.3 728.019 456.2804 28.3 14 
IADPEHDHTGFLTEYVATR (heavy)(+3) 36.3 42.3 728.019 941.9515 25.7 14 
IADPEHDHTGFLTEYVATR(+3) 36.3 42.3 724.683 839.4258 27 14 
IADPEHDHTGFLTEYVATR(+3) 36.3 42.3 724.683 738.3781 28.3 14 
IADPEHDHTGFLTEYVATR(+3) 36.3 42.3 724.683 609.3355 28.3 14 
IADPEHDHTGFLTEYVATR(+3) 36.3 42.3 724.683 446.2722 28.3 14 
IADPEHDHTGFLTEYVATR(+3) 36.3 42.3 724.683 936.9474 25.7 14 
IDPVNGQITTIAVLDR (heavy)(+2) 47.21 53.21 867.984 1310.73 32.2 16 
IDPVNGQITTIAVLDR (heavy)(+2) 47.21 53.21 867.984 1196.687 30.9 16 
IDPVNGQITTIAVLDR (heavy)(+2) 47.21 53.21 867.984 1011.607 33.5 16 
IDPVNGQITTIAVLDR (heavy)(+2) 47.21 53.21 867.984 898.5232 32.2 16 
IDPVNGQITTIAVLDR (heavy)(+2) 47.21 53.21 867.984 583.3438 30.9 16 
IDPVNGQITTIAVLDR(+2) 47.21 53.21 862.98 1300.722 32.2 16 
IDPVNGQITTIAVLDR(+2) 47.21 53.21 862.98 1186.679 30.9 16 
IDPVNGQITTIAVLDR(+2) 47.21 53.21 862.98 1001.599 33.5 16 
IDPVNGQITTIAVLDR(+2) 47.21 53.21 862.98 888.5149 32.2 16 
IDPVNGQITTIAVLDR(+2) 47.21 53.21 862.98 573.3355 30.9 16 
IGDYAGIK (heavy)(+2) 21.69 27.69 422.736 731.3814 16.1 20 
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IGDYAGIK (heavy)(+2) 21.69 27.69 422.736 674.3599 16.1 20 
IGTGSFGTVFR (heavy)(+2) 39.1 45.1 576.307 1038.524 22.2 14 
IGTGSFGTVFR (heavy)(+2) 39.1 45.1 576.307 880.4551 22.2 14 
IGTGSFGTVFR (heavy)(+2) 39.1 45.1 576.307 823.4336 23.5 14 
IGTGSFGTVFR (heavy)(+2) 39.1 45.1 576.307 736.4016 22.2 14 
IGTGSFGTVFR (heavy)(+2) 39.1 45.1 576.307 589.3332 23.5 14 
IGTGSFGTVFR(+2) 39.1 45.1 571.303 1028.516 22.2 14 
IGTGSFGTVFR(+2) 39.1 45.1 571.303 870.4468 22.2 14 
IGTGSFGTVFR(+2) 39.1 45.1 571.303 813.4254 23.5 14 
IGTGSFGTVFR(+2) 39.1 45.1 571.303 726.3933 22.2 14 
IGTGSFGTVFR(+2) 39.1 45.1 571.303 579.3249 23.5 14 
IPEQILGK (heavy)(+2) 25.53 31.53 453.28 792.4705 17.1 20 
IPEQILGK (heavy)(+2) 25.53 31.53 453.28 695.4178 17.1 20 
IPEQILGK (heavy)(+2) 25.53 31.53 453.28 566.3752 17.1 20 
IPEQILGK(+2) 25.53 31.53 449.273 784.4563 17.1 20 
IPEQILGK(+2) 25.53 31.53 449.273 687.4036 17.1 20 
IPEQILGK(+2) 25.53 31.53 449.273 558.361 17.1 20 
IPLENLQIIR (heavy)(+2) 44.52 50.52 609.875 1105.66 25.9 16 
IPLENLQIIR (heavy)(+2) 44.52 50.52 609.875 1008.608 25.9 16 
IPLENLQIIR (heavy)(+2) 44.52 50.52 609.875 895.5235 25.9 16 
IPLENLQIIR (heavy)(+2) 44.52 50.52 609.875 766.4809 27.2 16 
IPLENLQIIR (heavy)(+2) 44.52 50.52 609.875 539.3539 25.9 16 
IPLENLQIIR(+2) 44.52 50.52 604.871 1095.652 25.9 16 
IPLENLQIIR(+2) 44.52 50.52 604.871 998.5993 25.9 16 
IPLENLQIIR(+2) 44.52 50.52 604.871 885.5152 25.9 16 
IPLENLQIIR(+2) 44.52 50.52 604.871 756.4726 27.2 16 
IPLENLQIIR(+2) 44.52 50.52 604.871 529.3457 25.9 16 
IQSIAPSLQVITSK (heavy)(+2) 40.73 46.73 746.944 1251.74 22.9 16 
IQSIAPSLQVITSK (heavy)(+2) 40.73 46.73 746.944 1164.708 24.2 16 
IQSIAPSLQVITSK (heavy)(+2) 40.73 46.73 746.944 1051.624 24.2 16 
IQSIAPSLQVITSK (heavy)(+2) 40.73 46.73 746.944 980.5866 24.2 16 
IQSIAPSLQVITSK(+2) 40.73 46.73 742.937 1243.726 22.9 16 
IQSIAPSLQVITSK(+2) 40.73 46.73 742.937 1156.694 24.2 16 
IQSIAPSLQVITSK(+2) 40.73 46.73 742.937 1043.61 24.2 16 
IQSIAPSLQVITSK(+2) 40.73 46.73 742.937 972.5724 24.2 16 
ISELGAGNGGVVFK (heavy)(+2) 34.4 40.4 678.374 1026.582 23.1 14 
ISELGAGNGGVVFK (heavy)(+2) 34.4 40.4 678.374 913.4981 23.1 14 
ISELGAGNGGVVFK (heavy)(+2) 34.4 40.4 678.374 856.4767 23.1 14 
ISELGAGNGGVVFK (heavy)(+2) 34.4 40.4 678.374 785.4396 23.1 14 
ISELGAGNGGVVFK (heavy)(+2) 34.4 40.4 678.374 330.166 23.1 14 
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ISELGAGNGGVVFK(+2) 34.4 40.4 674.366 1018.568 23.1 14 
ISELGAGNGGVVFK(+2) 34.4 40.4 674.366 905.4839 23.1 14 
ISELGAGNGGVVFK(+2) 34.4 40.4 674.366 848.4625 23.1 14 
ISELGAGNGGVVFK(+2) 34.4 40.4 674.366 777.4254 23.1 14 
ISELGAGNGGVVFK(+2) 34.4 40.4 674.366 330.166 23.1 14 
IYNLC[+57.0]AER (heavy)(+2) 24.07 30.07 524.759 935.4279 20.4 20 
IYNLC[+57.0]AER (heavy)(+2) 24.07 30.07 524.759 772.3646 19.1 20 
IYNLC[+57.0]AER (heavy)(+2) 24.07 30.07 524.759 658.3216 19.1 20 
IYNLC[+57.0]AER (heavy)(+2) 24.07 30.07 524.759 545.2376 19.1 20 
IYNLC[+57.0]AER(+2) 24.07 30.07 519.755 925.4196 20.4 20 
IYNLC[+57.0]AER(+2) 24.07 30.07 519.755 762.3563 19.1 20 
IYNLC[+57.0]AER(+2) 24.07 30.07 519.755 648.3134 19.1 20 
IYNLC[+57.0]AER(+2) 24.07 30.07 519.755 535.2293 19.1 20 
IYSSNSGPTR (heavy)(+2) 12.91 18.91 546.271 978.4515 21.1 25 
IYSSNSGPTR (heavy)(+2) 12.91 18.91 546.271 815.3881 19.8 25 
IYSSNSGPTR (heavy)(+2) 12.91 18.91 546.271 728.3561 22.4 25 
IYSSNSGPTR (heavy)(+2) 12.91 18.91 546.271 440.2491 22.4 25 
IYSSNSGPTR(+2) 12.91 18.91 541.267 968.4432 21.1 25 
IYSSNSGPTR(+2) 12.91 18.91 541.267 805.3799 19.8 25 
IYSSNSGPTR(+2) 12.91 18.91 541.267 718.3478 22.4 25 
IYSSNSGPTR(+2) 12.91 18.91 541.267 430.2409 22.4 25 
LC[+57.0]DFGVSGQLIDSMANSFVGTR 
(heavy)(+3) 
55.78 61.78 795.379 861.4453 24 20 
LC[+57.0]DFGVSGQLIDSMANSFVGTR 
(heavy)(+3) 
55.78 61.78 795.379 790.4081 24 20 
LC[+57.0]DFGVSGQLIDSMANSFVGTR 
(heavy)(+3) 
55.78 61.78 795.379 676.3652 24 20 
LC[+57.0]DFGVSGQLIDSMANSFVGTR 
(heavy)(+3) 
55.78 61.78 795.379 589.3332 24 20 
LC[+57.0]DFGVSGQLIDSMANSFVGTR(+3
) 
55.78 61.78 792.043 851.437 24 20 
LC[+57.0]DFGVSGQLIDSMANSFVGTR(+3
) 
55.78 61.78 792.043 780.3999 24 20 
LC[+57.0]DFGVSGQLIDSMANSFVGTR(+3
) 
55.78 61.78 792.043 666.357 24 20 
LC[+57.0]DFGVSGQLIDSMANSFVGTR(+3
) 
55.78 61.78 792.043 579.3249 24 20 
LEFILAAHR (heavy)(+2) 33.81 39.81 540.315 837.4969 20.9 14 
LEFILAAHR (heavy)(+2) 33.81 39.81 540.315 690.4285 22.2 14 
LEFILAAHR (heavy)(+2) 33.81 39.81 540.315 577.3444 23.5 14 
LEFILAAHR (heavy)(+2) 33.81 39.81 540.315 464.2604 22.2 14 
LEFILAAHR (heavy)(+3) 33.81 39.81 360.546 577.3444 15.6 14 
LEFILAAHR (heavy)(+3) 33.81 39.81 360.546 464.2604 15.6 14 
LEFILAAHR(+2) 33.81 39.81 535.311 827.4886 20.9 14 
LEFILAAHR(+2) 33.81 39.81 535.311 680.4202 22.2 14 
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LEFILAAHR(+2) 33.81 39.81 535.311 567.3362 23.5 14 
LEFILAAHR(+2) 33.81 39.81 535.311 454.2521 22.2 14 
LEFILAAHR(+3) 33.81 39.81 357.209 567.3362 15.6 14 
LEFILAAHR(+3) 33.81 39.81 357.209 454.2521 15.6 14 
LFDAPEAPLPSR (heavy)(+2) 37.52 43.52 661.852 1062.545 22.5 14 
LFDAPEAPLPSR (heavy)(+2) 37.52 43.52 661.852 876.4813 22.5 14 
LFDAPEAPLPSR (heavy)(+2) 37.52 43.52 661.852 650.386 29 14 
LFDAPEAPLPSR (heavy)(+2) 37.52 43.52 661.852 579.3488 23.8 14 
LFDAPEAPLPSR (heavy)(+2) 37.52 43.52 661.852 376.1867 23.8 14 
LFDAPEAPLPSR(+2) 37.52 43.52 656.848 1052.537 22.5 14 
LFDAPEAPLPSR(+2) 37.52 43.52 656.848 866.473 22.5 14 
LFDAPEAPLPSR(+2) 37.52 43.52 656.848 640.3777 29 14 
LFDAPEAPLPSR(+2) 37.52 43.52 656.848 569.3406 23.8 14 
LFDAPEAPLPSR(+2) 37.52 43.52 656.848 376.1867 23.8 14 
LLDIDETEYHADGGK (heavy)(+3) 30.78 36.78 561.936 985.4465 21.2 16 
LLDIDETEYHADGGK (heavy)(+3) 30.78 36.78 561.936 884.3988 18.9 16 
LLDIDETEYHADGGK (heavy)(+3) 30.78 36.78 561.936 755.3562 22.5 16 
LLDIDETEYHADGGK (heavy)(+3) 30.78 36.78 561.936 592.2929 23.8 16 
LLDIDETEYHADGGK (heavy)(+3) 30.78 36.78 561.936 455.234 25.1 16 
LLDIDETEYHADGGK(+3) 30.78 36.78 559.265 977.4323 21.2 16 
LLDIDETEYHADGGK(+3) 30.78 36.78 559.265 876.3846 18.9 16 
LLDIDETEYHADGGK(+3) 30.78 36.78 559.265 747.342 22.5 16 
LLDIDETEYHADGGK(+3) 30.78 36.78 559.265 584.2787 23.8 16 
LLDIDETEYHADGGK(+3) 30.78 36.78 559.265 447.2198 25.1 16 
LLEYTPTAR (heavy)(+2) 25.98 31.98 537.296 847.4184 18.2 16 
LLEYTPTAR (heavy)(+2) 25.98 31.98 537.296 718.3758 19.5 16 
LLEYTPTAR (heavy)(+2) 25.98 31.98 537.296 555.3125 18.2 16 
LLEYTPTAR (heavy)(+2) 25.98 31.98 537.296 454.2648 19.5 16 
LLEYTPTAR(+2) 25.98 31.98 532.292 837.4101 18.2 16 
LLEYTPTAR(+2) 25.98 31.98 532.292 708.3675 19.5 16 
LLEYTPTAR(+2) 25.98 31.98 532.292 545.3042 18.2 16 
LLEYTPTAR(+2) 25.98 31.98 532.292 444.2565 19.5 16 
LLPPFKPQVTSEVDTR (heavy)(+3) 34.41 40.41 613.007 1141.572 27.8 16 
LLPPFKPQVTSEVDTR (heavy)(+3) 34.41 40.41 613.007 916.461 27.8 16 
LLPPFKPQVTSEVDTR (heavy)(+3) 34.41 40.41 613.007 817.3926 25.2 16 
LLPPFKPQVTSEVDTR (heavy)(+3) 34.41 40.41 613.007 716.3449 25.2 16 
LLPPFKPQVTSEVDTR (heavy)(+3) 34.41 40.41 613.007 629.3128 25.2 16 
LLPPFKPQVTSEVDTR(+3) 34.41 40.41 609.671 1131.564 27.8 16 
LLPPFKPQVTSEVDTR(+3) 34.41 40.41 609.671 906.4527 27.8 16 
LLPPFKPQVTSEVDTR(+3) 34.41 40.41 609.671 807.3843 25.2 16 
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LLPPFKPQVTSEVDTR(+3) 34.41 40.41 609.671 706.3366 25.2 16 
LLPPFKPQVTSEVDTR(+3) 34.41 40.41 609.671 619.3046 25.2 16 
LLYGEPPKSPR (heavy)(+2) 19.96 25.96 633.857 1040.54 25.4 20 
LLYGEPPKSPR (heavy)(+2) 19.96 25.96 633.857 877.4766 25.4 20 
LLYGEPPKSPR (heavy)(+2) 19.96 25.96 633.857 691.4125 26.7 20 
LLYGEPPKSPR (heavy)(+2) 19.96 25.96 633.857 594.3597 29.3 20 
LLYGEPPKSPR(+2) 19.96 25.96 628.853 1030.532 25.4 20 
LLYGEPPKSPR(+2) 19.96 25.96 628.853 867.4683 25.4 20 
LLYGEPPKSPR(+2) 19.96 25.96 628.853 681.4042 26.7 20 
LLYGEPPKSPR(+2) 19.96 25.96 628.853 584.3515 29.3 20 
LNGDFAQLNLK (heavy)(+2) 38.48 44.48 620.842 1013.551 21.1 14 
LNGDFAQLNLK (heavy)(+2) 38.48 44.48 620.842 956.5291 22.4 14 
LNGDFAQLNLK (heavy)(+2) 38.48 44.48 620.842 841.5022 22.4 14 
LNGDFAQLNLK (heavy)(+2) 38.48 44.48 620.842 694.4338 22.4 14 
LNGDFAQLNLK(+2) 38.48 44.48 616.835 1005.536 21.1 14 
LNGDFAQLNLK(+2) 38.48 44.48 616.835 948.5149 22.4 14 
LNGDFAQLNLK(+2) 38.48 44.48 616.835 833.488 22.4 14 
LNGDFAQLNLK(+2) 38.48 44.48 616.835 686.4196 22.4 14 
LNTSDFQK (heavy)(+2) 19.18 25.18 480.747 847.4036 17.6 20 
LNTSDFQK (heavy)(+2) 19.18 25.18 480.747 733.3606 16.3 20 
LNTSDFQK (heavy)(+2) 19.18 25.18 480.747 632.313 17.6 20 
LNTSDFQK (heavy)(+2) 19.18 25.18 480.747 545.2809 18.9 20 
LNTSDFQK(+2) 19.18 25.18 476.74 839.3894 17.6 20 
LNTSDFQK(+2) 19.18 25.18 476.74 725.3464 16.3 20 
LNTSDFQK(+2) 19.18 25.18 476.74 624.2988 17.6 20 
LNTSDFQK(+2) 19.18 25.18 476.74 537.2667 18.9 20 
LSDPANWLK (heavy)(+2) 39.81 45.81 526.286 938.4822 19.2 16 
LSDPANWLK (heavy)(+2) 39.81 45.81 526.286 851.4501 17.9 16 
LSDPANWLK (heavy)(+2) 39.81 45.81 526.286 736.4232 19.2 16 
LSDPANWLK (heavy)(+2) 39.81 45.81 526.286 639.3704 21.8 16 
LSDPANWLK (heavy)(+2) 39.81 45.81 526.286 316.1503 16.6 16 
LSDPANWLK(+2) 39.81 45.81 522.279 930.468 19.2 16 
LSDPANWLK(+2) 39.81 45.81 522.279 843.4359 17.9 16 
LSDPANWLK(+2) 39.81 45.81 522.279 728.409 19.2 16 
LSDPANWLK(+2) 39.81 45.81 522.279 631.3562 21.8 16 
LSDPANWLK(+2) 39.81 45.81 522.279 316.1503 16.6 16 
LTESLDFTDYASR (heavy)(+2) 42.42 48.42 764.363 1184.546 26 16 
LTESLDFTDYASR (heavy)(+2) 42.42 48.42 764.363 984.4297 24.7 16 
LTESLDFTDYASR (heavy)(+2) 42.42 48.42 764.363 869.4027 28.6 16 
LTESLDFTDYASR (heavy)(+2) 42.42 48.42 764.363 506.2597 33.8 16 
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LTESLDFTDYASR(+2) 42.42 48.42 759.359 1174.537 26 16 
LTESLDFTDYASR(+2) 42.42 48.42 759.359 974.4214 24.7 16 
LTESLDFTDYASR(+2) 42.42 48.42 759.359 859.3945 28.6 16 
LTESLDFTDYASR(+2) 42.42 48.42 759.359 496.2514 33.8 16 
LTFQLEPNPHTK (heavy)(+3) 29.36 35.36 478.26 943.5087 17.5 16 
LTFQLEPNPHTK (heavy)(+3) 29.36 35.36 478.26 701.382 17.5 16 
LTFQLEPNPHTK (heavy)(+3) 29.36 35.36 478.26 604.3293 17.1 16 
LTFQLEPNPHTK (heavy)(+3) 29.36 35.36 478.26 351.1947 16.2 16 
LTFQLEPNPHTK(+3) 29.36 35.36 475.589 935.4945 17.5 16 
LTFQLEPNPHTK(+3) 29.36 35.36 475.589 693.3678 17.5 16 
LTFQLEPNPHTK(+3) 29.36 35.36 475.589 596.3151 17.1 16 
LTFQLEPNPHTK(+3) 29.36 35.36 475.589 347.1876 16.2 16 
LTILEELR (heavy)(+2) 44.76 50.76 498.801 782.4646 18.5 16 
LTILEELR (heavy)(+2) 44.76 50.76 498.801 669.3805 18.5 16 
NDVAPTLMSVPR (heavy)(+2) 35.48 41.48 655.344 1080.611 19.7 16 
NDVAPTLMSVPR (heavy)(+2) 35.48 41.48 655.344 981.5425 19.7 16 
NDVAPTLMSVPR (heavy)(+2) 35.48 41.48 655.344 910.5054 21 16 
NDVAPTLMSVPR (heavy)(+2) 35.48 41.48 655.344 599.3209 23.5 16 
NDVAPTLMSVPR (heavy)(+2) 35.48 41.48 655.344 329.1456 21 16 
NDVAPTLMSVPR(+2) 35.48 41.48 650.339 1070.603 19.7 16 
NDVAPTLMSVPR(+2) 35.48 41.48 650.339 971.5343 19.7 16 
NDVAPTLMSVPR(+2) 35.48 41.48 650.339 900.4971 21 16 
NDVAPTLMSVPR(+2) 35.48 41.48 650.339 589.3126 23.5 16 
NDVAPTLMSVPR(+2) 35.48 41.48 650.339 329.1456 21 16 
NGFILDGFPR (heavy)(+2) 48.85 54.85 573.302 827.4649 20.9 14 
NGFILDGFPR (heavy)(+2) 48.85 54.85 573.302 714.3809 20.9 14 
NHLDYRPVALLFHK (heavy)(+3) 36.08 42.08 577.657 932.5807 19.2 14 
NHLDYRPVALLFHK (heavy)(+3) 36.08 42.08 577.657 439.2543 19.2 14 
NHLDYRPVALLFHK (heavy)(+3) 36.08 42.08 577.657 740.4317 19.2 14 
NHLDYRPVALLFHK (heavy)(+3) 36.08 42.08 577.657 626.3762 19.2 14 
NHLDYRPVALLFHK (heavy)(+3) 36.08 42.08 577.657 480.2201 19.2 14 
NHLDYRPVALLFHK(+3) 36.08 42.08 574.986 924.5665 19.2 14 
NHLDYRPVALLFHK(+3) 36.08 42.08 574.986 431.2401 19.2 14 
NHLDYRPVALLFHK(+3) 36.08 42.08 574.986 736.4246 19.2 14 
NHLDYRPVALLFHK(+3) 36.08 42.08 574.986 622.3691 19.2 14 
NHLDYRPVALLFHK(+3) 36.08 42.08 574.986 480.2201 19.2 14 
NLGYRDSGYYWEVPPSEVQLLK 
(heavy)(+3) 
51.15 57.15 874.442 1117.671 22 16 
NLGYRDSGYYWEVPPSEVQLLK 
(heavy)(+3) 
51.15 57.15 874.442 1018.602 22 16 
NLGYRDSGYYWEVPPSEVQLLK 
(heavy)(+3) 
51.15 57.15 874.442 921.5495 29.8 16 
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NLGYRDSGYYWEVPPSEVQLLK 
(heavy)(+3) 
51.15 57.15 874.442 1026.464 32.4 16 
NLGYRDSGYYWEVPPSEVQLLK 
(heavy)(+3) 
51.15 57.15 874.442 1189.527 29.8 16 
NLGYRDSGYYWEVPPSEVQLLK(+3) 51.15 57.15 871.77 1109.656 22 16 
NLGYRDSGYYWEVPPSEVQLLK(+3) 51.15 57.15 871.77 1010.588 22 16 
NLGYRDSGYYWEVPPSEVQLLK(+3) 51.15 57.15 871.77 913.5353 29.8 16 
NLGYRDSGYYWEVPPSEVQLLK(+3) 51.15 57.15 871.77 1026.464 32.4 16 
NLGYRDSGYYWEVPPSEVQLLK(+3) 51.15 57.15 871.77 1189.527 29.8 16 
NLQEILHGAVR (heavy)(+2) 35.06 41.06 630.358 904.5238 25.3 14 
NLQEILHGAVR (heavy)(+2) 35.06 41.06 630.358 662.3972 26.6 14 
NLQEILHGAVR (heavy)(+2) 35.06 41.06 630.358 549.3131 27.9 14 
NLQEILHGAVR (heavy)(+3) 35.06 41.06 420.574 662.3972 18.5 14 
NLQEILHGAVR (heavy)(+3) 35.06 41.06 420.574 549.3131 19.8 14 
NLQEILHGAVR (heavy)(+3) 35.06 41.06 420.574 412.2542 19.8 14 
NLQEILHGAVR(+2) 35.06 41.06 625.354 894.5156 25.3 14 
NLQEILHGAVR(+2) 35.06 41.06 625.354 652.3889 26.6 14 
NLQEILHGAVR(+2) 35.06 41.06 625.354 539.3049 27.9 14 
NLQEILHGAVR(+3) 35.06 41.06 417.238 652.3889 18.5 14 
NLQEILHGAVR(+3) 35.06 41.06 417.238 539.3049 19.8 14 
NLQEILHGAVR(+3) 35.06 41.06 417.238 402.2459 19.8 14 
NSLDYAK (heavy)(+2) 14.91 20.91 409.71 704.3705 15.2 25 
NSLDYAK (heavy)(+2) 14.91 20.91 409.71 617.3385 13.9 25 
NSLDYAK (heavy)(+2) 14.91 20.91 409.71 504.2544 16.5 25 
NSLDYAK (heavy)(+2) 14.91 20.91 409.71 389.2274 19.1 25 
NSLDYAK(+2) 14.91 20.91 405.703 696.3563 15.2 25 
NSLDYAK(+2) 14.91 20.91 405.703 609.3243 13.9 25 
NSLDYAK(+2) 14.91 20.91 405.703 496.2402 16.5 25 
NSLDYAK(+2) 14.91 20.91 405.703 381.2132 19.1 25 
NTGVISVVTTGLDR (heavy)(+2) 41.85 47.85 721.397 1070.608 23.2 16 
NTGVISVVTTGLDR (heavy)(+2) 41.85 47.85 721.397 957.5239 24.5 16 
NTGVISVVTTGLDR (heavy)(+2) 41.85 47.85 721.397 870.4919 24.5 16 
NTGVISVVTTGLDR (heavy)(+2) 41.85 47.85 721.397 771.4235 23.2 16 
NTGVISVVTTGLDR (heavy)(+2) 41.85 47.85 721.397 672.355 25.7 16 
NTGVISVVTTGLDR(+2) 41.85 47.85 716.393 1060.6 23.2 16 
NTGVISVVTTGLDR(+2) 41.85 47.85 716.393 947.5156 24.5 16 
NTGVISVVTTGLDR(+2) 41.85 47.85 716.393 860.4836 24.5 16 
NTGVISVVTTGLDR(+2) 41.85 47.85 716.393 761.4152 23.2 16 
NTGVISVVTTGLDR(+2) 41.85 47.85 716.393 662.3468 25.7 16 
NYLQSLPSK (heavy)(+2) 27.46 33.46 529.292 780.4705 19.5 16 
NYLQSLPSK (heavy)(+2) 27.46 33.46 529.292 667.3865 19.5 16 
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NYLQSLPSK (heavy)(+2) 27.46 33.46 529.292 539.3279 19.5 16 
NYLQSLPSK (heavy)(+2) 27.46 33.46 529.292 339.2118 19.5 16 
NYLQSLPSK(+2) 27.46 33.46 525.284 772.4563 19.5 16 
NYLQSLPSK(+2) 27.46 33.46 525.284 659.3723 19.5 16 
NYLQSLPSK(+2) 27.46 33.46 525.284 531.3137 19.5 16 
NYLQSLPSK(+2) 27.46 33.46 525.284 331.1976 19.5 16 
QTLPVIYVK (heavy)(+2) 34.84 40.84 534.83 839.5481 18.2 16 
QTLPVIYVK (heavy)(+2) 34.84 40.84 534.83 726.464 19.5 16 
QTLPVIYVK (heavy)(+2) 34.84 40.84 534.83 629.4112 19.7 16 
QTLPVIYVK (heavy)(+2) 34.84 40.84 534.83 417.2587 18.2 16 
QTLPVIYVK(+2) 34.84 40.84 530.823 831.5339 18.2 16 
QTLPVIYVK(+2) 34.84 40.84 530.823 718.4498 19.5 16 
QTLPVIYVK(+2) 34.84 40.84 530.823 621.397 19.7 16 
QTLPVIYVK(+2) 34.84 40.84 530.823 409.2445 18.2 16 
RDSSDDWEIPDGQITVGQR (heavy)(+3) 40.04 46.04 728.677 1080.567 20.6 16 
RDSSDDWEIPDGQITVGQR (heavy)(+3) 40.04 46.04 728.677 868.4875 29.7 16 
RDSSDDWEIPDGQITVGQR (heavy)(+3) 40.04 46.04 728.677 370.2073 18 16 
RDSSDDWEIPDGQITVGQR (heavy)(+3) 40.04 46.04 728.677 991.3752 21.9 16 
RDSSDDWEIPDGQITVGQR(+3) 40.04 46.04 725.341 1070.559 20.6 16 
RDSSDDWEIPDGQITVGQR(+3) 40.04 46.04 725.341 858.4792 29.7 16 
RDSSDDWEIPDGQITVGQR(+3) 40.04 46.04 725.341 360.199 18 16 
RDSSDDWEIPDGQITVGQR(+3) 40.04 46.04 725.341 991.3752 21.9 16 
RPHFPQFSYSASGR (heavy)(+3) 27.68 33.68 549.606 884.4136 18.6 16 
RPHFPQFSYSASGR (heavy)(+3) 27.68 33.68 549.606 737.3452 18.6 16 
RPHFPQFSYSASGR (heavy)(+3) 27.68 33.68 549.606 650.3132 18.6 16 
RPHFPQFSYSASGR (heavy)(+3) 27.68 33.68 549.606 487.2499 18.6 16 
RPHFPQFSYSASGR(+3) 27.68 33.68 546.27 874.4054 18.6 16 
RPHFPQFSYSASGR(+3) 27.68 33.68 546.27 727.3369 18.6 16 
RPHFPQFSYSASGR(+3) 27.68 33.68 546.27 640.3049 18.6 16 
RPHFPQFSYSASGR(+3) 27.68 33.68 546.27 477.2416 18.6 16 
RPHFPQFSYSASGRE (heavy)(+3) 28.08 34.08 591.289 862.3933 19.5 16 
RPHFPQFSYSASGRE (heavy)(+3) 28.08 34.08 591.289 775.3613 19.5 16 
RPHFPQFSYSASGRE (heavy)(+3) 28.08 34.08 591.289 612.298 19.5 16 
RPHFPQFSYSASGRE (heavy)(+3) 28.08 34.08 591.289 617.7902 19.5 16 
RPHFPQFSYSASGRE(+3) 28.08 34.08 589.285 856.3795 19.5 16 
RPHFPQFSYSASGRE(+3) 28.08 34.08 589.285 769.3475 19.5 16 
RPHFPQFSYSASGRE(+3) 28.08 34.08 589.285 606.2842 19.5 16 
RPHFPQFSYSASGRE(+3) 28.08 34.08 589.285 614.7833 19.5 16 
RPHFPQFSYSASGTA (heavy)(+3) 33.09 39.09 552.934 391.2201 18.7 16 
RPHFPQFSYSASGTA (heavy)(+3) 33.09 39.09 552.934 538.2885 23.5 16 
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RPHFPQFSYSASGTA (heavy)(+3) 33.09 39.09 552.934 763.3998 23.5 16 
RPHFPQFSYSASGTA (heavy)(+3) 33.09 39.09 552.934 499.2538 20.9 16 
RPHFPQFSYSASGTA (heavy)(+3) 33.09 39.09 552.934 624.3014 19.6 16 
RPHFPQFSYSASGTA(+3) 33.09 39.09 551.598 391.2201 18.7 16 
RPHFPQFSYSASGTA(+3) 33.09 39.09 551.598 538.2885 23.5 16 
RPHFPQFSYSASGTA(+3) 33.09 39.09 551.598 763.3998 23.5 16 
RPHFPQFSYSASGTA(+3) 33.09 39.09 551.598 499.2538 20.9 16 
RPHFPQFSYSASGTA(+3) 33.09 39.09 551.598 624.3014 19.6 16 
RTSM[+16.0]GGTQQQFVEGVR 
(heavy)(+3) 
18.51 24.51 602.964 716.3965 19.8 20 
RTSM[+16.0]GGTQQQFVEGVR 
(heavy)(+3) 
18.51 24.51 602.964 569.3281 19.8 20 
RTSM[+16.0]GGTQQQFVEGVR(+3) 18.51 24.51 599.628 706.3883 19.8 20 
RTSM[+16.0]GGTQQQFVEGVR(+3) 18.51 24.51 599.628 559.3198 19.8 20 
RTSMGGTQQQFVEGVR (heavy)(+3) 23.26 29.26 597.632 844.4551 19.5 20 
RTSMGGTQQQFVEGVR (heavy)(+3) 23.26 29.26 597.632 716.3965 19.5 20 
RTSMGGTQQQFVEGVR (heavy)(+3) 23.26 29.26 597.632 569.3281 19.5 20 
RTSMGGTQQQFVEGVR (heavy)(+3) 23.26 29.26 597.632 470.2597 19.5 20 
RTSMGGTQQQFVEGVR (heavy)(+3) 23.26 29.26 597.632 819.3778 19.5 20 
RTSMGGTQQQFVEGVR(+3) 23.26 29.26 594.296 834.4468 19.5 20 
RTSMGGTQQQFVEGVR(+3) 23.26 29.26 594.296 706.3883 19.5 20 
RTSMGGTQQQFVEGVR(+3) 23.26 29.26 594.296 559.3198 19.5 20 
RTSMGGTQQQFVEGVR(+3) 23.26 29.26 594.296 460.2514 19.5 20 
RTSMGGTQQQFVEGVR(+3) 23.26 29.26 594.296 819.3778 19.5 20 
SAAGAFGPELSR (heavy)(+2) 29.14 35.14 586.8 815.4285 21.3 16 
SAAGAFGPELSR (heavy)(+2) 29.14 35.14 586.8 668.3601 21.3 16 
SAAPHPGDIGDFINEGLK (heavy)(+3) 42.88 48.88 615.978 828.4705 20.1 16 
SAAPHPGDIGDFINEGLK (heavy)(+3) 42.88 48.88 615.978 681.4021 20.1 16 
SAAPHPGDIGDFINEGLK (heavy)(+3) 42.88 48.88 615.978 568.3181 18.8 16 
SAAPHPGDIGDFINEGLK (heavy)(+3) 42.88 48.88 615.978 325.2325 27.9 16 
SAAPHPGDIGDFINEGLK(+3) 42.88 48.88 613.307 820.4563 20.1 16 
SAAPHPGDIGDFINEGLK(+3) 42.88 48.88 613.307 673.3879 20.1 16 
SAAPHPGDIGDFINEGLK(+3) 42.88 48.88 613.307 560.3039 18.8 16 
SAAPHPGDIGDFINEGLK(+3) 42.88 48.88 613.307 317.2183 27.9 16 
SALQTEIANLLK (heavy)(+2) 54.26 60.26 654.884 1037.608 21 16 
SALQTEIANLLK (heavy)(+2) 54.26 60.26 654.884 909.5495 22.3 16 
SALQTEIANLLK (heavy)(+2) 54.26 60.26 654.884 808.5018 22.3 16 
SALQTEIANLLK (heavy)(+2) 54.26 60.26 654.884 679.4592 21 16 
SALQTEIANLLK (heavy)(+2) 54.26 60.26 654.884 566.3752 22.3 16 
SALQTEIANLLK(+2) 54.26 60.26 650.877 1029.594 21 16 
SALQTEIANLLK(+2) 54.26 60.26 650.877 901.5353 22.3 16 
176 
SALQTEIANLLK(+2) 54.26 60.26 650.877 800.4876 22.3 16 
SALQTEIANLLK(+2) 54.26 60.26 650.877 671.445 21 16 
SALQTEIANLLK(+2) 54.26 60.26 650.877 558.361 22.3 16 
SDKSPDLAPTPAPQSTPR (heavy)(+3) 19.07 25.07 625.654 1061.561 20.3 20 
SDKSPDLAPTPAPQSTPR (heavy)(+3) 19.07 25.07 625.654 863.4609 21.6 20 
SDKSPDLAPTPAPQSTPR (heavy)(+3) 19.07 25.07 625.654 695.371 24.2 20 
SDKSPDLAPTPAPQSTPR (heavy)(+3) 19.07 25.07 625.654 348.1892 22.9 20 
SDKSPDLAPTPAPQSTPR (heavy)(+3) 19.07 25.07 625.654 743.357 20.3 20 
SDKSPDLAPTPAPQSTPR(+3) 19.07 25.07 622.318 1051.553 20.3 20 
SDKSPDLAPTPAPQSTPR(+3) 19.07 25.07 622.318 853.4526 21.6 20 
SDKSPDLAPTPAPQSTPR(+3) 19.07 25.07 622.318 685.3628 24.2 20 
SDKSPDLAPTPAPQSTPR(+3) 19.07 25.07 622.318 343.185 22.9 20 
SDKSPDLAPTPAPQSTPR(+3) 19.07 25.07 622.318 743.357 20.3 20 
SLEATDSAFDNPDYWHSR (heavy)(+3) 39.57 45.57 707.644 970.4405 27.8 14 
SLEATDSAFDNPDYWHSR (heavy)(+3) 39.57 45.57 707.644 758.3608 30.4 14 
SLEATDSAFDNPDYWHSR (heavy)(+3) 39.57 45.57 707.644 960.9048 17.4 14 
SLEATDSAFDNPDYWHSR (heavy)(+3) 39.57 45.57 707.644 896.3835 18.7 14 
SLEATDSAFDNPDYWHSR (heavy)(+3) 39.57 45.57 707.644 860.8649 18.7 14 
SLEATDSAFDNPDYWHSR(+3) 39.57 45.57 704.308 960.4322 27.8 14 
SLEATDSAFDNPDYWHSR(+3) 39.57 45.57 704.308 748.3525 30.4 14 
SLEATDSAFDNPDYWHSR(+3) 39.57 45.57 704.308 955.9006 17.4 14 
SLEATDSAFDNPDYWHSR(+3) 39.57 45.57 704.308 891.3793 18.7 14 
SLEATDSAFDNPDYWHSR(+3) 39.57 45.57 704.308 855.8608 18.7 14 
SLELLFASGQNNK (heavy)(+2) 43.8 49.8 714.882 873.4305 23.1 16 
SLELLFASGQNNK (heavy)(+2) 43.8 49.8 714.882 726.362 23.1 16 
SLELLFASGQNNK (heavy)(+2) 43.8 49.8 714.882 655.3249 20.5 16 
SLELLFASGQNNK (heavy)(+2) 43.8 49.8 714.882 568.2929 20.5 16 
SLELLFASGQNNK (heavy)(+2) 43.8 49.8 714.882 443.25 24.4 16 
SLELLFASGQNNK(+2) 43.8 49.8 710.875 865.4163 23.1 16 
SLELLFASGQNNK(+2) 43.8 49.8 710.875 718.3478 23.1 16 
SLELLFASGQNNK(+2) 43.8 49.8 710.875 647.3107 20.5 16 
SLELLFASGQNNK(+2) 43.8 49.8 710.875 560.2787 20.5 16 
SLELLFASGQNNK(+2) 43.8 49.8 710.875 443.25 24.4 16 
SLIVAGLGDGSIR (heavy)(+2) 41.09 47.09 634.365 954.5242 21.6 16 
SLIVAGLGDGSIR (heavy)(+2) 41.09 47.09 634.365 855.4558 21.6 16 
SLIVAGLGDGSIR (heavy)(+2) 41.09 47.09 634.365 784.4187 20.3 16 
SLIVAGLGDGSIR (heavy)(+2) 41.09 47.09 634.365 727.3972 20.3 16 
SLIVAGLGDGSIR(+2) 41.09 47.09 629.361 944.516 21.6 16 
SLIVAGLGDGSIR(+2) 41.09 47.09 629.361 845.4476 21.6 16 
SLIVAGLGDGSIR(+2) 41.09 47.09 629.361 774.4104 20.3 16 
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SLIVAGLGDGSIR(+2) 41.09 47.09 629.361 717.389 20.3 16 
SLLAGLLK (heavy)(+2) 45.89 51.89 411.78 622.4378 14 16 
SLLAGLLK (heavy)(+2) 45.89 51.89 411.78 509.3537 16.6 16 
SLLAGLLK (heavy)(+2) 45.89 51.89 411.78 438.3166 16.6 16 
SLLAGLLK(+2) 45.89 51.89 407.773 614.4236 14 16 
SLLAGLLK(+2) 45.89 51.89 407.773 501.3395 16.6 16 
SLLAGLLK(+2) 45.89 51.89 407.773 430.3024 16.6 16 
SLLSGLLK (heavy)(+2) 46.57 52.57 419.778 638.4327 14.2 16 
SLLSGLLK (heavy)(+2) 46.57 52.57 419.778 525.3486 15.5 16 
SLLSGLLK (heavy)(+2) 46.57 52.57 419.778 438.3166 16.8 16 
SLLSGLLK(+2) 46.57 52.57 415.77 630.4185 14.2 16 
SLLSGLLK(+2) 46.57 52.57 415.77 517.3344 15.5 16 
SLLSGLLK(+2) 46.57 52.57 415.77 430.3024 16.8 16 
SNNIFLHEDLTVK (heavy)(+3) 34.81 40.81 513.274 962.5397 21.1 16 
SNNIFLHEDLTVK (heavy)(+3) 34.81 40.81 513.274 849.4556 19.8 16 
SNNIFLHEDLTVK (heavy)(+3) 34.81 40.81 513.274 712.3967 19.8 16 
SNNIFLHEDLTVK(+3) 34.81 40.81 510.603 954.5255 21.1 16 
SNNIFLHEDLTVK(+3) 34.81 40.81 510.603 841.4414 19.8 16 
SNNIFLHEDLTVK(+3) 34.81 40.81 510.603 704.3825 19.8 16 
SPDLAPTPAPQSTPR (heavy)(+2) 22.4 28.4 772.9 1132.598 28.9 20 
SPDLAPTPAPQSTPR (heavy)(+2) 22.4 28.4 772.9 1061.561 27.6 20 
SPDLAPTPAPQSTPR (heavy)(+2) 22.4 28.4 772.9 863.4609 30.2 20 
SPDLAPTPAPQSTPR (heavy)(+2) 22.4 28.4 772.9 695.371 27.3 20 
SPDLAPTPAPQSTPR (heavy)(+2) 22.4 28.4 772.9 484.2402 25 20 
SPDLAPTPAPQSTPR(+2) 22.4 28.4 767.896 1122.59 28.9 20 
SPDLAPTPAPQSTPR(+2) 22.4 28.4 767.896 1051.553 27.6 20 
SPDLAPTPAPQSTPR(+2) 22.4 28.4 767.896 853.4526 30.2 20 
SPDLAPTPAPQSTPR(+2) 22.4 28.4 767.896 685.3628 27.3 20 
SPDLAPTPAPQSTPR(+2) 22.4 28.4 767.896 484.2402 25 20 
SQQLSNDHIC[+57.0]YFLYQILR 
(heavy)(+3) 
54.63 60.63 770.052 1285.664 32.1 16 
SQQLSNDHIC[+57.0]YFLYQILR 
(heavy)(+3) 
54.63 60.63 770.052 1125.633 23.4 16 
SQQLSNDHIC[+57.0]YFLYQILR 
(heavy)(+3) 
54.63 60.63 770.052 962.5697 30.8 16 
SQQLSNDHIC[+57.0]YFLYQILR 
(heavy)(+3) 
54.63 60.63 770.052 815.5013 26.9 16 
SQQLSNDHIC[+57.0]YFLYQILR 
(heavy)(+3) 
54.63 60.63 770.052 702.4173 24.3 16 
SQQLSNDHIC[+57.0]YFLYQILR(+3) 54.63 60.63 766.716 1275.655 32.1 16 
SQQLSNDHIC[+57.0]YFLYQILR(+3) 54.63 60.63 766.716 1115.625 23.4 16 
SQQLSNDHIC[+57.0]YFLYQILR(+3) 54.63 60.63 766.716 952.5615 30.8 16 
SQQLSNDHIC[+57.0]YFLYQILR(+3) 54.63 60.63 766.716 805.4931 26.9 16 
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SQQLSNDHIC[+57.0]YFLYQILR(+3) 54.63 60.63 766.716 692.409 24.3 16 
SSAAPPPPPR (heavy)(+2) 12.72 18.72 493.768 670.391 18.4 25 
SSAAPPPPPR (heavy)(+2) 12.72 18.72 493.768 573.3383 18.4 25 
STSTPNVHMVSTTLPVDSR (heavy)(+3) 31.27 37.27 680.341 1084.587 21.5 16 
STSTPNVHMVSTTLPVDSR (heavy)(+3) 31.27 37.27 680.341 985.5188 25.7 16 
STSTPNVHMVSTTLPVDSR (heavy)(+3) 31.27 37.27 680.341 583.3074 19.2 16 
STSTPNVHMVSTTLPVDSR (heavy)(+3) 31.27 37.27 680.341 925.9689 19.2 16 
STSTPNVHMVSTTLPVDSR (heavy)(+3) 31.27 37.27 680.341 831.929 21.8 16 
STSTPNVHMVSTTLPVDSR(+3) 31.27 37.27 677.005 1074.579 21.5 16 
STSTPNVHMVSTTLPVDSR(+3) 31.27 37.27 677.005 975.5106 25.7 16 
STSTPNVHMVSTTLPVDSR(+3) 31.27 37.27 677.005 573.2991 19.2 16 
STSTPNVHMVSTTLPVDSR(+3) 31.27 37.27 677.005 920.9647 19.2 16 
STSTPNVHMVSTTLPVDSR(+3) 31.27 37.27 677.005 826.9249 21.8 16 
SYNC[+57.0]TPVSSPR (heavy)(+2) 16.88 22.88 639.294 1027.486 21.7 20 
SYNC[+57.0]TPVSSPR (heavy)(+2) 16.88 22.88 639.294 913.4435 21.7 20 
SYNC[+57.0]TPVSSPR (heavy)(+2) 16.88 22.88 639.294 753.4129 23 20 
SYNC[+57.0]TPVSSPR (heavy)(+2) 16.88 22.88 639.294 652.3652 24.3 20 
SYNC[+57.0]TPVSSPR (heavy)(+2) 16.88 22.88 639.294 456.244 23 20 
SYNC[+57.0]TPVSSPR(+2) 16.88 22.88 634.29 1017.478 21.7 20 
SYNC[+57.0]TPVSSPR(+2) 16.88 22.88 634.29 903.4353 21.7 20 
SYNC[+57.0]TPVSSPR(+2) 16.88 22.88 634.29 743.4046 23 20 
SYNC[+57.0]TPVSSPR(+2) 16.88 22.88 634.29 642.357 24.3 20 
SYNC[+57.0]TPVSSPR(+2) 16.88 22.88 634.29 446.2358 23 20 
TAGTSFMMTPYVVTR (heavy)(+2) 45.63 51.63 836.409 1254.625 28.5 16 
TAGTSFMMTPYVVTR (heavy)(+2) 45.63 51.63 836.409 1107.556 28.5 16 
TAGTSFMMTPYVVTR (heavy)(+2) 45.63 51.63 836.409 976.516 28.5 16 
TAGTSFMMTPYVVTR (heavy)(+2) 45.63 51.63 836.409 845.4755 27.2 16 
TAGTSFMMTPYVVTR (heavy)(+2) 45.63 51.63 836.409 744.4278 27.2 16 
TAGTSFMMTPYVVTR(+2) 45.63 51.63 831.404 1244.617 28.5 16 
TAGTSFMMTPYVVTR(+2) 45.63 51.63 831.404 1097.548 28.5 16 
TAGTSFMMTPYVVTR(+2) 45.63 51.63 831.404 966.5077 28.5 16 
TAGTSFMMTPYVVTR(+2) 45.63 51.63 831.404 835.4672 27.2 16 
TAGTSFMMTPYVVTR(+2) 45.63 51.63 831.404 734.4196 27.2 16 
TASEFDSAIAQDK (heavy)(+2) 27.3 33.3 695.832 1002.498 24.9 16 
TASEFDSAIAQDK (heavy)(+2) 27.3 33.3 695.832 469.2496 24.9 16 
TAYFSLDTR (heavy)(+2) 35.22 41.22 542.27 911.4497 17.1 14 
TAYFSLDTR (heavy)(+2) 35.22 41.22 542.27 748.3863 18.4 14 
TAYFSLDTR (heavy)(+2) 35.22 41.22 542.27 601.3179 19.7 14 
TAYFSLDTR (heavy)(+2) 35.22 41.22 542.27 336.1554 17.1 14 
TAYFSLDTR(+2) 35.22 41.22 537.266 901.4414 17.1 14 
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TAYFSLDTR(+2) 35.22 41.22 537.266 738.3781 18.4 14 
TAYFSLDTR(+2) 35.22 41.22 537.266 591.3097 19.7 14 
TAYFSLDTR(+2) 35.22 41.22 537.266 336.1554 17.1 14 
TDGSFIGYK (heavy)(+2) 26.8 32.8 498.249 779.4178 16.9 16 
TDGSFIGYK (heavy)(+2) 26.8 32.8 498.249 722.3963 18.2 16 
TDGSFIGYK (heavy)(+2) 26.8 32.8 498.249 635.3643 18.2 16 
TDGSFIGYK (heavy)(+2) 26.8 32.8 498.249 488.2959 20.8 16 
TDGSFIGYK (heavy)(+2) 26.8 32.8 498.249 375.2118 20.8 16 
TDGSFIGYK(+2) 26.8 32.8 494.242 771.4036 16.9 16 
TDGSFIGYK(+2) 26.8 32.8 494.242 714.3821 18.2 16 
TDGSFIGYK(+2) 26.8 32.8 494.242 627.3501 18.2 16 
TDGSFIGYK(+2) 26.8 32.8 494.242 480.2817 20.8 16 
TDGSFIGYK(+2) 26.8 32.8 494.242 367.1976 20.8 16 
TDSYSAGQSVEILDGVELGEPAHK 
(heavy)(+3) 
44.65 50.65 837.409 646.3398 31.4 16 
TDSYSAGQSVEILDGVELGEPAHK 
(heavy)(+3) 
44.65 50.65 837.409 460.2758 34 16 
TDSYSAGQSVEILDGVELGEPAHK 
(heavy)(+3) 
44.65 50.65 837.409 1022.525 22.3 16 
TDSYSAGQSVEILDGVELGEPAHK 
(heavy)(+3) 
44.65 50.65 837.409 979.0095 22.3 16 
TDSYSAGQSVEILDGVELGEPAHK 
(heavy)(+3) 
44.65 50.65 837.409 943.4909 22.3 16 
TDSYSAGQSVEILDGVELGEPAHK(+3) 44.65 50.65 834.738 638.3257 31.4 16 
TDSYSAGQSVEILDGVELGEPAHK(+3) 44.65 50.65 834.738 452.2616 34 16 
TDSYSAGQSVEILDGVELGEPAHK(+3) 44.65 50.65 834.738 1018.518 22.3 16 
TDSYSAGQSVEILDGVELGEPAHK(+3) 44.65 50.65 834.738 975.0024 22.3 16 
TDSYSAGQSVEILDGVELGEPAHK(+3) 44.65 50.65 834.738 939.4838 22.3 16 
TEPFDDFLFPASSR (heavy)(+2) 54.46 60.46 819.887 934.502 35.7 16 
TEPFDDFLFPASSR (heavy)(+2) 54.46 60.46 819.887 787.4336 31.8 16 
TEPFDDFLFPASSR (heavy)(+2) 54.46 60.46 819.887 674.3496 29.2 16 
TEPFDDFLFPASSR (heavy)(+2) 54.46 60.46 819.887 527.2812 30.5 16 
TEPFDDFLFPASSR (heavy)(+2) 54.46 60.46 819.887 704.8422 22.7 16 
TEPFDDFLFPASSR(+2) 54.46 60.46 814.883 924.4938 35.7 16 
TEPFDDFLFPASSR(+2) 54.46 60.46 814.883 777.4254 31.8 16 
TEPFDDFLFPASSR(+2) 54.46 60.46 814.883 664.3413 29.2 16 
TEPFDDFLFPASSR(+2) 54.46 60.46 814.883 517.2729 30.5 16 
TEPFDDFLFPASSR(+2) 54.46 60.46 814.883 699.8381 22.7 16 
TFC[+57.0]GTPEYLAPEVLEDNDYGR 
(heavy)(+3) 
51.84 57.84 819.369 1316.599 24.4 20 
TFC[+57.0]GTPEYLAPEVLEDNDYGR 
(heavy)(+3) 
51.84 57.84 819.369 991.4355 25.7 20 
TFC[+57.0]GTPEYLAPEVLEDNDYGR 
(heavy)(+3) 
51.84 57.84 819.369 878.3514 21.8 20 
TFC[+57.0]GTPEYLAPEVLEDNDYGR 
(heavy)(+3) 
51.84 57.84 819.369 749.3088 21.8 20 
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TFC[+57.0]GTPEYLAPEVLEDNDYGR(+3) 51.84 57.84 816.033 1306.591 24.4 20 
TFC[+57.0]GTPEYLAPEVLEDNDYGR(+3) 51.84 57.84 816.033 981.4272 25.7 20 
TFC[+57.0]GTPEYLAPEVLEDNDYGR(+3) 51.84 57.84 816.033 868.3432 21.8 20 
TFC[+57.0]GTPEYLAPEVLEDNDYGR(+3) 51.84 57.84 816.033 739.3006 21.8 20 
TGTTVPESIHSFIGDGLVKPEALNK 
(heavy)(+4) 
44.77 50.77 655.353 807.4814 26.4 16 
TGTTVPESIHSFIGDGLVKPEALNK 
(heavy)(+4) 
44.77 50.77 655.353 679.3865 27.7 16 
TGTTVPESIHSFIGDGLVKPEALNK 
(heavy)(+4) 
44.77 50.77 655.353 269.1699 29 16 
TGTTVPESIHSFIGDGLVKPEALNK 
(heavy)(+4) 
44.77 50.77 655.353 753.4139 20.9 16 
TGTTVPESIHSFIGDGLVKPEALNK 
(heavy)(+4) 
44.77 50.77 655.353 720.3911 18.6 16 
TGTTVPESIHSFIGDGLVKPEALNK(+4) 44.77 50.77 653.349 799.4672 26.4 16 
TGTTVPESIHSFIGDGLVKPEALNK(+4) 44.77 50.77 653.349 671.3723 27.7 16 
TGTTVPESIHSFIGDGLVKPEALNK(+4) 44.77 50.77 653.349 261.1557 29 16 
TGTTVPESIHSFIGDGLVKPEALNK(+4) 44.77 50.77 653.349 750.7425 20.9 16 
TGTTVPESIHSFIGDGLVKPEALNK(+4) 44.77 50.77 653.349 717.7197 18.6 16 
TGTTVPESIHSFIGDGLVKPEALNKK 
(heavy)(+4) 
40.59 46.59 687.377 807.4814 27.3 16 
TGTTVPESIHSFIGDGLVKPEALNKK 
(heavy)(+4) 
40.59 46.59 687.377 1144.13 24.7 16 
TGTTVPESIHSFIGDGLVKPEALNKK 
(heavy)(+4) 
40.59 46.59 687.377 829.7948 21.6 16 
TGTTVPESIHSFIGDGLVKPEALNKK 
(heavy)(+4) 
40.59 46.59 687.377 796.1122 19.5 16 
TGTTVPESIHSFIGDGLVKPEALNKK 
(heavy)(+4) 
40.59 46.59 687.377 763.0894 19.5 16 
TGTTVPESIHSFIGDGLVKPEALNKK(+4) 40.59 46.59 685.373 799.4672 27.3 16 
TGTTVPESIHSFIGDGLVKPEALNKK(+4) 40.59 46.59 685.373 1140.123 24.7 16 
TGTTVPESIHSFIGDGLVKPEALNKK(+4) 40.59 46.59 685.373 827.1234 21.6 16 
TGTTVPESIHSFIGDGLVKPEALNKK(+4) 40.59 46.59 685.373 793.4408 19.5 16 
TGTTVPESIHSFIGDGLVKPEALNKK(+4) 40.59 46.59 685.373 760.418 19.5 16 
THFPQFSYSASIR (heavy)(+3) 35.44 41.44 517.592 940.4762 17.3 16 
THFPQFSYSASIR (heavy)(+3) 35.44 41.44 517.592 706.3758 16 16 
THFPQFSYSASIR (heavy)(+3) 35.44 41.44 517.592 543.3125 16 16 
THFPQFSYSASIR (heavy)(+3) 35.44 41.44 517.592 456.2804 16 16 
THFPQFSYSASIR(+3) 35.44 41.44 514.256 930.468 17.3 16 
THFPQFSYSASIR(+3) 35.44 41.44 514.256 696.3675 16 16 
THFPQFSYSASIR(+3) 35.44 41.44 514.256 533.3042 16 16 
THFPQFSYSASIR(+3) 35.44 41.44 514.256 446.2722 16 16 
THFPQFSYSASIRE (heavy)(+3) 36.21 42.21 559.275 831.4239 18.5 14 
THFPQFSYSASIRE (heavy)(+3) 36.21 42.21 559.275 668.3606 17.2 14 
THFPQFSYSASIRE (heavy)(+3) 36.21 42.21 559.275 581.3286 15.9 14 
THFPQFSYSASIRE (heavy)(+3) 36.21 42.21 559.275 510.2914 15.9 14 
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THFPQFSYSASIRE(+3) 36.21 42.21 557.27 825.4101 18.5 14 
THFPQFSYSASIRE(+3) 36.21 42.21 557.27 662.3468 17.2 14 
THFPQFSYSASIRE(+3) 36.21 42.21 557.27 575.3148 15.9 14 
THFPQFSYSASIRE(+3) 36.21 42.21 557.27 504.2776 15.9 14 
TPPEAIALC[+57.0]SR (heavy)(+2) 27.02 33.02 612.817 1026.528 23.4 16 
TPPEAIALC[+57.0]SR (heavy)(+2) 27.02 33.02 612.817 929.4748 27.3 16 
TPPEAIALC[+57.0]SR (heavy)(+2) 27.02 33.02 612.817 800.4323 27.3 16 
TPPEAIALC[+57.0]SR (heavy)(+2) 27.02 33.02 612.817 729.3951 24.7 16 
TPPEAIALC[+57.0]SR (heavy)(+2) 27.02 33.02 612.817 616.3111 26 16 
TPPEAIALC[+57.0]SR(+2) 27.02 33.02 607.813 1016.519 23.4 16 
TPPEAIALC[+57.0]SR(+2) 27.02 33.02 607.813 919.4666 27.3 16 
TPPEAIALC[+57.0]SR(+2) 27.02 33.02 607.813 790.424 27.3 16 
TPPEAIALC[+57.0]SR(+2) 27.02 33.02 607.813 719.3869 24.7 16 
TPPEAIALC[+57.0]SR(+2) 27.02 33.02 607.813 606.3028 26 16 
TQADELPAC[+57.0]LLSAAR (heavy)(+2) 46.53 52.53 813.413 1396.713 27.7 16 
TQADELPAC[+57.0]LLSAAR (heavy)(+2) 46.53 52.53 813.413 1325.676 27.7 16 
TQADELPAC[+57.0]LLSAAR (heavy)(+2) 46.53 52.53 813.413 1081.606 27.7 16 
TQADELPAC[+57.0]LLSAAR (heavy)(+2) 46.53 52.53 813.413 968.5221 27.7 16 
TQADELPAC[+57.0]LLSAAR (heavy)(+2) 46.53 52.53 813.413 800.4323 27.7 16 
TQADELPAC[+57.0]LLSAAR(+2) 46.53 52.53 808.409 1386.705 27.7 16 
TQADELPAC[+57.0]LLSAAR(+2) 46.53 52.53 808.409 1315.667 27.7 16 
TQADELPAC[+57.0]LLSAAR(+2) 46.53 52.53 808.409 1071.598 27.7 16 
TQADELPAC[+57.0]LLSAAR(+2) 46.53 52.53 808.409 958.5139 27.7 16 
TQADELPAC[+57.0]LLSAAR(+2) 46.53 52.53 808.409 790.424 27.7 16 
TRTDSYSAGQSVEILDGVELGEPAHK 
(heavy)(+4) 
39.66 45.66 692.596 888.4665 24.8 16 
TRTDSYSAGQSVEILDGVELGEPAHK 
(heavy)(+4) 
39.66 45.66 692.596 646.3398 24.8 16 
TRTDSYSAGQSVEILDGVELGEPAHK 
(heavy)(+4) 
39.66 45.66 692.596 460.2758 27.4 16 
TRTDSYSAGQSVEILDGVELGEPAHK 
(heavy)(+4) 
39.66 45.66 692.596 850.9509 17 16 
TRTDSYSAGQSVEILDGVELGEPAHK 
(heavy)(+4) 
39.66 45.66 692.596 757.9007 17 16 
TRTDSYSAGQSVEILDGVELGEPAHK(+4) 39.66 45.66 690.592 880.4523 24.8 16 
TRTDSYSAGQSVEILDGVELGEPAHK(+4) 39.66 45.66 690.592 638.3257 24.8 16 
TRTDSYSAGQSVEILDGVELGEPAHK(+4) 39.66 45.66 690.592 452.2616 27.4 16 
TRTDSYSAGQSVEILDGVELGEPAHK(+4) 39.66 45.66 690.592 846.9438 17 16 
TRTDSYSAGQSVEILDGVELGEPAHK(+4) 39.66 45.66 690.592 753.8936 17 16 
TSMGGTQQQFVEGVR (heavy)(+2) 29.21 35.21 817.895 972.5137 30.5 16 
TSMGGTQQQFVEGVR (heavy)(+2) 29.21 35.21 817.895 844.4551 30.5 16 
TSMGGTQQQFVEGVR (heavy)(+2) 29.21 35.21 817.895 716.3965 30.5 16 
TSMGGTQQQFVEGVR (heavy)(+2) 29.21 35.21 817.895 470.2597 29.2 16 
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TSMGGTQQQFVEGVR (heavy)(+2) 29.21 35.21 817.895 341.2171 31.8 16 
TSMGGTQQQFVEGVR(+2) 29.21 35.21 812.891 962.5054 30.5 16 
TSMGGTQQQFVEGVR(+2) 29.21 35.21 812.891 834.4468 30.5 16 
TSMGGTQQQFVEGVR(+2) 29.21 35.21 812.891 706.3883 30.5 16 
TSMGGTQQQFVEGVR(+2) 29.21 35.21 812.891 460.2514 29.2 16 
TSMGGTQQQFVEGVR(+2) 29.21 35.21 812.891 331.2088 31.8 16 
TTSFAESC[+57.0]KPVQQPSAFGSMK 
(heavy)(+3) 
30 36 766.032 1284.65 29.4 16 
TTSFAESC[+57.0]KPVQQPSAFGSMK 
(heavy)(+3) 
30 36 766.032 832.4113 24.2 16 
TTSFAESC[+57.0]KPVQQPSAFGSMK 
(heavy)(+3) 
30 36 766.032 1047.497 22.9 16 
TTSFAESC[+57.0]KPVQQPSAFGSMK 
(heavy)(+3) 
30 36 766.032 930.4471 22.9 16 
TTSFAESC[+57.0]KPVQQPSAFGSMK 
(heavy)(+3) 
30 36 766.032 894.9286 21.6 16 
TTSFAESC[+57.0]KPVQQPSAFGSMK(+3) 30 36 763.361 1276.635 29.4 16 
TTSFAESC[+57.0]KPVQQPSAFGSMK(+3) 30 36 763.361 824.3971 24.2 16 
TTSFAESC[+57.0]KPVQQPSAFGSMK(+3) 30 36 763.361 1043.49 22.9 16 
TTSFAESC[+57.0]KPVQQPSAFGSMK(+3) 30 36 763.361 926.44 22.9 16 
TTSFAESC[+57.0]KPVQQPSAFGSMK(+3) 30 36 763.361 890.9215 21.6 16 
VADPDHDHTGFLTEYVATR (heavy)(+3) 35.02 41.02 718.675 1166.608 28.1 14 
VADPDHDHTGFLTEYVATR (heavy)(+3) 35.02 41.02 718.675 849.434 26.8 14 
VADPDHDHTGFLTEYVATR (heavy)(+3) 35.02 41.02 718.675 748.3863 26.8 14 
VADPDHDHTGFLTEYVATR (heavy)(+3) 35.02 41.02 718.675 619.3438 26.8 14 
VADPDHDHTGFLTEYVATR (heavy)(+3) 35.02 41.02 718.675 456.2804 28.1 14 
VADPDHDHTGFLTEYVATR(+3) 35.02 41.02 715.339 1156.6 28.1 14 
VADPDHDHTGFLTEYVATR(+3) 35.02 41.02 715.339 839.4258 26.8 14 
VADPDHDHTGFLTEYVATR(+3) 35.02 41.02 715.339 738.3781 26.8 14 
VADPDHDHTGFLTEYVATR(+3) 35.02 41.02 715.339 609.3355 26.8 14 
VADPDHDHTGFLTEYVATR(+3) 35.02 41.02 715.339 446.2722 28.1 14 
VIGNGSFGVVYQAK (heavy)(+2) 35.89 41.89 723.895 1234.631 24.7 14 
VIGNGSFGVVYQAK (heavy)(+2) 35.89 41.89 723.895 919.5127 26 14 
VIGNGSFGVVYQAK (heavy)(+2) 35.89 41.89 723.895 772.4443 26 14 
VIGNGSFGVVYQAK (heavy)(+2) 35.89 41.89 723.895 616.3544 24.7 14 
VIGNGSFGVVYQAK (heavy)(+2) 35.89 41.89 723.895 517.286 27.3 14 
VIGNGSFGVVYQAK(+2) 35.89 41.89 719.888 1226.616 24.7 14 
VIGNGSFGVVYQAK(+2) 35.89 41.89 719.888 911.4985 26 14 
VIGNGSFGVVYQAK(+2) 35.89 41.89 719.888 764.4301 26 14 
VIGNGSFGVVYQAK(+2) 35.89 41.89 719.888 608.3402 24.7 14 
VIGNGSFGVVYQAK(+2) 35.89 41.89 719.888 509.2718 27.3 14 
VIKC[+57.0]DPDC[+57.0]LR (heavy)(+2) 16.84 22.84 643.316 945.3792 24.5 20 
VIKC[+57.0]DPDC[+57.0]LR (heavy)(+2) 16.84 22.84 643.316 670.3216 29.7 20 
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VIKC[+57.0]DPDC[+57.0]LR (heavy)(+2) 16.84 22.84 643.316 458.2419 29.7 20 
VIKC[+57.0]DPDC[+57.0]LR (heavy)(+3) 16.84 22.84 429.213 670.3216 18.8 20 
VIKC[+57.0]DPDC[+57.0]LR (heavy)(+3) 16.84 22.84 429.213 573.2689 18.8 20 
VIKC[+57.0]DPDC[+57.0]LR (heavy)(+3) 16.84 22.84 429.213 458.2419 20.1 20 
VIKC[+57.0]DPDC[+57.0]LR (heavy)(+3) 16.84 22.84 429.213 616.3123 14.9 20 
VIKC[+57.0]DPDC[+57.0]LR(+2) 16.84 22.84 638.312 935.371 24.5 20 
VIKC[+57.0]DPDC[+57.0]LR(+2) 16.84 22.84 638.312 660.3134 29.7 20 
VIKC[+57.0]DPDC[+57.0]LR(+2) 16.84 22.84 638.312 448.2337 29.7 20 
VIKC[+57.0]DPDC[+57.0]LR(+3) 16.84 22.84 425.877 660.3134 18.8 20 
VIKC[+57.0]DPDC[+57.0]LR(+3) 16.84 22.84 425.877 563.2606 18.8 20 
VIKC[+57.0]DPDC[+57.0]LR(+3) 16.84 22.84 425.877 448.2337 20.1 20 
VIKC[+57.0]DPDC[+57.0]LR(+3) 16.84 22.84 425.877 616.3123 14.9 20 
VLDTSSLTQSAPASPTNK (heavy)(+2) 29.26 35.26 912.975 1109.568 29.9 16 
VLDTSSLTQSAPASPTNK (heavy)(+2) 29.26 35.26 912.975 1008.52 28.6 16 
VLDTSSLTQSAPASPTNK (heavy)(+2) 29.26 35.26 912.975 793.4294 28.6 16 
VLDTSSLTQSAPASPTNK (heavy)(+2) 29.26 35.26 912.975 722.3923 28.6 16 
VLDTSSLTQSAPASPTNK(+2) 29.26 35.26 908.967 1101.553 29.9 16 
VLDTSSLTQSAPASPTNK(+2) 29.26 35.26 908.967 1000.506 28.6 16 
VLDTSSLTQSAPASPTNK(+2) 29.26 35.26 908.967 785.4152 28.6 16 
VLDTSSLTQSAPASPTNK(+2) 29.26 35.26 908.967 714.3781 28.6 16 
VLGLLGALDPYK (heavy)(+2) 54.53 60.53 633.881 1054.602 21.6 16 
VLGLLGALDPYK (heavy)(+2) 54.53 60.53 633.881 884.4967 21.6 16 
VLGLLGALDPYK (heavy)(+2) 54.53 60.53 633.881 771.4127 20.3 16 
VLGLLGALDPYK (heavy)(+2) 54.53 60.53 633.881 415.2431 29.4 16 
VLGLLGALDPYK(+2) 54.53 60.53 629.873 1046.588 21.6 16 
VLGLLGALDPYK(+2) 54.53 60.53 629.873 876.4825 21.6 16 
VLGLLGALDPYK(+2) 54.53 60.53 629.873 763.3985 20.3 16 
VLGLLGALDPYK(+2) 54.53 60.53 629.873 407.2289 29.4 16 
VLNSIAYK (heavy)(+2) 21.81 27.81 458.273 816.4705 16.9 20 
VLNSIAYK (heavy)(+2) 21.81 27.81 458.273 703.3865 15.6 20 
VLNSIAYK (heavy)(+2) 21.81 27.81 458.273 589.3435 16.9 20 
VLNSIAYK (heavy)(+2) 21.81 27.81 458.273 502.3115 19.5 20 
VLNSIAYK (heavy)(+2) 21.81 27.81 458.273 389.2274 22.1 20 
VLNSIAYK(+2) 21.81 27.81 454.266 808.4563 16.9 20 
VLNSIAYK(+2) 21.81 27.81 454.266 695.3723 15.6 20 
VLNSIAYK(+2) 21.81 27.81 454.266 581.3293 16.9 20 
VLNSIAYK(+2) 21.81 27.81 454.266 494.2973 19.5 20 
VLNSIAYK(+2) 21.81 27.81 454.266 381.2132 22.1 20 
VSHKPSGLVMAR (heavy)(+3) 14.05 20.05 431.244 968.5585 18.8 25 
VSHKPSGLVMAR (heavy)(+3) 14.05 20.05 431.244 840.4636 18.8 25 
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VSHKPSGLVMAR (heavy)(+3) 14.05 20.05 431.244 486.2732 18.8 25 
VSHKPSGLVMAR (heavy)(+3) 14.05 20.05 431.244 387.2048 18.8 25 
VSHKPSGLVMAR(+3) 14.05 20.05 427.908 958.5502 18.8 25 
VSHKPSGLVMAR(+3) 14.05 20.05 427.908 830.4553 18.8 25 
VSHKPSGLVMAR(+3) 14.05 20.05 427.908 476.265 18.8 25 
VSHKPSGLVMAR(+3) 14.05 20.05 427.908 377.1966 18.8 25 
VSQPTAEQAQAFK (heavy)(+2) 21.28 27.28 706.866 1098.567 22.8 20 
VSQPTAEQAQAFK (heavy)(+2) 21.28 27.28 706.866 900.4665 28 20 
VSQPTAEQAQAFK (heavy)(+2) 21.28 27.28 706.866 829.4294 24.1 20 
VSQPTAEQAQAFK (heavy)(+2) 21.28 27.28 706.866 700.3868 26.7 20 
VSQPTAEQAQAFK (heavy)(+2) 21.28 27.28 706.866 572.3282 29.3 20 
VSQPTAEQAQAFK(+2) 21.28 27.28 702.859 1090.553 22.8 20 
VSQPTAEQAQAFK(+2) 21.28 27.28 702.859 892.4523 28 20 
VSQPTAEQAQAFK(+2) 21.28 27.28 702.859 821.4152 24.1 20 
VSQPTAEQAQAFK(+2) 21.28 27.28 702.859 692.3726 26.7 20 
VSQPTAEQAQAFK(+2) 21.28 27.28 702.859 564.314 29.3 20 
VVDPTPEQFQAFR (heavy)(+2) 39.89 45.89 772.392 1345.641 26.3 16 
VVDPTPEQFQAFR (heavy)(+2) 39.89 45.89 772.392 1230.614 27.6 16 
VVDPTPEQFQAFR (heavy)(+2) 39.89 45.89 772.392 1032.514 28.9 16 
VVDPTPEQFQAFR (heavy)(+2) 39.89 45.89 772.392 806.4183 34.1 16 
VVDPTPEQFQAFR(+2) 39.89 45.89 767.388 1335.633 26.3 16 
VVDPTPEQFQAFR(+2) 39.89 45.89 767.388 1220.606 27.6 16 
VVDPTPEQFQAFR(+2) 39.89 45.89 767.388 1022.505 28.9 16 
VVDPTPEQFQAFR(+2) 39.89 45.89 767.388 796.41 34.1 16 
YC[+57.0]RPESQEHPEADPGSAAPYLK 
(heavy)(+4) 
23.68 29.68 628.292 528.3272 19.1 20 
YC[+57.0]RPESQEHPEADPGSAAPYLK 
(heavy)(+4) 
23.68 29.68 628.292 456.2575 16.5 20 
YC[+57.0]RPESQEHPEADPGSAAPYLK 
(heavy)(+4) 
23.68 29.68 628.292 1050.431 28.2 20 
YC[+57.0]RPESQEHPEADPGSAAPYLK 
(heavy)(+4) 
23.68 29.68 628.292 1187.49 25.6 20 
YC[+57.0]RPESQEHPEADPGSAAPYLK 
(heavy)(+4) 
23.68 29.68 628.292 800.3283 19.1 20 
YC[+57.0]RPESQEHPEADPGSAAPYLK(+
4) 
23.68 29.68 626.289 520.313 19.1 20 
YC[+57.0]RPESQEHPEADPGSAAPYLK(+
4) 
23.68 29.68 626.289 452.2504 16.5 20 
YC[+57.0]RPESQEHPEADPGSAAPYLK(+
4) 
23.68 29.68 626.289 1050.431 28.2 20 
YC[+57.0]RPESQEHPEADPGSAAPYLK(+
4) 
23.68 29.68 626.289 1187.49 25.6 20 
YC[+57.0]RPESQEHPEADPGSAAPYLK(+
4) 
23.68 29.68 626.289 800.3283 19.1 20 
YLERGESIEPLDPSEK (heavy)(+3) 29.25 35.25 623.982 793.4182 19 16 
YLERGESIEPLDPSEK (heavy)(+3) 29.25 35.25 623.982 468.2544 25.5 16 
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YLERGESIEPLDPSEK (heavy)(+3) 29.25 35.25 623.982 397.2127 17.7 16 
YLERGESIEPLDPSEK (heavy)(+3) 29.25 35.25 623.982 1077.521 17.7 16 
YLERGESIEPLDPSEK(+3) 29.25 35.25 621.31 785.404 19 16 
YLERGESIEPLDPSEK(+3) 29.25 35.25 621.31 460.2402 25.5 16 
YLERGESIEPLDPSEK(+3) 29.25 35.25 621.31 393.2056 17.7 16 
YLERGESIEPLDPSEK(+3) 29.25 35.25 621.31 1077.521 17.7 16 
YSSDPTGALTEDSIDDTFLPVPEYINQSVP
K (heavy)(+3) 
55.24 61.24 1136.214 1378.746 26.9 20 
YSSDPTGALTEDSIDDTFLPVPEYINQSVP
K (heavy)(+3) 
55.24 61.24 1136.214 1182.624 25.4 20 
YSSDPTGALTEDSIDDTFLPVPEYINQSVP
K (heavy)(+3) 
55.24 61.24 1136.214 746.4185 23.9 20 
YSSDPTGALTEDSIDDTFLPVPEYINQSVP
K (heavy)(+3) 
55.24 61.24 1136.214 689.8765 23.9 20 
YSSDPTGALTEDSIDDTFLPVPEYINQSVP
K (heavy)(+3) 
55.24 61.24 1136.214 591.8159 23.9 20 
YSSDPTGALTEDSIDDTFLPVPEYINQSVP
K(+3) 
55.24 61.24 1133.543 1370.731 26.9 20 
YSSDPTGALTEDSIDDTFLPVPEYINQSVP
K(+3) 
55.24 61.24 1133.543 1174.61 25.4 20 
YSSDPTGALTEDSIDDTFLPVPEYINQSVP
K(+3) 
55.24 61.24 1133.543 742.4114 23.9 20 
YSSDPTGALTEDSIDDTFLPVPEYINQSVP
K(+3) 
55.24 61.24 1133.543 685.8694 23.9 20 
YSSDPTGALTEDSIDDTFLPVPEYINQSVP
K(+3) 
55.24 61.24 1133.543 587.8088 23.9 20 
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APPENDIX E: 
MULTIPLE MYELOMA PATIENT CLINICAL DATA 
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ID#-
127 
4.9.2015 G K + *H 2.0 H 142.73 6.98 
* H 
20.45 
H 
2424 
<50 <25 4 Revlimid 
Progressive 
Disease 
currently 
on 
treatment 
ID#-
127 
8.13.2015 G K + *H 4.6 H 609.18 H 54.9 
* H 
11.10 
*H 6172 <50 <25 3.2 Revlimid 
Progressive 
Disease 
changed 
treatment 
ID#-
127 
12.3.2015 G K + *H 0.8 H 20.15 L 1.97 
* H 
10.23 
1162 <50 31 4.1 Pomalyst/Dex 
Partial 
Response 
currently 
on 
treatment 
ID#-
127 
3.8.2016 G K + *H 0.3 H 22.04 11.54 
* H 
1.91 
L 494 89 <25 3 Pomalyst/Dex 
Partial 
Response 
currently 
on 
treatment 
ID#-
127 
6.23.2016 G K + *H 1.4 H 124.62 8.8 
* H 
14.16 
H 
1731 
<50 <25 3 Pomalyst/Dex 
Partial 
Response 
currently 
on 
treatment 
ID#-
127 
7.28.2016 G K + *H 2.4 H 300.47 4.97 
* H 
60.46 
H 
3120 
<50 <25 3 Pomalyst/Dex 
Progressive 
Disease 
currently 
on 
treatment 
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ID#-
110 
12.10.2014 G L + *H 0.5 11.2 *H 793 * L 0.01 1157 <50 <25 4 VDT-PACE 
Progressive 
Disease 
currently 
on 
treatment 
ID#-
110 
2.11.2015 - - - NA 7.38 H 404.58 * L 0.02 L 678 <50 <25 4 VDT-PACE 
Progressive 
Disease 
currently 
on 
treatment 
ID#-
110 
3.25.2015 - - - NA 11.31 H 319.64 * L 0.04 L 486 <50 <25 4.1 VDT-PACE 
Progressive 
Disease 
currently 
on 
treatment 
ID#-
110 
3.2.2016 G L + NA H 21.47 H 294.55 * L 0.07 L 485 <50 <25 3.9 Pomalidomide 
Partial 
Response 
currently 
on 
treatment 
ID#-
110 
4.13.2016 G L + * H0.1 12.8 H 315.73 * L 0.04 L 426 <50 <25  Pomalidomide 
Partial 
Response 
off 
treatment 
ID#-
110 
7.5.2016 G L + * H0.1 8.34 H 437.87 * L 0.02 L 411 <50 <25 3.7 KPomD 
Progressive 
Disease 
started 
7.5.2016 
ID#-
110 
8.2.2016 G L + * <0.1 5.19 *H 915 * L 0.01 L 320 <50 <25 3.7 KPomD 
Progressive 
Disease 
currently 
on 
treatment 
ID#-
110 
8.23.2016 - L + * <0.1 L 1.06 *H 1624 * L 0.00 <300 <50 <25 3.7 KPomD 
Progressive 
Disease 
off 
treatment 
ID#-
110 
9.13.2016 - L + * <0.1 L 0.72 *H 829 * L 0.00 <300 <50 <25 3.9 Daratumumab 
Progressive 
Disease 
currently 
on 
treatment 
ID#-
110 
10.18.2016 - L + * H0.1 6.32 H 1004.33 * L 0.01 <300 <50 <25 3.5 Daratumumab 
Progressive 
Disease 
currently 
on 
treatment 
ID#-
110 
11.1.2016 - L + * H0.1 6.43 *H 5189 * L 0.00 <300 <50 <25 3.5 KCP8602 
Progressive 
Disease 
started 
11.1.2016 
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APPENDIX F: 
IRB LETTERS FOR MYELOMA CLINICAL SAMPLES 
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APPENDIX G: 
LC-MRM TRANSITION LIST FOR IMMUNOGLOBULIN CRPS AND PATIENT VRPS FOR 
TSQ-VANTAGE 
 
Protein/Pt Peptide 
Precursor 
(m/z) 
Fragment 
(m/z) 
Collision 
Energy 
(V) 
Dwell 
Time 
(s) 
Start 
Time 
(min) 
End 
Time 
(min) 
IGHA1_HUMAN TPLTATLSK 466.277 830.498 19.5 0.016 3.9 4.4 
IGHA1_HUMAN TPLTATLSK 466.277 733.445 19.5 0.016 3.9 4.4 
IGHA1_HUMAN TPLTATLSK 466.277 620.361 20.8 0.016 3.9 4.4 
IGHA1_HUMAN TPLTATLSK 466.277 519.314 20.8 0.016 3.9 4.4 
IGHA1_HUMAN TPLTATLSK 469.785 837.515 19.5 0.016 3.9 4.4 
IGHA1_HUMAN TPLTATLSK 469.785 740.463 19.5 0.016 3.9 4.4 
IGHA1_HUMAN TPLTATLSK 469.785 627.379 20.8 0.016 3.9 4.4 
IGHA1_HUMAN TPLTATLSK 469.785 526.331 20.8 0.016 3.9 4.4 
IGHA2_HUMAN DASGATFTWTPSSGK 756.852 1010.494 25.6 0.016 4.84 5.34 
IGHA2_HUMAN DASGATFTWTPSSGK 756.852 863.426 25.6 0.016 4.84 5.34 
IGHA2_HUMAN DASGATFTWTPSSGK 756.852 576.299 25.4 0.016 4.84 5.34 
IGHA2_HUMAN DASGATFTWTPSSGK 756.852 475.251 30.8 0.016 4.84 5.34 
IgA2 mod DGSGATFTWTPSSGK 749.844 1010.494 25.4 0.016 4.77 5.27 
IgA2 mod DGSGATFTWTPSSGK 749.844 863.426 24.1 0.016 4.77 5.27 
IgA2 mod DGSGATFTWTPSSGK 749.844 576.299 26.7 0.016 4.77 5.27 
IgA2 mod DGSGATFTWTPSSGK 749.844 475.251 30.6 0.016 4.77 5.27 
IGHG1_HUMAN GPSVFPLAPSSK 593.827 1032.572 22 0.016 5.13 5.63 
IGHG1_HUMAN GPSVFPLAPSSK 593.827 846.472 20.7 0.016 5.13 5.63 
IGHG1_HUMAN GPSVFPLAPSSK 593.827 699.404 22 0.016 5.13 5.63 
IGHG1_HUMAN GPSVFPLAPSSK 593.827 418.230 25.9 0.016 5.13 5.63 
IGHG1_HUMAN GPSVFPLAPSSK 600.841 1046.600 22 0.016 5.13 5.63 
IGHG1_HUMAN GPSVFPLAPSSK 600.841 860.500 20.7 0.016 5.13 5.63 
IGHG1_HUMAN GPSVFPLAPSSK 600.841 713.432 22 0.016 5.13 5.63 
IGHG1_HUMAN GPSVFPLAPSSK 600.841 432.258 25.9 0.016 5.13 5.63 
IGHG2_HUMAN GLPAPIEK 412.747 327.695 18 0.016 3.81 4.26 
IGHG2_HUMAN GLPAPIEK 412.747 486.292 21 0.016 3.81 4.26 
IGHG2_HUMAN GLPAPIEK 412.747 654.382 15 0.016 3.81 4.26 
IGHG2_HUMAN GLPAPIEK 415.754 330.702 18 0.016 3.81 4.26 
192 
IGHG2_HUMAN GLPAPIEK 415.754 492.306 21 0.016 3.81 4.26 
IGHG2_HUMAN GLPAPIEK 415.754 660.396 15 0.016 3.81 4.26 
IGHG3_HUMAN WYVDGVEVHNAK 708.849 968.480 26.8 0.016 4.31 4.81 
IGHG3_HUMAN WYVDGVEVHNAK 708.849 853.453 26.3 0.016 4.31 4.81 
IGHG3_HUMAN WYVDGVEVHNAK 711.856 974.493 26.8 0.016 4.31 4.81 
IGHG3_HUMAN WYVDGVEVHNAK 711.856 859.466 26.3 0.016 4.31 4.81 
IGHG3_HUMAN WYVDGVEVHNAK 472.902 697.363 20.8 0.016 4.31 4.81 
IGHG3_HUMAN WYVDGVEVHNAK 472.902 568.320 20.8 0.016 4.31 4.81 
IGHG3_HUMAN WYVDGVEVHNAK 472.902 469.252 16.9 0.016 4.31 4.81 
IGHG3_HUMAN WYVDGVEVHNAK 472.902 484.743 20.8 0.016 4.31 4.81 
IGHG3_HUMAN WYVDGVEVHNAK 474.906 703.377 20.8 0.016 4.31 4.81 
IGHG3_HUMAN WYVDGVEVHNAK 474.906 574.334 20.8 0.016 4.31 4.81 
IGHG3_HUMAN WYVDGVEVHNAK 474.906 469.252 16.9 0.016 4.31 4.81 
IGHG3_HUMAN WYVDGVEVHNAK 474.906 487.750 20.8 0.016 4.31 4.81 
IGHG4_HUMAN GLPSSIEK 415.735 660.356 15.4 0.016 3.37 3.87 
IGHG4_HUMAN GLPSSIEK 415.735 563.304 20.6 0.016 3.37 3.87 
IGHG4_HUMAN GLPSSIEK 415.735 330.682 16.7 0.016 3.37 3.87 
IGHG4_HUMAN GLPSSIEK 419.742 668.370 15.4 0.016 3.37 3.87 
IGHG4_HUMAN GLPSSIEK 419.742 571.318 20.6 0.016 3.37 3.87 
IGHG4_HUMAN GLPSSIEK 419.742 334.689 16.7 0.016 3.37 3.87 
IGHM_HUMAN DGFFGNPR 455.214 590.305 17.9 0.016 4.53 5.03 
IGHM_HUMAN DGFFGNPR 455.214 443.236 19.2 0.016 4.53 5.03 
IGHM_HUMAN DGFFGNPR 455.214 320.124 15.3 0.016 4.53 5.03 
IGHM_HUMAN DGFFGNPR 458.221 596.318 17.9 0.016 4.53 5.03 
IGHM_HUMAN DGFFGNPR 458.221 449.250 19.2 0.016 4.53 5.03 
IGHM_HUMAN DGFFGNPR 458.221 320.124 15.3 0.016 4.53 5.03 
IGKC_HUMAN 
VDNALQSGNSQESVT
EQDSK 
1068.488 893.421 38.9 0.016 3.15 3.65 
IGKC_HUMAN 
VDNALQSGNSQESVT
EQDSK 
1068.488 707.321 35 0.016 3.15 3.65 
IGKC_HUMAN 
VDNALQSGNSQESVT
EQDSK 
1068.488 606.273 37 0.016 3.15 3.65 
IGKC_HUMAN 
VDNALQSGNSQESVT
EQDSK 
1068.488 477.230 40.2 0.016 3.15 3.65 
IGKC_HUMAN 
VDNALQSGNSQESVT
EQDSK 
1072.495 901.435 38.9 0.016 3.15 3.65 
IGKC_HUMAN 
VDNALQSGNSQESVT
EQDSK 
1072.495 715.335 35 0.016 3.15 3.65 
IGKC_HUMAN 
VDNALQSGNSQESVT
EQDSK 
1072.495 614.287 37 0.016 3.15 3.65 
IGKC_HUMAN 
VDNALQSGNSQESVT
EQDSK 
1072.495 485.245 40.2 0.016 3.15 3.65 
IGKC_HUMAN 
VDNALQSGNSQESVT
EQDSK 
712.661 893.421 28.6 0.016 3.15 3.65 
IGKC_HUMAN 
VDNALQSGNSQESVT
EQDSK 
712.661 606.273 24.7 0.016 3.15 3.65 
193 
IGKC_HUMAN 
VDNALQSGNSQESVT
EQDSK 
715.332 901.435 28.6 0.016 3.15 3.65 
IGKC_HUMAN 
VDNALQSGNSQESVT
EQDSK 
715.332 614.287 24.7 0.016 3.15 3.65 
LAC_HUMAN YAASSYLSLTPEQWK 872.433 988.510 29.1 0.016 5.68 6.18 
LAC_HUMAN YAASSYLSLTPEQWK 872.433 788.394 29.1 0.016 5.68 6.18 
LAC_HUMAN YAASSYLSLTPEQWK 872.433 687.346 30.4 0.016 5.68 6.18 
LAC_HUMAN YAASSYLSLTPEQWK 876.440 996.524 29.1 0.016 5.68 6.18 
LAC_HUMAN YAASSYLSLTPEQWK 876.440 796.408 29.1 0.016 5.68 6.18 
LAC_HUMAN YAASSYLSLTPEQWK 876.440 695.360 30.4 0.016 5.68 6.18 
ALBU_HUMAN LVNEVTEFAK 575.311 937.463 20.2 0.016 4.6 5.1 
ALBU_HUMAN LVNEVTEFAK 575.311 694.377 21.5 0.016 4.6 5.1 
ALBU_HUMAN LVNEVTEFAK 575.311 595.309 20.2 0.016 4.6 5.1 
ALBU_HUMAN LVNEVTEFAK 578.820 937.463 20.2 0.016 4.6 5.1 
ALBU_HUMAN LVNEVTEFAK 578.820 694.377 21.5 0.016 4.6 5.1 
ALBU_HUMAN LVNEVTEFAK 578.820 595.309 20.2 0.016 4.6 5.1 
IGHE_HUMAN DFTPPTVK 452.742 642.382 16.5 0.016 3.99 4.49 
IGHE_HUMAN DFTPPTVK 452.742 541.334 19.1 0.016 3.99 4.49 
IGHE_HUMAN DFTPPTVK 452.742 444.282 20.6 0.016 3.99 4.49 
IGHE_HUMAN DFTPPTVK 456.749 650.396 16.5 0.016 3.99 4.49 
IGHE_HUMAN DFTPPTVK 456.749 549.349 19.1 0.016 3.99 4.49 
IGHE_HUMAN DFTPPTVK 456.749 452.296 20.6 0.016 3.99 4.49 
IGHD_HUMAN EPAAQAPVK 455.753 684.404 20.5 0.016 2.6 3.1 
IGHD_HUMAN EPAAQAPVK 455.753 613.367 18 0.016 2.6 3.1 
IGHD_HUMAN EPAAQAPVK 455.753 542.330 17.9 0.016 2.6 3.1 
IGHD_HUMAN EPAAQAPVK 455.753 414.271 17.9 0.016 2.6 3.1 
IGHD_HUMAN EPAAQAPVK 458.760 684.404 20.5 0.016 2.6 3.1 
IGHD_HUMAN EPAAQAPVK 458.760 613.367 18 0.016 2.6 3.1 
IGHD_HUMAN EPAAQAPVK 458.760 542.330 17.9 0.016 2.6 3.1 
IGHD_HUMAN EPAAQAPVK 458.760 414.271 17.9 0.016 2.6 3.1 
Kappa_VRP ATGIPAR 343.203 614.362 17.1 0.016 2.62 3.12 
Kappa_VRP ATGIPAR 343.203 513.314 15.8 0.016 2.62 3.12 
Kappa_VRP ATGIPAR 343.203 456.293 15.8 0.016 2.62 3.12 
Kappa_VRP ATGIPAR 348.207 624.370 17.1 0.016 2.62 3.12 
Kappa_VRP ATGIPAR 348.207 523.323 15.8 0.016 2.62 3.12 
Kappa_VRP ATGIPAR 348.207 466.301 15.8 0.016 2.62 3.12 
Heavy_VRP VAGESLK 352.203 604.330 16.1 0.016 2.54 3.04 
Heavy_VRP VAGESLK 352.203 533.293 14.8 0.016 2.54 3.04 
Heavy_VRP VAGESLK 352.203 347.229 18.7 0.016 2.54 3.04 
Heavy_VRP VAGESLK 356.210 612.344 16.1 0.016 2.54 3.04 
Heavy_VRP VAGESLK 356.210 541.307 14.8 0.016 2.54 3.04 
194 
Heavy_VRP VAGESLK 356.210 355.243 18.7 0.016 2.54 3.04 
Heavy_VRP YYADSVK 423.206 682.341 18.2 0.016 2.78 3.28 
Heavy_VRP YYADSVK 423.206 519.277 16.9 0.016 2.78 3.28 
Heavy_VRP YYADSVK 423.206 333.213 20.8 0.016 2.78 3.28 
Heavy_VRP YYADSVK 427.213 690.355 18.2 0.016 2.78 3.28 
Heavy_VRP YYADSVK 427.213 527.292 16.9 0.016 2.78 3.28 
Heavy_VRP YYADSVK 427.213 341.227 20.8 0.016 2.78 3.28 
LV102_HUMAN SGTSASLAISGLR 610.336 816.494 23.8 0.016 4.7 5.2 
LV102_HUMAN SGTSASLAISGLR 610.336 729.462 23.8 0.016 4.7 5.2 
LV102_HUMAN SGTSASLAISGLR 610.336 616.378 23.8 0.016 4.7 5.2 
LV102_HUMAN SGTSASLAISGLR 615.340 826.502 23.8 0.016 4.7 5.2 
LV102_HUMAN SGTSASLAISGLR 615.340 739.470 23.8 0.016 4.7 5.2 
LV102_HUMAN SGTSASLAISGLR 615.340 626.386 23.8 0.016 4.7 5.2 
Pt110_Kappa SNIGSNTVTWYR 699.344 1083.522 25.5 0.02 4.5 5.5 
Pt110_Kappa SNIGSNTVTWYR 699.344 1026.500 25.5 0.02 4.5 5.5 
Pt110_Kappa SNIGSNTVTWYR 699.344 939.468 26.4 0.02 4.5 5.5 
Pt110_Kappa SNIGSNTVTWYR 699.344 825.425 26.4 0.02 4.5 5.5 
Pt110_Kappa SNIGSNTVTWYR 699.344 625.309 24.8 0.02 4.5 5.5 
Pt110_Kappa SNIGSNTVTWYR 704.348 1093.530 25.5 0.02 4.5 5.5 
Pt110_Kappa SNIGSNTVTWYR 704.348 1036.509 25.5 0.02 4.5 5.5 
Pt110_Kappa SNIGSNTVTWYR 704.348 949.477 26.4 0.02 4.5 5.5 
Pt110_Kappa SNIGSNTVTWYR 704.348 835.434 26.4 0.02 4.5 5.5 
Pt110_Kappa SNIGSNTVTWYR 704.348 635.318 24.8 0.02 4.5 5.5 
Pt127_Heavy NTLSLQMNSLR 638.838 748.377 21 0.02 5.5 6.2 
Pt127_Heavy NTLSLQMNSLR 638.838 861.461 22 0.02 5.5 6.2 
Pt127_Heavy NTLSLQMNSLR 638.838 948.493 21 0.02 5.5 6.2 
Pt127_Heavy NTLSLQMNSLR 638.838 1061.577 20 0.02 5.5 6.2 
Pt127_Heavy NTLSLQMNSLR 643.842 758.385 21 0.02 5.5 6.2 
Pt127_Heavy NTLSLQMNSLR 643.842 871.469 22 0.02 5.5 6.2 
Pt127_Heavy NTLSLQMNSLR 643.842 958.501 21 0.02 5.5 6.2 
Pt127_Heavy NTLSLQMNSLR 643.842 1071.585 20 0.02 5.5 6.2 
Pt127_Kappa ALTFGGGTK 426.235 419.225 16 0.02 3.7 4.3 
Pt127_Kappa ALTFGGGTK 426.235 566.293 14 0.02 3.7 4.3 
Pt127_Kappa ALTFGGGTK 426.235 667.341 11 0.02 3.7 4.3 
Pt127_Kappa ALTFGGGTK 430.242 427.239 16 0.02 3.7 4.3 
Pt127_Kappa ALTFGGGTK 430.242 574.307 14 0.02 3.7 4.3 
Pt127_Kappa ALTFGGGTK 430.242 675.355 11 0.02 3.7 4.3 
 
 
